<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Endocrinol (Lausanne)</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Endocrinol (Lausanne)</journal-id>
<journal-id journal-id-type="publisher-id">Front. Endocrinol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Endocrinology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-2392</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30792693</article-id>
<article-id pub-id-type="pmc">6374316</article-id>
<article-id pub-id-type="doi">10.3389/fendo.2019.00039</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Endocrinology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Endocrine-Mediated Mechanisms of Metabolic Disruption and New Approaches to Examine the Public Health Threat</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kassotis</surname>
<given-names>Christopher D.</given-names>
</name>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/531149/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stapleton</surname>
<given-names>Heather M.</given-names>
</name>
</contrib>
</contrib-group>
<aff><institution>Nicholas School of the Environment, Duke University</institution>, <addr-line>Durham, NC</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Robert Sargis, University of Illinois at Chicago, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Jacqueline M. Stephens, Louisiana State University, United States; Mark Andrew Lawson, University of California, San Diego, United States</p>
</fn>
<corresp id="c001">*Correspondence: Christopher D. Kassotis <email>christopher.kassotis@duke.edu</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Systems and Translational Endocrinology, a section of the journal Frontiers in Endocrinology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>39</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>1</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Kassotis and Stapleton.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Kassotis and Stapleton</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Obesity and metabolic disorders are of great societal concern and generate substantial human health care costs globally. Interventions have resulted in only minimal impacts on disrupting this worsening health trend, increasing attention on putative environmental contributors. Exposure to numerous environmental contaminants have, over decades, been demonstrated to result in increased metabolic dysfunction and/or weight gain in cell and animal models, and in some cases, even in humans. There are numerous mechanisms through which environmental contaminants may contribute to metabolic dysfunction, though certain mechanisms, such as activation of the peroxisome proliferator activated receptor gamma or the retinoid x receptor, have received considerably more attention than less-studied mechanisms such as antagonism of the thyroid receptor, androgen receptor, or mitochondrial toxicity. As such, research on putative metabolic disruptors is growing rapidly, as is our understanding of molecular mechanisms underlying these effects. Concurrent with these advances, new research has evaluated current models of adipogenesis, and new models have been proposed. Only in the last several years have studies really begun to address complex mixtures of contaminants and how these mixtures may disrupt metabolic health in environmentally relevant exposure scenarios. Several studies have begun to assess environmental mixtures from various environments and study the mechanisms underlying their putative metabolic dysfunction; these studies hold real promise in highlighting crucial mechanisms driving observed organismal effects. In addition, high-throughput toxicity databases (ToxCast, etc.) may provide future benefits in prioritizing chemicals for <italic>in vivo</italic> testing, particularly once the causative molecular mechanisms promoting dysfunction are better understood and expert critiques are used to hone the databases. In this review, we will review the available literature linking metabolic disruption to endocrine-mediated molecular mechanisms, discuss the novel application of environmental mixtures and implications for <italic>in vivo</italic> metabolic health, and discuss the putative utility of applying high-throughput toxicity databases to answering complex organismal health outcome questions.</p>
</abstract>
<kwd-group>
<kwd>endocrine disrupting chemicals</kwd>
<kwd>obesogen</kwd>
<kwd>diabetogen</kwd>
<kwd>adipogenesis</kwd>
<kwd>3T3-L1</kwd>
<kwd>obesity</kwd>
<kwd>diabetes</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">National Institute of Environmental Health Sciences<named-content content-type="fundref-id">10.13039/100000066</named-content></funding-source>
<award-id rid="cn001">F32 ES027320</award-id>
<award-id rid="cn001">R01 ES016099</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="283"></ref-count>
<page-count count="22"></page-count>
<word-count count="20113"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Endocrine Disruptors as Causative Factor in Metabolic Disruption</title>
<p>Endocrine disrupting chemicals (EDCs) have been demonstrated to directly modulate metabolism <italic>in vivo</italic> and/or triglyceride accumulation <italic>in vitro</italic> through various receptor-mediated pathways (<xref ref-type="bibr" rid="B1">1</xref>–<xref ref-type="bibr" rid="B5">5</xref>), suggesting a potential causative link between exposure to EDCs and the increasing global prevalence of metabolic disorders, including obesity (<xref ref-type="bibr" rid="B6">6</xref>). Chronic metabolic health conditions are rapidly increasing in prevalence and cost to society worldwide: in the US, 39.6 and 9.7% of adults aged 20 and older are currently classified as obese or have been diagnosed with diabetes, respectively, with increasing occurrence in younger age groups as well (<xref ref-type="bibr" rid="B7">7</xref>–<xref ref-type="bibr" rid="B10">10</xref>). These conditions contribute to a rising share of health care costs; in the US, &gt;$600 million is directed to obesity-related and diabetes-related illnesses in adults (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). These effects are mirrored in animal populations, with an analysis of &gt;20,000 animals from 24 populations reporting increased weight gain in numerous species including monkeys, both laboratory and urban mice, cats, dogs, etc. (<xref ref-type="bibr" rid="B12">12</xref>). Notably, attempted interventions have yielded minimal effects, and analyses have determined that activity, caloric intake, and genetics are insufficient to explain the magnitude and speed of this change (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). As fat cell development is driven and modulated by nuclear hormone receptor signaling (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B15">15</xref>–<xref ref-type="bibr" rid="B17">17</xref>), EDCs that activate or inhibit these hormone pathways may be causative agents in promoting modulation of fat cell development, energy homeostasis, basal metabolic rate, hormonal control of appetite and satiety, and brain circuitry controlling food intake and energy expenditure and ultimately contributing to the development of Metabolic Syndrome (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref ref-type="bibr" rid="B18">18</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Representative EDCs Capable of Affecting Adipogenesis. Representative endocrine disrupting chemicals (EDCs) capable of affecting adipogenesis and/or metabolic health through the specified nuclear receptor pathways listed above. Gross circle size intended to express a general sense of the reported research into assessing these varying mechanisms; for example, PPARγ, RXRα, and GR have previously received the bulk of the research, whereas others have received less. Agonists for the receptors are depicted with a (+) following the chemicals, whereas antagonists are denoted with the (−). Standard positive and negative control chemicals for each receptor (for evaluating these pathways) are bolded to distinguish from the other EDC examples. PPAR, peroxisome proliferator activated receptor; RXR, retinoid X receptor; AR, androgen receptor; ER, estrogen receptor; CAR, constitutive androstane receptor; TR, thyroid receptor; FXR, farnesoid X receptor; LXR, liver X receptor; GR, glucocorticoid receptor.</p>
</caption>
<graphic xlink:href="fendo-10-00039-g0001"></graphic>
</fig>
<p>Numerous environmental toxicants have been demonstrated as metabolic disruptors <italic>in vivo</italic>, supporting EDCs as a causative factor in these adverse health trends (<xref ref-type="bibr" rid="B14">14</xref>). There is a rich literature demonstrating effects of antibiotics on weight gain in humans and diverse animal species. Experiments demonstrating their efficacy in promoting weight gain in agricultural species were published by the 1950's, presumably operating through effects on gut microbiota impacting the processing of carbohydrates in the diet (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). More recent publications have demonstrated that several weeks of subtherapeutic antibiotics increase fat mass and weight, particularly when begun during gestation (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>), and human epidemiological studies have demonstrated increased risk of becoming overweight when children were exposed early in life (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Other notable examples include diethylstilbestrol (DES), a pharmaceutical provided to pregnant women in the 1940's through 1970's in the mistaken assumption it would reduce rates of abortion, miscarriage, and premature labor (<xref ref-type="bibr" rid="B25">25</xref>); it was later determined to induce a variety of adverse health effects in both males and females exposed during gestation (<xref ref-type="bibr" rid="B26">26</xref>–<xref ref-type="bibr" rid="B29">29</xref>). DES has been demonstrated to promote triglyceride accumulation <italic>in vitro</italic>, seemingly through an estrogen-receptor mediated mechanism (<xref ref-type="bibr" rid="B30">30</xref>), and both gestational and perinatal DES exposure increases body weight, body fat, and alters serum lipid profiles in rodent models throughout life (<xref ref-type="bibr" rid="B31">31</xref>–<xref ref-type="bibr" rid="B33">33</xref>). Increased risks of obesity in human adults exposed prenatally to DES have also been reported (<xref ref-type="bibr" rid="B34">34</xref>), delineating apparent translational effects. Our lab has recently demonstrated that common chemicals and environmental mixtures associated with unconventional oil and gas (UOG) operations can activate the peroxisome proliferator activated receptor gamma (PPARγ) and promote triglyceride accumulation and pre-adipocyte proliferation <italic>in vitro</italic> (<xref ref-type="bibr" rid="B35">35</xref>), and that gestational exposure to a mixture of UOG chemicals resulted in increased body weights through weaning in a rodent model (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). UOG development has also been associated with increased prevalence of low birth weight and small for gestational age births in the Northeast US (<xref ref-type="bibr" rid="B38">38</xref>), and decreased prevalence of low birth weights and increased risk of higher birth weight babies in Colorado (<xref ref-type="bibr" rid="B39">39</xref>); both low (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>) and high (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>) birth weights are associated with greater risks for obesity later in life.</p>
<p>As costs associated with <italic>in vivo</italic> screening of putative metabolism disruptors are prohibitively high, utilizing lower-order testing, and screening is essential to narrow higher-order testing to chemicals most likely to be active. Various pre-adipocyte and mesenchymal stem cell models (both rodent and human, primarily) have been utilized to assess putative <italic>in vivo</italic> metabolic disruptors <italic>in vitro</italic>; 3T3-L1 mouse pre-adipocytes have proven reliable as an <italic>in vitro</italic> screen for identifying likely obesogenic chemicals <italic>in vivo</italic>, and other models such as the OP9 mouse bone marrow-derived stromal pre-adipocyte cell line (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>) allow for assessments of varying molecular pathways important for the process of differentiation. Additionally, various multipotent mesenchymal cells and cell lines (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>) offer the additional ability to assess commitment to the adipocyte lineage as a distinct process from adipocyte differentiation (<xref ref-type="bibr" rid="B48">48</xref>). However, these assays are lengthy and their relative abilities to correctly identify chemicals may depend on both cell line and cell source. As such, there is a critical need to develop better methods for correctly predicting metabolic disruptors. Several high-throughput (HTP) screening programs now exist (Tox21, ToxCast) that report activity across mechanisms known to modulate metabolic health for thousands of chemicals. Harnessing these data sets to broadly assess high-scoring chemicals (across these molecular pathways) for more targeted <italic>in vitro</italic> and <italic>in vivo</italic> testing could provide a valuable tool for reducing research costs and more broadly assessing the tens of thousands of commercial chemicals for potential contributions to adverse health outcomes in humans and/or animals.</p>
<p>In addition to high-throughput screening, assessments of mixtures have become more commonplace in recent years. Tools to evaluate the chemical constituents and biological activities associated with complex environmental mixtures have vastly increased the capabilities within this sphere, though standard approaches to mixtures are still lacking in many respects, particularly in terms of relevance to human and animal exposure. One notable mixture that has received increasing attention is indoor house dust; our laboratory and others have collected and analytically characterized house dust from different environments around the world and routinely report numerous classes of EDCs (known to be hormonally active), including flame retardants, phthalates, pesticides, perfluoroalkyl substances (PFAS), and others that span a wide range of concentrations (<xref ref-type="bibr" rid="B49">49</xref>–<xref ref-type="bibr" rid="B51">51</xref>). Humans, and perhaps most importantly small children, are chronically exposed to household dust, and thus receive exposure to EDCs present in the dust. The EPA estimates children ingest 60–100 mg of dust per day from indoor environments (<xref ref-type="bibr" rid="B52">52</xref>), contributing to chronic oral and inhalation exposures to EDCs (<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B54">54</xref>), and compounded by other routes of exposure. Notably, numerous studies have demonstrated clear links between levels of indoor semi-volatile indoor contaminants (SVOCs) on hand wipes with levels in house dust (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B56">56</xref>), with other studies demonstrating clear links with urinary and serum levels (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>), providing evidence for this exposure route contributing to an increased body burden of specific chemicals. As such, environmental matrices such as this may represent a clear exposure route for humans and could provide critical information on biological effects of summed mixture exposures.</p>
</sec>
<sec id="s2">
<title>Nuclear Receptor Mechanisms Mediating Metabolic Disruption</title>
<p>While activation of the peroxisome proliferator activated receptor gamma (PPARγ) is likely the best-described mechanism through which adipogenesis is initiated/promoted, activation or inhibition of numerous other receptor systems have been described to directly or indirectly modulate adipocyte lineage commitment and/or differentiation of pre-adipocytes and subsequent accumulation of triglycerides, including thyroid receptor-beta (TRβ), glucocorticoid receptor (GR), estrogen receptor (ER), androgen receptor (AR), liver X receptor (LXR), retinoid X receptor (RXR), and others (<xref ref-type="bibr" rid="B59">59</xref>) (<xref ref-type="table" rid="T1">Table 1</xref>). Several studies have assessed the expression of nuclear receptors throughout the differentiation process, reporting that 30 nuclear receptors were expressed throughout the differentiation process to varying degrees and at varying timepoints (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B60">60</xref>). Recent work by Chappell et al. demonstrated putative GR-mediated effects prior to PPARγ activation after exposure of 3T3-L1 cells to tetrabrominated bisphenol A (TBBPA) (<xref ref-type="bibr" rid="B61">61</xref>). Notably, EDCs capable of acting through each of these pathways have been described previously to modulate metabolic health <italic>in vitro, in vivo</italic>, or in human epidemiological studies; though importantly, certain molecular mechanisms have received far greater research attention than others (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Major hormone receptor pathways capable of promoting adipogenesis.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Receptor</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Activity</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold><italic>In vitro</italic> effects</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold><italic>In vivo</italic> effects</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Epidemiological effects</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PPARγ</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte differentiation, also some promotion of pre-adipocyte proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased adipose fat deposition, body weights</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased body weights, reverse hyperglycemia/treat diabetes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PPARβ/δ</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte differentiation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation improves lipid profiles, depletes lipid accumulation, increases resistance to diet-induced obesity</td>
<td align="left" colspan="1" rowspan="1" valign="top">PPARβ/δ agonists reduce LDL cholesterol, triglycerides, insulin, and increase HDL cholesterol<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PPARα</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte differentiation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activation improves hyperinsulinemia and hyperglycemia, reduces weight and adiposity</td>
<td align="left" colspan="1" rowspan="1" valign="top">PPARα agonists reduce serum triglycerides and LDL cholesterol, increase HDL cholesterol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">RXRα</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte lineage commitment, adipocyte differentiation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ablated RXR mice are resistant to diet/chemical-induced obesity</td>
<td align="left" colspan="1" rowspan="1" valign="top">RXR agonists increase plasma triglycerides, cholesterol, decreased thyroid hormones</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte differentiation, pre-adipocyte proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">GR knock-down mice are resistant to diet-induced obesity, have improved insulin sensitivity and glucose tolerance, and increased energy expenditure</td>
<td align="left" colspan="1" rowspan="1" valign="top">Excess glucocorticoids associated with increased weight, adiposity, and decreased glucose tolerance/insulin sensitivity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">TR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antagonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte differentiation</td>
<td align="left" colspan="1" rowspan="1" valign="top">TR null mice exhibit increased adipogenesis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Low thyroid hormone levels promote weight gain, high levels promote weight loss</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ER</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inhibits adipocyte differentiation, promotes pre-adipocyte proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">ERKO mice exhibit increased adiposity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased estrogen in menopause associated with increased abdominal obesity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">AR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antagonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte differentiation, no effect on pre-adipocyte proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">AR agonism has anti-adipogenic effects in rodents</td>
<td align="left" colspan="1" rowspan="1" valign="top">Low androgen levels associated with increased abdominal obesity, reversed with supplementation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">LXR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte differentiation, pre-adipocyte proliferation</td>
<td align="left" colspan="1" rowspan="1" valign="top">LXR knockout mice exhibit less adipose and are glucose-intolerant; agonist treatment reduces energy expenditure</td>
<td align="left" colspan="1" rowspan="1" valign="top">LXR agonist treatments increase triglycerides, cholesterol, and other negative molecular markers</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PXR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte differentiation</td>
<td align="left" colspan="1" rowspan="1" valign="top">PXR ablation inhibits diet-induced obesity, insulin resistance, and fatty liver disease; agonist treatment promotes adiposity in mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">PXR agonist treatments reported to induce hyperglycemia and increase diabetes risk</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CAR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte differentiation</td>
<td align="left" colspan="1" rowspan="1" valign="top">CAR agonist treatment enhances insulin sensitivity, improves glucose and lipid metabolism, reverses diet-induced obesity</td>
<td align="left" colspan="1" rowspan="1" valign="top">CAR agonist treatment decreases plasma glucose and improves insulin sensitivity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">FXR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonists induce adipocyte differentiation, antagonists reverse</td>
<td align="left" colspan="1" rowspan="1" valign="top">FXR agonist induces weight gain and glucose intolerance in mice</td>
<td align="left" colspan="1" rowspan="1" valign="top">FXR agonist treatments promote reduced lipid accumulation and increased glucose uptake, reduced HDL and increased LDL cholesterol, improved insulin sensitivity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">InsR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte differentiation, triglyceride accumulation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased weight gain and glucose intolerance</td>
<td align="left" colspan="1" rowspan="1" valign="top">Insulin supplementation promote increased weight gain, cholesterol, and blood pressure</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">IGFR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Agonism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Promotes adipocyte differentiation, triglyceride accumulation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased weight gain and glucose intolerance</td>
<td align="left" colspan="1" rowspan="1" valign="top">Increased weight gain, triglycerides</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Descriptive effects for several major hormone receptor pathways that influence the process of adipogenesis and weight maintenance. Summarized evidence is provided for direction of effects, as well as in vitro, in vivo, and human epidemiological evidence. References and more detailed descriptions can be found within the relevant subsections of the manuscript, within section Nuclear Receptor Mechanisms Mediating Metabolic Disruption</italic>.</p>
<fn id="TN1">
<label>*</label>
<p><italic>Due to lack of specific, potent, and available ligands, there is minimal reported work in humans. Summarized work describes effects observed in monkey models following treatment with receptor-specific agonists</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Mechanisms of EDC Exposure and Potential Human Metabolic Health Effects. Graphical depiction of the potential sources and exposure pathways for humans to endocrine disrupting chemicals (EDCs), the molecular mechanisms related to metabolic health through which these EDCs may act to drive specific mechanistic effects, all of which may contribute to potential adverse health risks for humans. Effects reported are representative and are not comprehensive to all molecular mechanisms and mechanistic effects.</p>
</caption>
<graphic xlink:href="fendo-10-00039-g0002"></graphic>
</fig>
<sec>
<title>Peroxisome Proliferator Activated Receptors (PPARs)</title>
<p>PPARγ is often considered the only nuclear receptor whose activation is necessary and sufficient to initiate adipogenesis (<xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>). Treatment of 3T3-L1 cells as well as other pre-adipocyte and/or other committed adipocyte lineage cells with PPARγ agonists induces a potent and efficacious increase in triglyceride accumulation, which has long been realized (<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>); as such, PPARγ agonists such as rosiglitazone and/or troglitazone are routinely utilized as positive control ligands for these assays (<xref ref-type="bibr" rid="B63">63</xref>). Utilized as therapeutic agents to treat type 2 diabetes, these thiazolidinediones may act to improve insulin sensitivity via induction of PPARγ in diverse tissue types, proliferation of smaller adipocytes that are more insulin-sensitive, or via mediation of the tumor necrosis factor alpha (TNF-α), leptin, or fatty acid signaling pathways [reviewed in (<xref ref-type="bibr" rid="B66">66</xref>)]. To establish the necessity of this pathway to adipogenesis, Rosen et al. utilized embryonic stem cell and chimeric mouse models. They demonstrated that PPARγ-null cells tended to not generate adipocytes, suggesting an essential role for this receptor in their formation. They further demonstrated gene dosage effects <italic>in vitro</italic>; cells lacking both copies of PPARγ could not be induced to differentiate, cells with one copy exhibited an intermediate degree of differentiation, and wild-type cells exhibited robust differentiation and efficacious expression of adipocyte-specific molecular markers (<xref ref-type="bibr" rid="B62">62</xref>). Clonal expansion and growth arrest occurs concurrently with expression of two proteins, PPARγ and the CCAAT enhancer binding protein alpha (C/EBPα), and these markers are both important for the differentiation of pre-adipocytes to adipocytes (<xref ref-type="bibr" rid="B63">63</xref>). Further experiments in this laboratory demonstrated that while C/EBPα is also a primary marker for the initiation of differentiation, it operates within a single initiating pathway with PPARγ (<xref ref-type="bibr" rid="B67">67</xref>). In cells deficient of PPARγ, C/EBPα was not capable of promoting adipogenesis by itself, suggesting an important but non-essential role in inducing and maintaining PPARγ expression, as well as an accessory role in mediating insulin sensitivity via direct induction of the insulin receptor (<xref ref-type="bibr" rid="B67">67</xref>).</p>
<p>The other PPAR isoforms, α and β/δ, have received considerably less attention as it relates to adipogenesis, though gain/loss-of-function experiments suggest putative roles. Experiments <italic>in vitro</italic> demonstrated that induction with a PPARβ/δ-specific ligand induced robust triglyceride accumulation in wild type cells (<xref ref-type="bibr" rid="B68">68</xref>) [and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B69">69</xref>)], while PPARβ/δ-null cells differentiate and accumulate triglycerides less efficaciously following PPARγ-mediated induction (<xref ref-type="bibr" rid="B68">68</xref>). This suggests that while PPARβ/δ is not necessary for adipogenesis, the interplay of these isoforms is necessary to induce maximal differentiation and triglyceride accumulation in adipocytes. This was supported by other work reporting that PPARβ/δ activation promotes PPARγ expression, potentially bolstering adipogenesis, and providing a supportive role (<xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B71">71</xref>). When examining the isoforms in isolation, Brun et al. reported that receptor isoform-specific activation via ligands failed to induce adipogenesis and triglyceride accumulation for PPARβ/δ, but did for PPARα, if to a lesser extent and over a longer time-course than via activation of PPARγ (<xref ref-type="bibr" rid="B72">72</xref>). RNA isolations on day five demonstrated that PPARα-treated cells had minimal or no induction of various adipocyte markers, relative to robust induction in the PPARγ-treated cells; however, both had robust expression by day seven post-induction, while PPARβ/δ exhibited only minimal expression at much later time points (<xref ref-type="bibr" rid="B72">72</xref>). Further experiments demonstrated that C/EBPα acted cooperatively with PPARγ to stimulate adipogenesis as expected, but not with PPARα or β/δ (<xref ref-type="bibr" rid="B72">72</xref>), suggesting distinct mechanisms. PPARβ/δ activation in mice has anti-adipogenic effects, improving lipid profiles, reducing lipid accumulation, and increasing resistance to diet-induced obesity (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>). PPARα activation in mice has similarly been demonstrated to result in anti-adipogenic effects, including improved hyperinsulinemia and hyperglycemia, lowered triglycerides, increased resistance to diet-induced obesity, and decreased weight and adiposity (<xref ref-type="bibr" rid="B75">75</xref>–<xref ref-type="bibr" rid="B77">77</xref>). Fenofibrates (PPARα agonists) administered to humans have similarly been demonstrated to decrease serum triglycerides and LDL cholesterol and increase HDL cholesterol (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B79">79</xref>). While absence of good selective PPARβ/δ agonists has hindered human therapeutic examination, limited work with a selective and potent PPARβ/δ agonist in rhesus monkeys reported lowered LDL cholesterol, triglycerides, insulin, and increased HDL cholesterol (<xref ref-type="bibr" rid="B80">80</xref>).</p>
</sec>
<sec>
<title>Retinoid X Receptor (RXRα)</title>
<p>PPARγ functions as a heterodimer with RXR, suggesting that this receptor might also have dependent and/or independent roles in adipogenesis (<xref ref-type="bibr" rid="B62">62</xref>). Indeed, more than a decade ago, it was reported that organotins, potent activators of both PPARγ and RXRα, were also extremely potent inducers of adipogenesis (<xref ref-type="bibr" rid="B81">81</xref>, <xref ref-type="bibr" rid="B82">82</xref>). Other studies have confirmed that receptor-specific activation of RXRα promotes both adipogenic differentiation and pre-adipocyte proliferation (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>). Mechanistic experiments have further determined that of more than 5000 PPARγ:RXR DNA-binding sites in adipocytes, most are occupied by non-PPARγ:RXR heterodimers during the early stages of differentiation and transition to PPARγ:RXR in the later stages of differentiation (<xref ref-type="bibr" rid="B85">85</xref>). Mice with ablated adipocyte-RXRα are resistant to diet and chemical-induced obesity and exhibit impaired lipolysis during fasting (<xref ref-type="bibr" rid="B86">86</xref>); RXR agonists have also been demonstrated to sensitize diabetic and obese mice to insulin (<xref ref-type="bibr" rid="B87">87</xref>) and decrease hyperglycemia, hypertriglyceridemia, hyperinsulinemia, and both weight gain and food intake in several rodent models (<xref ref-type="bibr" rid="B87">87</xref>–<xref ref-type="bibr" rid="B89">89</xref>). More recent work from the Blumberg lab elegantly described RXR activation as an essential signal for commitment of mesenchymal stem cells to the adipocyte cell lineage, as well as separately promoting subsequent differentiation (<xref ref-type="bibr" rid="B48">48</xref>). Follow-up investigation determined that RXR activation-induced adipocyte differentiation created a functionally distinct adipocyte relative to those induced by PPARγ activation; RXR activation resulted in decreased glucose uptake, expression of adiponectin, and did not induce molecular pathways involved in adipocyte browning, suggesting a dysfunctional white adipose tissue that could potentially contribute to elevated obesity and/or diabetes risk (<xref ref-type="bibr" rid="B90">90</xref>). Therapeutic treatment by rexinoids in humans has reported increased plasma triglycerides, increased plasma cholesterol, and decreased thyroid hormones (<xref ref-type="bibr" rid="B91">91</xref>–<xref ref-type="bibr" rid="B93">93</xref>).</p>
</sec>
<sec>
<title>Liver X Receptor (LXR), Constitutive Androstane Receptor (CAR), Pregnane X Receptor (PXR), and Farnesoid X Receptor (FXR)</title>
<p>LXR, CAR, FXR, AND PXR are permissive binding partners with RXR, forming receptor heterodimers that can be activated by ligands for either receptor or both (potentially resulting in a synergistic effect), reviewed in Shulman et al. (<xref ref-type="bibr" rid="B94">94</xref>). LXRα is expressed primarily in the adipose, liver, intestine, and kidney, while the β isoform is ubiquitously expressed; LXRs mediate cholesterol transport, stimulating cholesterol efflux from macrophages, promoting transport in serum and uptake into liver, increase degradation of cholesterol into bile acids, inhibit absorption in the intestine, and synthesize fatty acids and triglycerides (<xref ref-type="bibr" rid="B94">94</xref>). Some disparate results have been reported <italic>in vitro:</italic> Hummasti et al. reported that LXR agonists failed to promote triglyceride accumulation and/or adipocyte differentiation in 3T3-L1 cells and 3T3-F442A cells, though did regulate adipocyte-specific gene expression (<xref ref-type="bibr" rid="B95">95</xref>). However, other studies have described LXR-mediated promotion of triglyceride accumulation, adipocyte differentiation, adipocyte-specific gene expression, and pre-adipocyte proliferation both <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B96">96</xref>, <xref ref-type="bibr" rid="B97">97</xref>), potentially via activation of PPARγ (<xref ref-type="bibr" rid="B96">96</xref>, <xref ref-type="bibr" rid="B97">97</xref>). These disparate results could be explained by cells lines and/or cell sources, as we previously reported different LXR expression and responsiveness in varying pre-adipocyte sources (<xref ref-type="bibr" rid="B60">60</xref>). Selective knockdown experiments have demonstrated LXRα as the primary regulator of lipolysis (<xref ref-type="bibr" rid="B98">98</xref>), with the β isoform more involved in cholesterol regulation (<xref ref-type="bibr" rid="B99">99</xref>). LXRβ-specific knockout mice have less adipose, but normal insulin sensitivity and adipocyte hormones; however, they are glucose-intolerant and accumulate lipid in pancreatic islets, putatively mediated by regulation of cholesterol transporters (<xref ref-type="bibr" rid="B99">99</xref>). Adipocytes have been demonstrated to be smaller in LXR deficient mice (<xref ref-type="bibr" rid="B97">97</xref>), and energy expenditure is increased, with reduced triglyceride accumulation in brown adipose (<xref ref-type="bibr" rid="B100">100</xref>); in parallel, energy expenditure is reduced in LXR agonist-treated wild type mice, and triglyceride accumulation was increased in brown adipose (<xref ref-type="bibr" rid="B100">100</xref>). In humans, LXR expression is higher in obese individuals, and receptor isoform polymorphisms have been associated with increased risks of obesity (<xref ref-type="bibr" rid="B101">101</xref>). Therapeutic treatment with LXR agonists resulted in increased plasma and hepatic triglycerides, cholesterol, and other negative metabolic markers in humans as well as primate and rodent models (<xref ref-type="bibr" rid="B102">102</xref>), despite some beneficial effects.</p>
<p>CAR and PXR are two closely-related liver-enriched receptors that have also been associated with metabolic function, and were reviewed in detail previously (<xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B104">104</xref>). While originally appreciated as regulating xenobiotic metabolizing enzymes, they have also been demonstrated to help regulate energy homeostasis, immune function, lipid metabolism, and glucose homeostasis (<xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B104">104</xref>). PXR appears to mediate effects through PPARγ, with PXR activation directly inducing PPARγ and other lipogenic gene expression such as Cd36, though potentially in a species-specific manner (<xref ref-type="bibr" rid="B104">104</xref>). CAR may promote effects on energy homeostasis through crosstalk with PPARα, or similarly to PXR, through activation of the free fatty acid uptake transporter Cd36 and inhibition of sterol regulatory element-binding protein (SREBP) (<xref ref-type="bibr" rid="B105">105</xref>). In animals, PXR ablation inhibits diet-induced obesity, insulin resistance, and fatty liver disease in various rodent models, suggesting PXR antagonism as a putative anti-obesogenic and anti-diabetic pathway (<xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B106">106</xref>). PXR agonist treatment in mice promotes hepatic triglyceride accumulation, and constitutively active PXR mice exhibit enlarged and fatty liver disease, reviewed in (<xref ref-type="bibr" rid="B107">107</xref>). Treatment with CAR agonists, in contrast, enhances insulin sensitivity, improves glucose and lipid metabolism, and reverses diet-induced obesity in rodents, reviewed in (<xref ref-type="bibr" rid="B103">103</xref>). In humans, the CAR agonist phenobarbital has been reported to decrease plasma glucose levels and improve insulin sensitivity in patients with diabetes (<xref ref-type="bibr" rid="B103">103</xref>, <xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B109">109</xref>), and though PXR is particularly promiscuous, activation of PXR by rifampicin, statins, and other pharmaceuticals have been reported to induce hyperglycemia in patients and increase the risk of developing diabetes (<xref ref-type="bibr" rid="B106">106</xref>). While activation of CAR is seemingly more therapeutically beneficial relative to PXR, it also carries with it side effects such as liver hyperplasia and carcinogenesis (<xref ref-type="bibr" rid="B103">103</xref>), among other effects.</p>
<p>Modulation of FXR has also been assessed as it relates to adipogenesis and a potential therapeutic target in treating metabolic syndrome, reviewed in (<xref ref-type="bibr" rid="B110">110</xref>). Endogenously activated by bile acids, FXR regulates bile acid synthesis, enterohepatic circulation, lipid metabolism, and thus indirectly regulates other bile acid associated receptors, discussed in Prawitt et al. (<xref ref-type="bibr" rid="B111">111</xref>). Researchers have described that FXR is expressed in adipocytes from adult mice and in differentiated 3T3-L1 cells, but not in the undifferentiated pre-adipocytes (<xref ref-type="bibr" rid="B112">112</xref>). Treatment with an FXR agonist increased adipocyte differentiation in 3T3-L1 cells, whereas treatment with an FXR antagonist reversed this (<xref ref-type="bibr" rid="B112">112</xref>); FXR agonist treatment also enhanced insulin signaling and insulin-stimulated glucose uptake (<xref ref-type="bibr" rid="B113">113</xref>). Pro-apoptotic and anti-adipogenic effects of guggelsterone (FXR antagonist) have also been reported by other researchers (<xref ref-type="bibr" rid="B114">114</xref>). Treatment with an FXR agonist in mice with diet-induced obesity worsened weight gain and glucose intolerance, seemingly mediated through reduction of the bile acid pool size and energy expenditure (<xref ref-type="bibr" rid="B115">115</xref>). However, other research in mouse models suggests beneficial effects for FXR agonist (GW4064) treatment (<xref ref-type="bibr" rid="B111">111</xref>, <xref ref-type="bibr" rid="B116">116</xref>). FXR knockout/deficient mice exhibit decreased adipose tissue, lower leptin concentrations, elevated plasma free fatty acids, resistance to rosiglitazone-induced obesity, and their embryonic fibroblasts are also resistant to rosiglitazone-induced triglyceride accumulation and differentiation due to increased lipolysis and decreased lipogenesis (<xref ref-type="bibr" rid="B113">113</xref>, <xref ref-type="bibr" rid="B117">117</xref>, <xref ref-type="bibr" rid="B118">118</xref>); despite these apparent positive metabolic effects, FXR deficient animals (both mice and rabbits) also exhibit impaired glucose tolerance and insulin resistance, which are corrected with FXR agonist supplementation (<xref ref-type="bibr" rid="B113">113</xref>, <xref ref-type="bibr" rid="B119">119</xref>). FXR expression has also been demonstrated to be downregulated and/or dysfunctional in obese humans (<xref ref-type="bibr" rid="B110">110</xref>, <xref ref-type="bibr" rid="B120">120</xref>), suggesting downregulation may play a potential role in human obesity. PXR mice exhibit FXR agonist therapeutic trials in humans have reported reduced liver lipid accumulation and increased glucose uptake [reviewed in (<xref ref-type="bibr" rid="B110">110</xref>)], reduced HDL cholesterol and increased LDL cholesterol, and improvements in insulin resistance [reviewed in (<xref ref-type="bibr" rid="B111">111</xref>)], suggesting that FXR antagonists and/or selective FXR receptor modulators might promote more beneficial effects in some tissues and for specific metabolic endpoints (<xref ref-type="bibr" rid="B116">116</xref>).</p>
</sec>
<sec>
<title>Thyroid Receptor (TR)</title>
<p>TR also forms a heterodimer with RXR, though in contrast to other receptors discussed above, it is considered a non-permissive heterodimer (can be activated only by thyroid receptor ligands and not RXR ligands), reviewed in Shulman et al. (<xref ref-type="bibr" rid="B94">94</xref>). While less frequently assessed as a contributory molecular pathway for adipogenesis, one of the defining characteristics of thyroid hormone action is maintenance of metabolic health and maintenance of lipid and carbohydrate metabolism, blood pressure, and body mass [reviewed in (<xref ref-type="bibr" rid="B94">94</xref>, <xref ref-type="bibr" rid="B121">121</xref>)]. Hypothyroidism (low thyroxine (T4) and triiodothyronine (T3), high thyroid stimulating hormone (TSH)) is characterized by weight gain, while hyperthyroidism (high T4 and T3, low TSH) is characterized by weight loss (<xref ref-type="bibr" rid="B122">122</xref>, <xref ref-type="bibr" rid="B123">123</xref>). As such, thyroid hormones are generally considered anti-obesogenic, and hypothyroid-associated adiposity can be reduced with supplementation (<xref ref-type="bibr" rid="B124">124</xref>–<xref ref-type="bibr" rid="B126">126</xref>). TRα primarily regulates thermogenesis and TRβ primarily regulates cholesterol metabolism and lipogenesis, as well as a number of genes and enzymes necessary for pre-adipocyte proliferation and adipocyte differentiation, either directly or via PPARγ [reviewed in (<xref ref-type="bibr" rid="B121">121</xref>)]. Studies have demonstrated some disparate findings regarding the role of TR in adipogenesis itself. For example, antagonism of TR has been demonstrated to efficaciously modulate adipocyte differentiation, purportedly via PPARγ, reviewed in (<xref ref-type="bibr" rid="B16">16</xref>); however, we've previously demonstrated that 3T3-L1 treatment with 1–850 (TR antagonist) resulted in efficacious triglyceride accumulation (<xref ref-type="bibr" rid="B60">60</xref>), and TR-null mice exhibit increased adipogenesis (<xref ref-type="bibr" rid="B127">127</xref>). Others, in contrast, have reported that treatment with triiodothyronine (T3; TR agonist) promoted adipocyte gene expression and decreased pre-adipocyte proliferation in Ob L771 mouse pre-adipocytes (<xref ref-type="bibr" rid="B128">128</xref>) or triglyceride accumulation and lipogenic gene expression in 3T3-L1 pre-adipocytes (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B129">129</xref>). Other work suggested differing roles at varying levels of treatment; when 3T3-F442A cells were treated with hyperthyroid T3 levels, the proportion of adipocytes was increased but expression of lipogenic enzymes and triglyceride accumulation were decreased, whereas lower levels stimulated adipose conversion, expression of lipogenic enzymes, and pre-adipocyte proliferation (<xref ref-type="bibr" rid="B130">130</xref>).</p>
</sec>
<sec>
<title>Glucocorticoid Receptor (GR)</title>
<p>The GR is intimately connected to lipid metabolism, with a wealth of <italic>in vitro, in vivo</italic>, and human epidemiological evidence supporting its role in adipose formation and maintenance [reviewed in (<xref ref-type="bibr" rid="B131">131</xref>)]. Treatment with dexamethasone induces a potent and efficacious triglyceride accumulation and pre-adipocyte proliferation response in various mesenchymal and pre-adipocyte models, often to greater extents and at lower concentrations than through direct activation of PPARγ (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B132">132</xref>), potentially mediated at least in part through activation of PPARγ (<xref ref-type="bibr" rid="B133">133</xref>), though in other cases without meaningful activation of PPARγ (<xref ref-type="bibr" rid="B134">134</xref>); in support, treatment with GR antagonists inhibits differentiation in various mesenchymal and pre-adipocyte models (<xref ref-type="bibr" rid="B135">135</xref>). Other studies have reported that glucocorticoids alone were insufficient to promote adipogenesis either in 3T3-L1 cells (<xref ref-type="bibr" rid="B136">136</xref>) or in other models (<xref ref-type="bibr" rid="B137">137</xref>), though stimulated robust differentiation in combination with insulin (<xref ref-type="bibr" rid="B137">137</xref>). As mentioned above, Chappell et al. demonstrated putative GR-mediated effects prior to PPARγ activation after exposure to tetrabrominated bisphenol A (TBBPA) (<xref ref-type="bibr" rid="B61">61</xref>), which may explain why isobutylmethylxanthine (IBMX; PPARγ ligand) treatment prior to dexamethasone (GR agonist) failed to induce significant differentiation using the same cell model in another lab, while dexamethasone treatment before IBMX promoted robust differentiation (<xref ref-type="bibr" rid="B138">138</xref>). The authors posited that glucocorticoid activation may be necessary for an intermediate commitment state prior to differentiation via PPARγ (<xref ref-type="bibr" rid="B138">138</xref>); however, this could also be due to differing responsiveness to PPARγ and GR ligands based on 3T3-L1 cell source, which we have reported on previously (<xref ref-type="bibr" rid="B60">60</xref>).</p>
<p>Other research has evaluated the putative role of the mineralocorticoid receptor (MR), an additional high-affinity binder of glucocorticoids; treatment of 3T3-F442A and 3T3-L1 cells with the mineralocorticoid agonist aldosterone promoted adipocyte differentiation, which appeared to be mediated through PPARγ activation; inhibition and knock-down of the MR inhibited adipogenesis, whereas knock-down of the GR did not (<xref ref-type="bibr" rid="B139">139</xref>). More recent work, however, demonstrated that silencing GR, but not MR, inhibited the pro-adipogenic activity of cortisol, and also decreased leptin and adiponectin, whereas MR knock-down actually increased leptin (<xref ref-type="bibr" rid="B140">140</xref>). Research in mice investigated knocking out local glucocorticoid action via 11β-hydroxysteroid dehydrogenase (glucocorticoid inactivator) overexpression exhibited resistance to diet-induced obesity/reduced fat accumulation, decreased food intake, improved insulin sensitivity and glucose tolerance, and increased energy expenditure (<xref ref-type="bibr" rid="B141">141</xref>). Glucocorticoid excess in mice in contrast resulted in decreased osteogenic gene expression and mineralization and increased expression of adipogenic genes (<xref ref-type="bibr" rid="B142">142</xref>). Cushing's syndrome (excess cortisol production) is associated with increased weight gain, hypertension, type 2 diabetes, and fatty tissue deposits (<xref ref-type="bibr" rid="B143">143</xref>, <xref ref-type="bibr" rid="B144">144</xref>), suggesting a pro-adipogenic effect of glucocorticoids in humans as well. Further, prenatal/antenatal dexamethasone (GR agonist) is often utilized to promote development of lungs in infants at risk of being born premature (<xref ref-type="bibr" rid="B145">145</xref>, <xref ref-type="bibr" rid="B146">146</xref>). Epidemiological studies have reported that dexamethasone treatment is associated with reduced birth weight in infants, even after correcting for weeks of gestation (<xref ref-type="bibr" rid="B145">145</xref>, <xref ref-type="bibr" rid="B146">146</xref>), and exhibited hypertension and greater subsequent administration of insulin for hyperglycemia (<xref ref-type="bibr" rid="B146">146</xref>).</p>
</sec>
<sec>
<title>Estrogens and Androgens</title>
<p>Often considered opposing sex steroids, androgens, and estrogens have also been described to have opposing effects on adipogenesis, reviewed in Cooke and Naaz (<xref ref-type="bibr" rid="B147">147</xref>). Experiments comparing differentiation extent in rat pre-adipocytes determined no effects for either androgens or estrogens in promoting differentiation in male pre-adipocytes; however, estrogens elicited a pro-adipogenic effect (via pre-adipocyte proliferation) and androgens elicited an anti-androgenic effect in female cells, potentially mediated by modulation of insulin growth factor 1 receptor (IGF1R) and PPARγ expression (<xref ref-type="bibr" rid="B148">148</xref>). This promotion of pre-adipocyte proliferation by estrogens has been successfully replicated in both male and female omental pre-adipocytes (<xref ref-type="bibr" rid="B149">149</xref>), while the inhibitory effect of estrogens on differentiation/triglyceride accumulation may be dose-dependent (<xref ref-type="bibr" rid="B150">150</xref>). Related work has determined some of the inhibitory effects of estrogens on adipogenesis appear to occur through the G-protein-coupled estrogen receptor 1 (GPER) rather than the classical estrogen receptor itself (<xref ref-type="bibr" rid="B151">151</xref>), and that inhibitory effects on adipogenesis are concurrent with enhancement of osteogenesis (<xref ref-type="bibr" rid="B152">152</xref>). Interestingly, estrogen receptor knock-out (ERKO) mice exhibit increased fat pad weights, adipocyte size, and adipocyte numbers relative to wild type control animals, as well as insulin resistance and impaired glucose tolerance (<xref ref-type="bibr" rid="B153">153</xref>). This is mirrored in humans, as decreased estrogen levels at menopause are associated with increased abdominal obesity that is ameliorated with estrogen replacement therapy [reviewed in (<xref ref-type="bibr" rid="B154">154</xref>)], an effect also observed in ovariectomized female mice (<xref ref-type="bibr" rid="B155">155</xref>).</p>
<p>Androgens are generally considered anti-obesogenic [reviewed in (<xref ref-type="bibr" rid="B156">156</xref>, <xref ref-type="bibr" rid="B157">157</xref>)], and treatment with androgens has been demonstrated to inhibit adipogenesis in adipose tissue samples from both sexes (<xref ref-type="bibr" rid="B158">158</xref>) and reduce fat mass in humans [reviewed in (<xref ref-type="bibr" rid="B159">159</xref>)]. Dihydrotestosterone inhibits triglyceride accumulation and adipocyte gene expression in human mesenchymal stem cells and pre-adipocytes from various depots, whereas anti-androgen co-treatment attenuated those effects, and had no apparent impact on pre-adipocyte proliferation in either model (<xref ref-type="bibr" rid="B160">160</xref>). Other research has replicated these findings, suggesting some of the effects occur through inhibition of the multipotent stem cell to pre-adipocyte commitment (<xref ref-type="bibr" rid="B161">161</xref>, <xref ref-type="bibr" rid="B162">162</xref>). In contrast, anti-androgens have been suggested to act as obesogens; androgen receptor knock out (ARKO) mice exhibit increased obesity (<xref ref-type="bibr" rid="B163">163</xref>), flutamide has been demonstrated to modulate lipid profiles in women (<xref ref-type="bibr" rid="B164">164</xref>), and hypogonadism (characterized by testosterone deficiency) is associated with obesity, hypertension, dyslipidemia, insulin resistance, and other metabolic effects, which may be corrected with androgen supplementation (<xref ref-type="bibr" rid="B159">159</xref>).</p>
</sec>
<sec>
<title>Other Receptors</title>
<p>A variety of other receptors, from the nuclear receptor family, receptor tyrosine kinase family, and others, have described roles in adipogenesis and/or lipogenesis. For example, both the insulin and IGF-1 receptors have widely accepted roles in growth, tissue-specific hypertrophy, and weight maintenance (<xref ref-type="bibr" rid="B165">165</xref>–<xref ref-type="bibr" rid="B168">168</xref>). Many others, including the aryl hydrocarbon, retinoic acid, low density lipoprotein receptors, among others, have established roles in adipogenesis but could not be discussed in detail within the scope of this review. Importantly, while the bulk of study has assessed activation of PPARγ and RXR, numerous other receptor systems interplay to promote and maintain adipocytes, and must be taken into account when evaluating environmental mixtures.</p>
</sec>
</sec>
<sec id="s3">
<title>Mitochondrial Toxicity as a Contributory Factor to Metabolic Disruption</title>
<p>Mitochondria are the major location of fatty acid oxidation, making them essential in lipid metabolism; as such, dysfunction can contribute to numerous adverse metabolic health consequences, including altered lipid accumulation, metabolism, and insulin resistance (<xref ref-type="bibr" rid="B169">169</xref>, <xref ref-type="bibr" rid="B170">170</xref>). Mitochondrial function is intimately connected with metabolic health, as it helps regulate energy expenditure, production of ATP, and removal of reactive oxygen species (ROS); ROS reduce oxygen consumption and inhibit fatty acid oxidation in adipocytes, promoting lipid accumulation [reviewed in (<xref ref-type="bibr" rid="B169">169</xref>)]. ROS production mainly occurs at complex I and III in mitochondria, and is increased when excess electrons are provided to the mitochondrial respiratory chains (when proton gradient is high and ATP demand is low), as described in Kim et al. (<xref ref-type="bibr" rid="B171">171</xref>). Excess electrons are transferred to oxygen, converted to superoxide, and subsequently to hydrogen peroxide; this ROS acts to damage proteins, DNA, and lipids, and activates pathways (via activation of serine kinases) that phosphorylate insulin receptor substrate proteins and inhibit insulin signaling, thus promoting insulin resistance and ultimately resulting in metabolic dysfunction (<xref ref-type="bibr" rid="B171">171</xref>, <xref ref-type="bibr" rid="B172">172</xref>). Mitochondrial dysfunction and resultant lipid accumulation in accessory tissues is also capable of further impeding insulin signaling and glucose metabolism, promoting further dysfunction (<xref ref-type="bibr" rid="B173">173</xref>); indeed, maternal obesity during pregnancy in rodents contributes to a transgenerational mitochondrial dysfunction phenotype (inhibited insulin signaling for three generations) (<xref ref-type="bibr" rid="B174">174</xref>). Notably, chronic oxidative stress has been well-described in obese individuals, suggesting a link between ROS production/management and hyperplasia [reviewed in (<xref ref-type="bibr" rid="B175">175</xref>)]. To minimize damage from these ROS, cells require a balance between ATP synthesis through oxidative phosphorylation and dissipation of the proton gradient (<xref ref-type="bibr" rid="B169">169</xref>). Mitochondrial dysfunction can also directly contribute to cardiovascular disease, another hallmark disease of metabolic syndrome, and myocardial metabolic function is intimately connected to obesity, diabetes, and altered insulin signaling [reviewed in (<xref ref-type="bibr" rid="B176">176</xref>)]. Research suggests that decreases in ATP production due to inhibited mitochondrial respiration, increased oxidative stress, and inhibited calcium signaling can all contribute to diastolic dysfunction via reduced velocity of myocardial relaxation velocity and myocardial compliance (<xref ref-type="bibr" rid="B173">173</xref>, <xref ref-type="bibr" rid="B176">176</xref>).</p>
<p>Adipocytes are capable of regulating metabolic insults by altering their number, morphology, as well as the intracellular mitochondrial distribution (<xref ref-type="bibr" rid="B169">169</xref>). Mitochondrial biogenesis is an essential component of adipogenesis, with mitochondrial numbers increasing markedly after initiation of pre-adipocyte differentiation and reaching a maximum toward the end; this can be noted via treatment with the PPARγ agonist rosiglitazone, wherein treated cells demonstrate increased mitochondrial content and function, with increased basal oxygen consumption, ATP respiration, and proton leak (<xref ref-type="bibr" rid="B173">173</xref>, <xref ref-type="bibr" rid="B177">177</xref>, <xref ref-type="bibr" rid="B178">178</xref>). ATP levels are naturally reduced with increasing degree of adipocyte differentiation, putatively due to increased ATP demands for lipogenesis (<xref ref-type="bibr" rid="B179">179</xref>), and reduced levels are further exacerbated when electron transport chain inhibition occurs (<xref ref-type="bibr" rid="B178">178</xref>). Reduced mitochondrial biogenesis, ATP levels, and dysfunctional mitochondrial electron transport have been reported in both humans and animals with metabolic syndrome (<xref ref-type="bibr" rid="B173">173</xref>, <xref ref-type="bibr" rid="B179">179</xref>). PPARγ co-activator 1α (PGC-1α) is a master regulator of mitochondrial biogenesis and gene expression and is a potent co-activator of PPAR isoforms: expression in fat or muscle cells increases mtDNA content, expression of mitochondrial genes, and mitochondrial respiration (<xref ref-type="bibr" rid="B176">176</xref>). PGC-1α-stimulated biogenesis in the heart ultimately promotes overt heart failure, another mechanism through which metabolic dysfunction can lead to cardiac dysfunction (<xref ref-type="bibr" rid="B176">176</xref>). Biogenesis appears closely linked to adipocyte differentiation, as up-regulation of mitochondrial biogenesis is well-reported following induction of adipogenesis and for up to 10 days post-differentiation (<xref ref-type="bibr" rid="B177">177</xref>, <xref ref-type="bibr" rid="B180">180</xref>), suggesting that mitochondria are needed to supply the substrates and factors necessary to support adipogenesis-driven lipogenesis. Mitochondria also have functionally distinct roles in white vs. brown adipose tissue. White adipose tissue is composed of numerous depots of large lipid droplet adipocytes throughout the body and is essential for maintenance of metabolic health. Brown adipose tissue, in contrast, is smaller and localized to the neck and upper-chest in adult humans, and is composed of adipocytes with large numbers of smaller lipid droplets and more numerous mitochondria [reviewed in (<xref ref-type="bibr" rid="B180">180</xref>)]. In brown adipose tissue, the heat derived from thermogenesis is produced primarily by the high mitochondrial content of these cells, via oxidation of fatty acids and other components (<xref ref-type="bibr" rid="B180">180</xref>). Uncoupling proteins (UCPs) play a key role in this process, serving to uncouple mitochondrial respiration from ATP generation by inducing a proton leak, which subsequently allows for energy dissipation as heat (<xref ref-type="bibr" rid="B180">180</xref>).</p>
<p>Numerous environmental toxicants have been demonstrated to promote mitochondrial dysfunction, and these contaminants may also advance metabolic dysfunction, leading to obesity, and diabetes. Certain mitochondrial disorders that are characterized by impaired oxidative phosphorylation are also associated with disrupted lipid homeostasis: myoclonic epilepsy with ragged red fibers is associated with triglyceride accumulation in muscles and multiple symmetrical lipomatosis, a condition characterized by abnormally small white adipocytes containing numerous small lipid droplets rather than the classical large central droplet that displaces the nucleus (<xref ref-type="bibr" rid="B170">170</xref>). Mitochondrial oxidative phosphorylation inhibitors and protein synthesis inhibitors impair mitochondrial respiration and promote triglyceride accumulation in 3T3-L1 cells, which retain their precursor fibroblastic morphology and do not express adipocyte-specific markers (<xref ref-type="bibr" rid="B170">170</xref>, <xref ref-type="bibr" rid="B180">180</xref>). Previous research has demonstrated that treatment of 3T3-L1 cells with rotenone (a complex I inhibitor), antimycin A, stigmatellin, and myxothiazol (complex III inhibitors), and oligomycin (ATP synthase inhibitor) promoted triglyceride accumulation in a dose-dependent manner (<xref ref-type="bibr" rid="B170">170</xref>). Interestingly, these mitochondrial respiration inhibitors promoted triglyceride accumulation in numerous small lipid droplets, cells retained their fibroblastic morphology, and classical adipocyte-specific genes were not expressed in these cells (<xref ref-type="bibr" rid="B170">170</xref>), suggesting a differentiation-independent mechanism of triglyceride accumulation. Specifically, antimycin A, which inhibits complex III, induces triglyceride accumulation in pre-adipocytes via a putative differentiation-independent mechanism (<xref ref-type="bibr" rid="B170">170</xref>); these cells exhibit multi-vesicular lipid accumulation, reduced expression of standard differentiation markers (FABP4, C/EBP), and suppression of PPARγ and RXR, supporting other studies suggesting mitochondrial dysfunction may inhibit adipocyte differentiation (<xref ref-type="bibr" rid="B178">178</xref>).</p>
<p>We recently demonstrated a similar phenotype in experiments with pyraclostrobin, a strobilurin-class fungicide used on strawberries, spinach, and other produce items, with production of &gt;2 million pounds per year (<xref ref-type="bibr" rid="B181">181</xref>, <xref ref-type="bibr" rid="B182">182</xref>). Pyraclostrobin and other strobilurin fungicides have been demonstrated to inhibit complex III (<xref ref-type="bibr" rid="B183">183</xref>), suggesting a potential mechanism for metabolic disruption. We previously reported that pyraclostrobin, azoxystrobin, fluoxastrobin, and trifloxystrobin all induced both triglyceride accumulation and pre-adipocyte proliferation in 3T3-L1 cells (<xref ref-type="bibr" rid="B184">184</xref>). Previous research in 3T3-L1 cells and a human adipose-derived stem cell model suggested this did not occur through activation of PPARγ and that standard differentiation markers were lacking (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B185">185</xref>), supporting the case for a differentiation-independent mechanism. Mechanism was further interrogated in our laboratory through co-exposure experiments in 3T3-L1 cells; we reported that PPARγ antagonists did not protect against pyraclostrobin-mediated triglyceride accumulation (<xref ref-type="bibr" rid="B177">177</xref>). Instead, pyraclostrobin promoted mitochondrial dysfunction, including reduced ATP, mitochondrial membrane potential, basal mitochondrial respiration, ATP-linked respiration, and spare respiratory capacity (<xref ref-type="bibr" rid="B177">177</xref>). In addition, pyraclostrobin-treated cells exhibited reduced expression of genes regulating glucose transport, glycolysis, fatty acid oxidation, and lipogenesis (<xref ref-type="bibr" rid="B177">177</xref>). Lastly, co-treatment with a cAMP responsive element binding protein (CREB) inhibitor reduced pyraclostrobin-mediated triglyceride accumulation (<xref ref-type="bibr" rid="B177">177</xref>). These results all suggest that toxicants capable of disrupting mitochondrial function may also have the potential to affect metabolic health, via modulation of lipogenesis and other metabolic processes.</p>
<p>Similarly, a recent study reported that several samples of oil sands process-affected water (OSPW), wastewater produced during the extraction of bitumen from oil sands, exhibited PPARγ agonist activity and promoted triglyceride accumulation in 3T3-L1 cells (<xref ref-type="bibr" rid="B186">186</xref>). Causative ligand characterization identified several hydroxylated/polyoxygenated carboxylic acids and hydroxylated sulfates as the major PPARγ ligands (<xref ref-type="bibr" rid="B186">186</xref>); naphthenic acids, a mixture of carboxylic acids and natural component of petroleum, are a major component of OSPW. Interestingly, while these are posited as promoting adipogenesis via PPARγ activation, a recent publication demonstrated that naphthenic acids isolated from oil sands water acted to uncouple oxidative phosphorylation, inhibit respiration, and increase the production of ROS (<xref ref-type="bibr" rid="B187">187</xref>). As noted above, these are mechanisms that can promote triglyceride accumulation in cells, suggesting that this may be an additional mechanism for the observed adipogenic effects of these waters in the previous publication (<xref ref-type="bibr" rid="B186">186</xref>). Notably, this occurred at environmentally-relevant concentrations for OSPW, suggesting that this or a combination of these mechanisms may promote the environmental sample-induced adipogenicity.</p>
<p>Mitochondrial ROS is produced by pre-adipocytes during and throughout differentiation, and its presence activates several early-stage differentiation markers, including C/EBP, PPAR, and CREB (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B188">188</xref>). Direct impacts on adipogenesis appear less certain, which has been delineated in greater detail previously (<xref ref-type="bibr" rid="B189">189</xref>); research suggests that ROS may be essential for adipogenesis, but also may perturb the process. Some research has demonstrated that ROS promoted mitotic clonal expansion in 3T3-L1 cells (<xref ref-type="bibr" rid="B190">190</xref>), a necessary step prior to induction of differentiation. Other research has described inhibitory effects on differentiation, with ROS inhibiting both pre-adipocyte proliferation and adipocyte differentiation/triglyceride accumulation (<xref ref-type="bibr" rid="B180">180</xref>, <xref ref-type="bibr" rid="B191">191</xref>, <xref ref-type="bibr" rid="B192">192</xref>). Still other researchers, via co-treatment experiments utilizing antioxidants, demonstrated that ROS impacted differentiation but not pre-adipocyte proliferation: treatment with an antioxidant (reducing ROS) reduced lipid accumulation in mesenchymal stem cells (<xref ref-type="bibr" rid="B193">193</xref>). However, the varying cell models used for these experiments may mediate these apparent differences; all studies agree that ROS appear to modulate early-stage differentiation, though the mechanisms of this modulation appear to vary based on cell lines, sources, and experimental details.</p>
<p>Several mitochondrial toxicants have been demonstrated to promote insulin resistance and/or metabolic syndrome in epidemiological studies, reviewed in detail previously (<xref ref-type="bibr" rid="B172">172</xref>, <xref ref-type="bibr" rid="B194">194</xref>), though this research area has as of yet received limited attention in the context of metabolic disruption. Several organochlorine pesticides have been implicated in metabolic effects via mitochondrial dysfunction. Specifically, atrazine has been demonstrated to directly inhibit complexes I and III, reducing oxygen consumption and leading to accumulation of superoxides; chronic exposure in rats has been demonstrated to decrease basal metabolic rate, and increase body weight, intra-abdominal fat, and promote insulin resistance independent of food intake or activity levels (<xref ref-type="bibr" rid="B172">172</xref>, <xref ref-type="bibr" rid="B195">195</xref>). Much of the remaining literature has focused on the role of polychlorinated biphenyls (PCBs). Several congeners have been demonstrated to promote mitochondrial dysfunction <italic>in vitro</italic> (<xref ref-type="bibr" rid="B196">196</xref>, <xref ref-type="bibr" rid="B197">197</xref>), exposure resulted in/exacerbated obesity, insulin resistance, and hyperinsulinemia in mice (<xref ref-type="bibr" rid="B198">198</xref>), and higher exposure to PCBs has been linked to increased risk of obesity, dyslipidemia, and/or insulin resistance in a number of epidemiological studies (<xref ref-type="bibr" rid="B199">199</xref>–<xref ref-type="bibr" rid="B202">202</xref>).</p>
</sec>
<sec id="s4">
<title>Available <italic>in vitro</italic> Models of Adipogenesis and Metabolic Disruption</title>
<p>Numerous <italic>in vitro</italic> models have been developed and utilized for the purpose of identifying potential metabolic disrupting chemicals, reviewed in detail previously (<xref ref-type="bibr" rid="B203">203</xref>, <xref ref-type="bibr" rid="B204">204</xref>). Generally, these models can be described as assessing two key parameters of adipocyte development: commitment to the adipocyte lineage from multipotent precursor cells (generally through the use of mesenchymal stem cell (MSC) models) and differentiation into mature adipocytes (generally through the use of pre-adipocyte models). MSC models have the additional benefit of being capable of assessing both endpoints, though are seemingly less frequently utilized than the available pre-adipocyte models. In addition, several research groups have begun to report on the three-dimensional culture of pre-adipocytes, which may shed additional light on mechanisms in a more physiologically relevant system. All of these assays are lengthy and their relative abilities to correctly identify chemicals may depend on both cell line and cell source. As such, there is a critical need to develop better methods for correctly predicting metabolic disruptors. While murine models have historically been used preferentially, a growing number of species utilized and a growing movement toward utilization of human models may help expand our understanding of translational mechanisms and potential environmental contaminant impacts on human health.</p>
<p>Perhaps the best known pre-adipocyte model is the 3T3-L1 mouse cell line. First described in the 1970's, it has proven reliable as an <italic>in vitro</italic> screen over several decades for identifying likely obesogenic chemicals <italic>in vivo</italic> (<xref ref-type="bibr" rid="B205">205</xref>, <xref ref-type="bibr" rid="B206">206</xref>). These cells are already committed to the adipocyte lineage and cannot develop into other cell types; however, they generally require activation of particular signaling pathways to promote further development. Following exposure to adipogenic chemicals, these cells differentiate into adipocytes, accumulate triglycerides, and come to resemble a mature human white fat cell (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B205">205</xref>, <xref ref-type="bibr" rid="B206">206</xref>). While 3T3-L1 cells have seemingly come to be considered the de facto model of adipogenesis, some inherent concerns remain about their utility. As we have described recently (<xref ref-type="bibr" rid="B60">60</xref>), while this line has been well-characterized (<xref ref-type="bibr" rid="B207">207</xref>), it is somewhat unreliable in sourcing. For example, while we know much about the molecular mechanisms underpinning the development of mature adipocytes based on this cell line, nuclear receptor expression related to adipogenesis is markedly different between different lots and sources of this cell line (<xref ref-type="bibr" rid="B60">60</xref>). Moreover, on investigation into this apparent discord in source, we discovered that the American Type Culture Collection (ATCC) maintains five distinct lots of 3T3-L1 cells, which all seemingly have differing degrees of differentiation success. This issue with cell line integrity was highlighted in a recent paper (<xref ref-type="bibr" rid="B208">208</xref>), suggesting that these differences can contribute to real discrepancies in the ability to replicate findings across laboratories. As the current ATCC cells are meaningfully different in the expression of key adipogenic pathways from the Zenbio-sourced cells (which are sourced from the isolating laboratory), it is unclear whether our understanding of the mechanisms underlying adipogenesis are from the original cells, the ATCC cells, or where these research paths diverge. Care needs to be taken to assess reproducibility across stocks and between laboratories and carefully untangle where the research underlying this cell line belongs. Other pre-adipocyte models also exist, including the OP9 mouse bone marrow-derived stromal pre-adipocyte cell line (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>), a line that allows for considerably faster differentiation, though which we have demonstrated to exhibit different nuclear receptor expression and differing degrees of responsiveness to adipogenic chemicals (<xref ref-type="bibr" rid="B60">60</xref>). These varying pre-adipocyte models allow for assessments of varying molecular pathways important for the process of differentiation via both source of the cells and species [discussed further in (<xref ref-type="bibr" rid="B204">204</xref>)].</p>
<p>Various multipotent mesenchymal cells and cell lines (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>) offer the additional ability to assess commitment to the adipocyte lineage as a distinct process from adipocyte differentiation (<xref ref-type="bibr" rid="B48">48</xref>). MSC use and applicability in adipogenesis research has been reviewed in detail previously (<xref ref-type="bibr" rid="B209">209</xref>). The variability of these cell lines are reportedly lower than the pre-adipocyte models, they are purportedly easier to isolate and culture, and they have additional utility in that they can be utilized to assess both differentiation of adipocytes but also commitment to the adipocyte lineage vs. other cell lineages. For example, many researchers have utilized these cell lines to evaluate the interplay between commitment to the osteogenic vs. adipogenic lineages following exposure to specific environmental contaminants (<xref ref-type="bibr" rid="B210">210</xref>–<xref ref-type="bibr" rid="B213">213</xref>). Recent work elegantly described a novel protocol for evaluating both adipogenic lineage commitment and subsequent differentiation as distinct processes in primary MSCs (<xref ref-type="bibr" rid="B48">48</xref>), which has been described previously for the C3H10T1/2 stem cell model (<xref ref-type="bibr" rid="B214">214</xref>, <xref ref-type="bibr" rid="B215">215</xref>). These advancements raise the utility of this model and warrants further investigation into replicability, reproducibility of this model across laboratories, and comparisons of translation to human health relative to the pre-adipocyte models currently utilized.</p>
<p>Lastly, a number of research labs have begun to describe spheroid cell cultures of adipocyte models (<xref ref-type="bibr" rid="B216">216</xref>–<xref ref-type="bibr" rid="B220">220</xref>), which may carry some inherent benefits over the standard adherent monolayer cultures. These studies have suggested that spheroid culture improves the efficiency, extent, and/or speed of differentiation (<xref ref-type="bibr" rid="B216">216</xref>–<xref ref-type="bibr" rid="B221">221</xref>), retains the multipotent potential of these cells (<xref ref-type="bibr" rid="B217">217</xref>, <xref ref-type="bibr" rid="B222">222</xref>), and transcriptomic analyses have suggested a potentially more representative model of adipocyte gene expression relative to known <italic>in vivo</italic> mechanisms (<xref ref-type="bibr" rid="B216">216</xref>). These models may allow for a more comprehensive understanding of adipose physiology than was possible via interrogation of the monolayer cell cultures, and should be evaluated further for replicability and translation potential relative to the standard monolayer cultures.</p>
</sec>
<sec id="s5">
<title>Metabolic Disruption Potential of Environmental Mixtures</title>
<p>As noted above, the assessments of environmental samples have proven an interesting new approach to evaluating potential mixture toxicity. With tens of thousands of chemicals in use and new chemicals regularly added, there are too many to characterize individually, and certainly no capabilities to assess all potential combinations of them (<xref ref-type="bibr" rid="B223">223</xref>, <xref ref-type="bibr" rid="B224">224</xref>). Body burden studies have and continue to report human exposure to hundreds of chemicals on a regular basis (<xref ref-type="bibr" rid="B225">225</xref>, <xref ref-type="bibr" rid="B226">226</xref>), demonstrating the problem of realistic mixture exposure studies. To add to the complexity, research has reported additive effects on several hormone receptors both <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B227">227</xref>–<xref ref-type="bibr" rid="B231">231</xref>), demonstrating that mixtures can induce effects at levels below those induced by individual chemicals. From a toxicological perspective, evaluating whole environmental samples: wastewater, surface/groundwater, indoor house dust, air samples, etc. for biological activities has emerged as a promising tact to assess potential adverse health concerns from exposure to actual mixtures present in the environment, given that it can evaluate more realistic environmentally relevant exposures (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Utility of Utilizing Environmental Mixtures for Human Health Assessments. Graphical depiction comparing individual chemicals and environmental mixtures for the assessment of potential human health effects. While environmental mixtures have less use in identifying causative chemicals in all cases (though tools like effect directed analysis (EDA) and toxicity identification evaluation (TIE) can be used to elucidate this), these mixtures are more relevant in reflecting the suite of chemicals that people are exposed to on a daily basis than utilizing single chemicals alone, and more often reflect actual environmental exposure concentrations. In this figure, the blue lines indicate positive relationships and the red lines indicate difficulty for single chemicals or mixtures in assessing the related outcome.</p>
</caption>
<graphic xlink:href="fendo-10-00039-g0003"></graphic>
</fig>
<p>Numerous natural and exogenous contaminants can contribute to human exposure; as such, measuring the total receptor bioactivities has proven useful for assessing the total magnitude of potential effects (<xref ref-type="bibr" rid="B232">232</xref>–<xref ref-type="bibr" rid="B239">239</xref>). While analytical chemistry techniques and equipment have drastically improved, allowing for more precise measurements of contaminants at lower concentrations, recent research has suggested we lack complete information on all causative bioactive chemicals present in the environment (<xref ref-type="bibr" rid="B240">240</xref>, <xref ref-type="bibr" rid="B241">241</xref>). While non-targeted analytical efforts have improved, we still lack sufficient software and comprehensive protocols to enable robust and reproducible non-targeted assessments of contaminants across laboratories. To address this need of addressing mixture toxicity without necessarily understanding the full chemical complexity, bioassays have been utilized to assess biological activities of actual environmental samples. Reporter gene assays are one such commonly-utilized tool, assessing total receptor activities (agonism and antagonism), and valued due to their low cost, ease of use, reliability, high sensitivity, and ease of adapting for multiple receptors (<xref ref-type="bibr" rid="B227">227</xref>–<xref ref-type="bibr" rid="B244">244</xref>). These assays provide the capability to assess the total receptor activity of potentially numerous low-concentration EDCs (without identifying each causative chemical) rather than assessing each constituent chemical individually.</p>
<p>Applying this method to human epidemiological research has shown great potential; a number of researchers have rigorously characterized how <italic>in vivo</italic> mixtures of contaminants correspond with total hormone receptor bioactivities of human and animal matrices (serum, tissues, etc.) (<xref ref-type="bibr" rid="B245">245</xref>–<xref ref-type="bibr" rid="B251">251</xref>). Moreover, some researchers have begun to utilize bioactivities directly to assess human health outcomes. For example, researchers have correlated the total placental estrogenic activity with increased reproductive malformations (<xref ref-type="bibr" rid="B252">252</xref>) and impaired motor development (<xref ref-type="bibr" rid="B253">253</xref>), total adipose estrogenic activity with increased risk for breast cancer (<xref ref-type="bibr" rid="B254">254</xref>), and placental estrogenic activity with increased birth weight in boys (<xref ref-type="bibr" rid="B255">255</xref>). Other research has failed to report significant associations, including a lack of any association between adipose estrogenic activity and risk for type-2 diabetes (<xref ref-type="bibr" rid="B256">256</xref>), potentially due to a greater role for other receptors in pathogenesis (<xref ref-type="bibr" rid="B257">257</xref>). These studies demonstrate the potential utility of this method, particularly when targeted based on a comprehensive understanding of etiology and molecular mechanisms.</p>
<p>Several studies have begun to apply these techniques to metabolic endpoints, assessing pertinent receptor bioactivities (GR, PPARγ, and others) as well as utilizing less high-throughput adipogenesis or other assays for predicting <italic>in vivo</italic> metabolic disruption potentials. Some of these environmental case studies are discussed in greater detail below:</p>
<sec>
<title>Metabolic Disruption Potential of Indoor House Dust</title>
<p>As noted above, numerous studies have documented the detection of EDCs from diverse chemical classes in indoor house dust samples from a variety of sources. A number of studies have assessed the bioactivities for solvent-extracted house dust, reporting PPARγ, GR, and ER agonist activities as well as AR and TR antagonist activities, at concentrations ≥ 15 μg dust equivalence per mL (DEQ/mL, mass of extracted dust per volume of assay medium) (<xref ref-type="bibr" rid="B258">258</xref>–<xref ref-type="bibr" rid="B260">260</xref>). Our laboratory also assessed the modulation of PPARγ by house dust extracts, reporting that 21 of 24 examined indoor house dust extracts exhibited significant PPARγ binding at 3 mg DEQ/mL (120 μg dust per assay well) using a relative binding affinity assay (<xref ref-type="bibr" rid="B261">261</xref>) and 15 of 25 extracts activated PPARγ at ≤ 50% of the maximal positive control response at concentrations ≥100 μg DEQ/mL (4 μg/well) using a commercially-available reporter assay (<xref ref-type="bibr" rid="B262">262</xref>, <xref ref-type="bibr" rid="B263">263</xref>). This work demonstrated activation of pathways known to regulate adipogenesis at very low concentrations, and subsequently informed our follow-up studies examining higher-order effects on adipogenesis.</p>
<p>We recently evaluated &gt;40 common SVOCs that are routinely detected in indoor house dust samples for adipogenic activity in the 3T3-L1 murine pre-adipocyte cell model. We found that &gt; two-thirds of these chemicals independently induced significant triglyceride accumulation and/or pre-adipocyte proliferation (<xref ref-type="bibr" rid="B184">184</xref>). Specifically, pyraclostrobin (strobilurin fungicide), dibutyl phthalate (DBP), tert-butyl-phenyl diphenyl phosphate (TBPDP), and the isopropylated triaryl phosphates (ITPs, mixture of isomers) exhibited near or supra-maximal triglyceride accumulation relative to the rosiglitazone (positive control)-induced maximum (<xref ref-type="bibr" rid="B184">184</xref>). We further assessed eleven house dust extracts collected from central North Carolina (NC), USA households; we found that ten of these 11 extracts exhibited significant triglyceride accumulation and/or pre-adipocyte proliferation at &lt; 20 μg of dust/well (<xref ref-type="bibr" rid="B184">184</xref>). This activity occurred at orders of magnitude lower concentrations than those the EPA estimates children to consume each day. As such, this raises concerns for potential impacts on <italic>in vivo</italic> metabolic health.</p>
<p>A recent follow-up to this study evaluated the adipogenic activity of 137 house dust extracts from central NC households and attempted to determine putative causative chemicals, molecular mechanisms, and potential impacts on human metabolic health (<xref ref-type="bibr" rid="B264">264</xref>). We reported that 90% of the dust extracts exhibited significant adipogenic activity, &lt; 60% via significant triglyceride accumulation, and &gt;70% of samples via significant pre-adipocyte proliferation, with &gt;40% of effects occurring at &lt; 10 μg dust/well (<xref ref-type="bibr" rid="B264">264</xref>). Increasing dust-induced triglyceride accumulation was positively correlated with serum thyroid stimulating hormone levels in adult residents, and negatively correlated with serum free triiodothyronine (T3) and thyroxine (T4) (<xref ref-type="bibr" rid="B264">264</xref>). Interestingly, proliferation tended to be positively correlated with residents' body mass index (BMI; <italic>p</italic> &lt; 0.10), potentially suggesting adipogenic chemicals present in the dust are associated with the weights of residents, but further research with larger sample sizes are needed to substantiate this. We further assessed TR antagonism as a potential contributory causative mechanism in these effects, and found that TRβ antagonism of these extracts (<xref ref-type="bibr" rid="B265">265</xref>) was positively correlated with triglyceride accumulation (<xref ref-type="bibr" rid="B264">264</xref>). Both T3 co-treatment and siRNA knock-down of TR inhibited the dust-induced triglyceride accumulation of these extracts, supporting the role of TR antagonism as a contributory molecular mechanism.</p>
</sec>
<sec>
<title>Metabolic Disruption Potential of Oil and Gas-Associated Wastewaters</title>
<p>Three separate sets of studies have assessed different aspects of oil and gas operations and metabolic disruption, reporting <italic>in vitro</italic> and/or <italic>in vivo</italic> evidence of metabolic disruption by oil and gas associated environmental mixtures. The first assessed three replicate samples of oil sands process-affected water (OSPW), wastewater produced during the extraction of bitumen from oil sands (<xref ref-type="bibr" rid="B186">186</xref>). They reported that an OSPW sample activated PPARγ at concentrations as low as 0.025x relative water concentration (40-fold dilution relative to pure water). This sample was further fractionated, with the majority of PPARγ activity in fractions two and five (five fractions), and fractions three through five exhibited significant triglyceride accumulation and induction of adipogenic genes (fatty acid binding protein and lipoprotein lipase). A pull-down assay and chemical analysis was further utilized to identify the causative ligands present in fraction five that were inducing the adipogenic effects; this analysis revealed hydroxylated/polyoxygenated carboxylic acids and hydroxylated sulfates as the major PPARγ ligands inducing adipogenesis in these samples (<xref ref-type="bibr" rid="B186">186</xref>), though the small sample size requires further substantiation.</p>
<p>Another set of studies assessed the metabolic disruption potential of crude oil singly or mixed with Corexit oil dispersant mixture (<xref ref-type="bibr" rid="B266">266</xref>, <xref ref-type="bibr" rid="B267">267</xref>). To distinguish these mixtures, they utilized several simpler mixtures in culture media, including: Corexit 9500 + MC252 oil, varying dilutions of MC252 oil, and varying dilutions of Corexit with corn oil; they found that the Corexit + oil treatments stimulated PPARγ, while the MC252 oil alone did not, suggesting a component of Corexit promoting the observed effects (<xref ref-type="bibr" rid="B267">267</xref>). The Corexit + oil mixture was further fractionated to determine causative ligands, with Tween 80 and dioctyl sodium sulfosuccinate (DOSS) identified as highly abundant chemicals in the active fraction (<xref ref-type="bibr" rid="B267">267</xref>). DOSS was further demonstrated to be active in PPAR response element-luciferase transgenic mice and stimulate triglyceride accumulation and expression of fatty acid binding protein (Fabp4) in 3T3-L1 cells (<xref ref-type="bibr" rid="B267">267</xref>). Follow-up work assessed the Corexit + oil mixture and Corexit alone for activation of RXRα, finding dose-dependent activation, presumably mediated by Corexit constituents (<xref ref-type="bibr" rid="B266">266</xref>). Constituent chemicals were further evaluated, and DOSS, Span 80, and Tween 80 all demonstrated some degree of RXRα activity, with Span 80 also stimulating triglyceride accumulation and adipocyte gene expression in 3T3-L1 cells. Interestingly, a combination of DOSS and Span 80 resulted in putative synergistic effects on adipocyte differentiation, potentially due to diverging molecular mechanisms (Span 80 exhibited a much more efficacious response for RXRα than PPARγ, while DOSS exhibited no RXRα activity but did activate PPARγ) (<xref ref-type="bibr" rid="B266">266</xref>).</p>
<p>The last set of studies, from our laboratory, evaluated unconventional oil and gas associated wastewater and chemicals. Our work on this topic began with receptor activity testing for 24 common hydraulic fracturing chemicals, reporting that 21 and 7 chemicals antagonized AR and TR in two cell-based assays, and that mixtures of these chemicals appeared to act synergistically for TR and additively for AR (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B268">268</xref>). We further documented AR and TR antagonist activities in surface, ground, and/or drinking water near UOG operations in several regions, including CO, WY, WV, and ND [(<xref ref-type="bibr" rid="B268">268</xref>), Kassotis et al., in preparation, (<xref ref-type="bibr" rid="B269">269</xref>–<xref ref-type="bibr" rid="B271">271</xref>)], and evaluated a mixture of 23 common UOG chemicals via a gestational exposure experiment in C57 mice, reported putative metabolic effects (offspring exhibited increased body weights, among other effects) (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). We further interrogated this by evaluating the ability of this 23-mix, several UOG wastewater samples, and several UOG wastewater-impacted surface water samples to stimulate adipogenesis in 3T3-L1 cells and activate PPARγ in a reporter gene assay (<xref ref-type="bibr" rid="B35">35</xref>). We demonstrated that UOG wastewater samples exhibited significant triglyceride accumulation and/or pre-adipocyte proliferation at relative water concentrations as low as 0.001x, UOG-impacted surface water extracts at concentrations as low as 0.04x, and the 23-mix at 1 μM; these effects co-occurred with PPARγ activation for some samples but not others (<xref ref-type="bibr" rid="B35">35</xref>), suggesting differing mechanisms. Related work demonstrated highly efficacious triglyceride accumulation for various non-ionic alkylphenol and alcohol polyethoxylates in the absence of PPARγ activation and potentially mediated by TR antagonism (<xref ref-type="bibr" rid="B272">272</xref>). These compounds are reportedly found at high concentrations in UOG wastewater (<xref ref-type="bibr" rid="B273">273</xref>–<xref ref-type="bibr" rid="B275">275</xref>) and may be responsible for some of the observed non-PPARγ-mediated effects observed in the UOG samples.</p>
</sec>
</sec>
<sec id="s6">
<title>Potential Utility of High-Throughput Databases to Predicting Metabolic Disruption</title>
<p>The costs and time investments associated with <italic>in vivo</italic> examination of putative metabolism disruptors are prohibitively high; as such, utilizing lower-order testing and screening is critical to target higher-order testing on chemicals most likely to be active. Application of numerous <italic>in vitro</italic> models for assessing putative “obesogens” or “metabolic disruptors” over the last several decades has revealed numerous contaminants capable of affecting metabolic health (<xref ref-type="bibr" rid="B18">18</xref>), with recent publications suggesting that these contaminants are likely common in indoor and outdoor environments (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B184">184</xref>, <xref ref-type="bibr" rid="B272">272</xref>). While these pre-adipocyte and mesenchymal stem cell models are useful in determining potential <italic>in vivo</italic> metabolic disruptors, they are also time and energy intensive and their relative abilities to correctly identify chemicals may depend on both cell line and source. Further, their mechanisms of assessing adipogenic commitment, adipocyte differentiation, adipocyte proliferation, and/or lipid accumulation may not capture the full spectrum of endpoints that compose metabolic dysfunction more broadly, particularly endpoints related to “diabetogens”. As such, there is a critical need to develop better methods for correctly predicting metabolic disruptors, and while more simplistic models such as activation of PPARγ are often applied, the vast suite of mechanisms influencing this process (discussed above) require a more holistic approach to integrating causative molecular mechanisms. Several high-throughput (HTP) screening programs now exist (Tox21, ToxCast) that report activity across numerous molecular mechanisms for thousands of chemicals, many that are known to be relevant to metabolic health. Harnessing these data sets to broadly assess high-scoring chemicals (across relevant molecular pathways for select endpoints of interest) for more targeted higher-order testing may provide a valuable tool for reducing time and research costs and achieving a more broad assessment of the tens of thousands of commercial chemicals for potential contribution to adverse health outcomes in humans and/or animals.</p>
<p>This issue of utilizing HTP data in predictive models is not new and has been applied by a number of researchers to various <italic>in vivo</italic> endpoints, with varying degrees of success (<xref ref-type="bibr" rid="B276">276</xref>). Most of these methods have utilized ToxCast Phase I data, due to the more recent release (October 2015) of Phase II results, and as a result, some of the inherent issues reported by these studies have since been addressed. For example, Schwarzman et al. attempted to build a model to predict breast carcinogens, though had insufficient data on particular endpoints critical to altered mammary development (<xref ref-type="bibr" rid="B277">277</xref>). Many of the pathways missing, including prolactin, progesterone, and estrogen receptor beta effects, among others, are now pathways with associated assays in the Phase II database. Russell et al. applied a broad approach to predicting 60 <italic>in vivo</italic> endpoints, 56 of which were predicted at &lt; 55% accuracy (<xref ref-type="bibr" rid="B278">278</xref>), though notably did not aggregate assays to predict <italic>in vivo</italic> endpoints. Given that health outcomes are nearly always driven by overlapping molecular pathways, this is not altogether surprising. Other researchers utilized assay aggregation and were more successful in building predictive models that performed with promising accuracy (&gt;70%). Martin et al. utilized a suite of ToxCast assays to develop a predictive model for rat reproductive toxicity, achieving ~75% accuracies for training and test sets (<xref ref-type="bibr" rid="B279">279</xref>). Notably, this model incorrectly predicted five of 21 external validation chemicals as predicted negatives, all of which reduced early offspring survival with limited accompanying effects on reproductive performance or reproductive tract development, suggesting a gap in assays targeting these endpoints. Another model applied ToxCast data to rat prenatal developmental toxicity, with &gt;70% accuracy with species-specific models (<xref ref-type="bibr" rid="B280">280</xref>), and found that if they further refined this to more specific developmental outcomes, they got even better predictive success (80–90%). Liu et al. utilized both Phase I and Phase II data to predict hepatotoxicity (hypertrophy, injury, and proliferative lesions), and reported 53–61% accuracy using only Phase I data, but &gt;80% when utilizing the expanded Phase II data (<xref ref-type="bibr" rid="B281">281</xref>).</p>
<p>Recently, Auerbach et al. presented predictive models of putative obesogenic and/or diabetogenic chemicals through analyzing ToxCast HTP results (<xref ref-type="bibr" rid="B282">282</xref>). The researchers, utilizing experts in a diversity of metabolic health disciplines, selected known molecular pathways that had been previously demonstrated to modulate metabolic health, and combined them into a combined score metric for predicting likely vs. less-likely metabolic disrupting chemicals. Janesick et al. recently tested a portion of this method, utilizing a suite of assays deemed relevant for adipocyte differentiation (16 assays across 8 molecular mechanisms) to assess 24 chemicals (11 with highest activation scores across the selected assays, 6 with medium activation scores, and 7 presumed negative controls with low activation scores) for activation of RXRα, PPARγ, and triglyceride accumulation in 3T3-L1 cells (<xref ref-type="bibr" rid="B47">47</xref>). They reported that 7 of 17 high and medium-scoring and 2 of 7 low-scoring chemicals were active in 3T3-L1 cells, suggesting poor predictivity (high rates of both false positives and false negatives). The authors suggested several potential hypotheses for the poor performance, including: poor performance of PPARγ assays, incorrect selection of assays for the predictive model, and improper weighting of endpoints (rather than based on mechanism importance) and assays within each endpoint (rather than based on assay performance).</p>
<p>We recently undertook an effort to improve the predictive utility of this model by expanding the pathways and attempting to incorporate some of the suggestions made by Janesick et al. (<xref ref-type="bibr" rid="B47">47</xref>). Among these, we expanded the outcome by performing a targeted literature search on all chemicals and any evidence of effects on metabolic health. This model performed best when used as a gross metabolic disruption prediction model, using literature searches to identify any <italic>in vitro</italic> or <italic>in vivo</italic> evidence of adipogenesis or disrupted metabolic health (weight gain, adipose development, insulin/glucose signaling, effects on appetite/satiety, etc.). When applied to a novel set of chemicals for which we had assessed adipogenic activities in 3T3-L1 cells (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B184">184</xref>), the original prediction model performed well at predicting gross metabolic disruption; we observed low rates of both false negatives (7.9%) and false positives (7.9%), and an apparent accuracy of 84% (<xref ref-type="bibr" rid="B283">283</xref>).</p>
<p>We also attempted to bolster this model through inclusion of additional pathways known to modulate metabolic health, in hopes of reducing false negatives, though discovered that expanding the model to incorporate all of these pathways would produce an inappropriately large and unwieldy model with a considerably inflated false positive detection rate. Nonetheless, we determined that additional pathways could be incorporated into the model if there were a better method for de-selecting less important or artifactual pathways. Z score corrections were designed to address this by removing the bioactivities nearest cytotoxicity as presumed false negatives/non-specific effects. In our analysis, utilizing the cytotoxicity-derived z score values to remove putative cytotoxicity-impacted pathways was effective at reducing false positives, but at the expense of increasing false negatives. We determined that utilizing Z score corrections (even with a low threshold) was not an effective option to clarify important pathways and reduce false positives.</p>
<p>Results from these publications suggest that further improvements should focus on bolstering molecular pathways with poor-performing assays or where replicate experiments and/or assays are not available for a given endpoint within ToxCast. Ensuring data integrity and robustness is of profound importance to correct predictions. Efforts such as this have tremendous putative utility, as screening all chemicals and mixtures of chemicals for all endpoints is not feasible, and determining a screen of HTP assays could save tremendous time and cost and allow for a dramatically narrowed scope of testing <italic>in vivo</italic>. Further testing is required to substantiate this adipogenic prediction model for predicting <italic>in vivo</italic> metabolic disruption across a larger chemical space, but these preliminary results and success with other complex biological effects demonstrate a clear potential for implementation into predicting metabolic disruption and potentially helping reduce and better target <italic>in vitro</italic> and <italic>in vivo</italic> chemical assessments in the future.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>CK and HS planned and outlined the proposed review. CK wrote the review, and HS read and bolstered the review via feedback and guidance.</p>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> Project supported by a grant (R01 ES016099) and a fellowship (F32 ES027320; CK) from the National Institute of Environmental Health Sciences.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chamorro-Garcia</surname><given-names>R</given-names></name><name><surname>Sahu</surname><given-names>M</given-names></name><name><surname>Abbey</surname><given-names>RJ</given-names></name><name><surname>Laude</surname><given-names>J</given-names></name><name><surname>Pham</surname><given-names>N</given-names></name><name><surname>Blumberg</surname><given-names>B</given-names></name></person-group>. <article-title>Transgenerational inheritance of increased fat depot size, stem cell reprogramming, and hepatic steatosis elicited by prenatal exposure to the obesogen tributyltin in mice</article-title>. <source/>Environ Health Perspect. (<year>2013</year>) <volume>121</volume>:<fpage>359</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1205701</pub-id><pub-id pub-id-type="pmid">23322813</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heindel</surname><given-names>JJ</given-names></name><name><surname>vom Saal</surname><given-names>FS</given-names></name><name><surname>Blumberg</surname><given-names>B</given-names></name><name><surname>Bovolin</surname><given-names>P</given-names></name><name><surname>Calamandrei</surname><given-names>G</given-names></name><name><surname>Ceresini</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Parma consensus statement on metabolic disruptors</article-title>. <source/>Environ Health (<year>2015</year>) <volume>14</volume>:<fpage>54</fpage>. <pub-id pub-id-type="doi">10.1186/s12940-015-0042-7</pub-id><pub-id pub-id-type="pmid">26092037</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ycaza</surname><given-names>J</given-names></name><name><surname>Blumberg</surname><given-names>B</given-names></name></person-group>. <article-title>The environmental obesogen tributyltin chloride acts via peroxisome proliferator activated receptor gamma to induce adipogenesis in murine 3T3-L1 preadipocytes</article-title>. <source/>J Steroid Biochem Mol Biol. (<year>2011</year>) <volume>127</volume>:<fpage>9</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2011.03.012</pub-id><pub-id pub-id-type="pmid">21397693</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patisaul</surname><given-names>HB</given-names></name><name><surname>Roberts</surname><given-names>SC</given-names></name><name><surname>Mabrey</surname><given-names>N</given-names></name><name><surname>McCaffrey</surname><given-names>KA</given-names></name><name><surname>Gear</surname><given-names>RB</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Accumulation and endocrine disrupting effects of the flame retardant mixture Firemaster(R) 550 in rats: an exploratory assessment</article-title>. <source/>J Biochem Mol Toxicol. (<year>2013</year>) <volume>27</volume>:<fpage>124</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1002/jbt.21439</pub-id><pub-id pub-id-type="pmid">23139171</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riu</surname><given-names>A</given-names></name><name><surname>McCollum</surname><given-names>CW</given-names></name><name><surname>Pinto</surname><given-names>CL</given-names></name><name><surname>Grimaldi</surname><given-names>M</given-names></name><name><surname>Hillenweck</surname><given-names>A</given-names></name><name><surname>Perdu</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Halogenated bisphenol-A analogs act as obesogens in zebrafish larvae (Danio rerio)</article-title>. <source/>Toxicol Sci. (<year>2014</year>) <volume>139</volume>:<fpage>48</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfu036</pub-id><pub-id pub-id-type="pmid">24591153</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>The Endocrine Disruption Exchange (TEDX)</collab></person-group>
<source/>TEDX List of Potential Endocrine Disruptors (<year>2018</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://endocrinedisruption.org/interactive-tools/tedx-list-of-potential-endocrine-disruptors/search-the-tedx-list">https://endocrinedisruption.org/interactive-tools/tedx-list-of-potential-endocrine-disruptors/search-the-tedx-list</ext-link></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skinner</surname><given-names>AC</given-names></name><name><surname>Ravanbakht</surname><given-names>SN</given-names></name><name><surname>Skelton</surname><given-names>JA</given-names></name><name><surname>Perrin</surname><given-names>EM</given-names></name><name><surname>Armstrong</surname><given-names>SC</given-names></name></person-group>
<article-title>Prevalence of obesity and severe obesity in US children, 1999–2016</article-title>. <source/>Pediatrics (<year>2018</year>) <volume>24</volume>:<fpage>1116</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2017-3459</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Hales</surname><given-names>CM, Carroll, MD, Fryar, CD, Ogden, CL,. Prevalence of Obesity Among Adults Youth: United States, 2015–2016. Hyattsville, MD: National Center for Health Statistics</given-names></name></person-group> (<year>2017</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/data/databriefs/db288.pdf">https://www.cdc.gov/nchs/data/databriefs/db288.pdf</ext-link></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz</surname><given-names>D</given-names></name><name><surname>Becerra</surname><given-names>M</given-names></name><name><surname>Jagai</surname><given-names>JS</given-names></name><name><surname>Ard</surname><given-names>K</given-names></name><name><surname>Sargis</surname><given-names>RM</given-names></name></person-group>. <article-title>Disparities in environmental exposures to endocrine-disrupting chemicals and diabetes risk in vulnerable populations</article-title>. <source/>Diabetes Care (<year>2018</year>) <volume>41</volume>:<fpage>193</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.2337/dc16-2765</pub-id><pub-id pub-id-type="pmid">29142003</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Dall</surname><given-names>TM</given-names></name><name><surname>Beronjia</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Semilla</surname><given-names>AP</given-names></name><name><surname>Chakrabarti</surname><given-names>R</given-names></name><etal></etal></person-group>
<source/>Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care (<year>2018</year>) <volume>41</volume>:<fpage>917</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">29567642</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biener</surname><given-names>A</given-names></name><name><surname>Cawley</surname><given-names>J</given-names></name><name><surname>Meyerhoefer</surname><given-names>C</given-names></name></person-group>. <article-title>The impact of obesity on medical care costs and labor market outcomes in the US</article-title>. <source/>Clin Chem. (<year>2018</year>) <volume>64</volume>:<fpage>108</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1373/clinchem.2017.272450</pub-id><pub-id pub-id-type="pmid">29097513</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klimentidis</surname><given-names>YC</given-names></name><name><surname>Beasley</surname><given-names>TM</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name><name><surname>Murati</surname><given-names>G</given-names></name><name><surname>Glass</surname><given-names>GE</given-names></name><name><surname>Guyton</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Canaries in the coal mine: a cross-species analysis of the plurality of obesity epidemics</article-title>. <source/>Proc Biol Sci. (<year>2011</year>) <volume>278</volume>:<fpage>1626</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1098/rspb.2010.1890</pub-id><pub-id pub-id-type="pmid">21106594</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>TJ</given-names></name><name><surname>Todd</surname><given-names>A</given-names></name><name><surname>O'Malley</surname><given-names>C</given-names></name><name><surname>Moore</surname><given-names>HJ</given-names></name><name><surname>Husband</surname><given-names>AK</given-names></name><name><surname>Bambra</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Community pharmacy-delivered interventions for public health priorities: a systematic review of interventions for alcohol reduction, smoking cessation and weight management, including meta-analysis for smoking cessation</article-title>. <source/>BMJ Open (<year>2016</year>) <volume>6</volume>:<fpage>e009828</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2015-009828</pub-id><pub-id pub-id-type="pmid">26928025</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baillie-Hamilton</surname><given-names>PF</given-names></name></person-group>. <article-title>Chemical toxins: a hypothesis to explain the global obesity epidemic</article-title>. <source/>J Altern Complement Med. (<year>2002</year>) <volume>8</volume>:<fpage>185</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1089/107555302317371479</pub-id><pub-id pub-id-type="pmid">12006126</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Bookout</surname><given-names>AL</given-names></name><name><surname>Downes</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>RT</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name><etal></etal></person-group>. <article-title>A nuclear receptor atlas: 3T3-L1 adipogenesis</article-title>. <source/>Mol Endocrinol. (<year>2005</year>) <volume>19</volume>:<fpage>2437</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1210/me.2004-0539</pub-id><pub-id pub-id-type="pmid">16051663</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>SY</given-names></name></person-group>. <article-title>Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors</article-title>. <source/>J Mol Endocrinol. (<year>2010</year>) <volume>44</volume>:<fpage>143</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1677/JME-09-0107</pub-id><pub-id pub-id-type="pmid">19741045</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niemela</surname><given-names>SM</given-names></name><name><surname>Miettinen</surname><given-names>S</given-names></name><name><surname>Konttinen</surname><given-names>Y</given-names></name><name><surname>Waris</surname><given-names>T</given-names></name><name><surname>Kellomaki</surname><given-names>M</given-names></name><name><surname>Ashammakhi</surname><given-names>NA</given-names></name><etal></etal></person-group>. <article-title>Fat tissue: views on reconstruction and exploitation</article-title>. <source/>J Craniofac Surg. (<year>2007</year>) <volume>18</volume>:<fpage>325</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1097/scs.0b013e3180333b6a</pub-id><pub-id pub-id-type="pmid">17414282</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heindel</surname><given-names>JJ</given-names></name><name><surname>Blumberg</surname><given-names>B</given-names></name><name><surname>Cave</surname><given-names>M</given-names></name><name><surname>Machtinger</surname><given-names>R</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Mendez</surname><given-names>MA</given-names></name><etal></etal></person-group>. <article-title>Metabolism disrupting chemicals and metabolic disorders</article-title>. <source/>Reprod Toxicol. (<year>2017</year>) <volume>68</volume>:<fpage>3</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.reprotox.2016.10.001</pub-id><pub-id pub-id-type="pmid">27760374</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coates</surname><given-names>ME</given-names></name><name><surname>Dickinson</surname><given-names>CD</given-names></name><name><surname>Harrison</surname><given-names>GF</given-names></name><name><surname>Kon</surname><given-names>SK</given-names></name><name><surname>Cummins</surname><given-names>SH</given-names></name><name><surname>Cuthbertson</surname><given-names>WF</given-names></name></person-group>. <article-title>Mode of action of antibiotics in stimulating growth of chicks</article-title>. <source/>Nature (<year>1951</year>) <volume>168</volume>:<fpage>332</fpage>. <pub-id pub-id-type="doi">10.1038/168332a0</pub-id><pub-id pub-id-type="pmid">14875083</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>RS</given-names></name><name><surname>Braude</surname><given-names>R</given-names></name><name><surname>Mitchell</surname><given-names>KG</given-names></name></person-group>. <article-title>Antibiotic and copper supplements for fattening pigs</article-title>. <source/>Br J Nutr. (<year>1955</year>) <volume>9</volume>:<fpage>378</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1079/BJN19550054</pub-id><pub-id pub-id-type="pmid">13284220</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>LM</given-names></name><name><surname>Yamanishi</surname><given-names>S</given-names></name><name><surname>Sohn</surname><given-names>J</given-names></name><name><surname>Alekseyenko</surname><given-names>AV</given-names></name><name><surname>Leung</surname><given-names>JM</given-names></name><name><surname>Cho</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences</article-title>. <source/>Cell (<year>2014</year>) <volume>158</volume>:<fpage>705</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.05.052</pub-id><pub-id pub-id-type="pmid">25126780</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>I</given-names></name><name><surname>Yamanishi</surname><given-names>S</given-names></name><name><surname>Cox</surname><given-names>L</given-names></name><name><surname>Methe</surname><given-names>BA</given-names></name><name><surname>Zavadil</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Antibiotics in early life alter the murine colonic microbiome and adiposity</article-title>. <source/>Nature (<year>2012</year>) <volume>488</volume>:<fpage>621</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/nature11400</pub-id><pub-id pub-id-type="pmid">22914093</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajslev</surname><given-names>TA</given-names></name><name><surname>Andersen</surname><given-names>CS</given-names></name><name><surname>Gamborg</surname><given-names>M</given-names></name><name><surname>Sorensen</surname><given-names>TI</given-names></name><name><surname>Jess</surname><given-names>T</given-names></name></person-group>. <article-title>Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics</article-title>. <source/>Int J Obes. (<year>2011</year>) <volume>35</volume>:<fpage>522</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/ijo.2011.27</pub-id><pub-id pub-id-type="pmid">21386800</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trasande</surname><given-names>L</given-names></name><name><surname>Blustein</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Corwin</surname><given-names>E</given-names></name><name><surname>Cox</surname><given-names>LM</given-names></name><name><surname>Blaser</surname><given-names>MJ</given-names></name></person-group>. <article-title>Infant antibiotic exposures and early-life body mass</article-title>. <source/>Int J Obes. (<year>2013</year>) <volume>37</volume>:<fpage>16</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/ijo.2012.132</pub-id><pub-id pub-id-type="pmid">22907693</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>AB</given-names></name><name><surname>Colton</surname><given-names>T</given-names></name><name><surname>Gundersen</surname><given-names>J</given-names></name><name><surname>Noller</surname><given-names>KL</given-names></name><name><surname>Tilley</surname><given-names>BC</given-names></name><name><surname>Strama</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Fertility and outcome of pregnancy in women exposed in utero to diethylstilbestrol</article-title>. <source/>N Engl J Med. (<year>1980</year>) <volume>302</volume>:<fpage>5</fpage>. <pub-id pub-id-type="doi">10.1056/NEJM198003133021105</pub-id><pub-id pub-id-type="pmid">7351908</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>AL</given-names></name><name><surname>Hubby</surname><given-names>MM</given-names></name><name><surname>Blough</surname><given-names>RR</given-names></name><name><surname>Azizi</surname><given-names>F</given-names></name></person-group>. <article-title>A comparison of pregnancy experience in DES-exposed and DES-unexposed daughters</article-title>. <source/>J Reprod Med. (<year>1980</year>) <volume>24</volume>:<fpage>62</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/00006254-198007000-00023</pub-id><pub-id pub-id-type="pmid">7359503</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>AL</given-names></name><name><surname>Scully</surname><given-names>RE</given-names></name><name><surname>Robboy</surname><given-names>SJ</given-names></name></person-group>
<article-title>Prenatal diethylstilbestrol exposure and human genital tract abnormalities</article-title>. <source/>Natl Cancer Inst Monogr. (<year>1979</year>) <volume>51</volume>:<fpage>11</fpage>.</mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoover</surname><given-names>RN</given-names></name><name><surname>Hyer</surname><given-names>M</given-names></name><name><surname>Pfeiffer</surname><given-names>RM</given-names></name><name><surname>Adam</surname><given-names>E</given-names></name><name><surname>Bond</surname><given-names>B</given-names></name><name><surname>Cheville</surname><given-names>AL</given-names></name><etal></etal></person-group>. <article-title>Adverse health outcomes in women exposed in utero to diethylstilbestrol</article-title>. <source/>N Engl J Med. (<year>2011</year>) <volume>365</volume>:<fpage>1304</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1013961</pub-id><pub-id pub-id-type="pmid">21991952</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newbold</surname><given-names>RR</given-names></name><name><surname>Bullock</surname><given-names>BC</given-names></name><name><surname>Mc Lachlan</surname><given-names>JA</given-names></name></person-group>. <article-title>Exposure to diethylstilbestrol during pregnancy permanently alters the ovary and oviduct</article-title>. <source/>Biol Reprod. (<year>1983</year>) <volume>28</volume>:<fpage>735</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1095/biolreprod28.3.735</pub-id><pub-id pub-id-type="pmid">6850046</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>CJ</given-names></name><name><surname>Cheng</surname><given-names>XJ</given-names></name><name><surname>Xia</surname><given-names>HF</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name></person-group>. <article-title>The endocrine disruptor diethylstilbestrol induces adipocyte differentiation and promotes obesity in mice</article-title>. <source/>Toxicol Appl Pharmacol. (<year>2012</year>) <volume>263</volume>:<fpage>102</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2012.06.003</pub-id><pub-id pub-id-type="pmid">22710028</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newbold</surname><given-names>RR</given-names></name><name><surname>Padilla-Banks</surname><given-names>E</given-names></name><name><surname>Jefferson</surname><given-names>WN</given-names></name></person-group>. <article-title>Environmental estrogens and obesity</article-title>. <source/>Mol Cell Endocrinol. (<year>2009</year>) <volume>304</volume>:<fpage>84</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2009.02.024</pub-id><pub-id pub-id-type="pmid">19433252</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newbold</surname><given-names>RR</given-names></name><name><surname>Padilla-Banks</surname><given-names>E</given-names></name><name><surname>Snyder</surname><given-names>RJ</given-names></name><name><surname>Jefferson</surname><given-names>WN</given-names></name></person-group>. <article-title>Perinatal exposure to environmental estrogens and the development of obesity</article-title>. <source/>Mol Nutr Food Res. (<year>2007</year>) <volume>51</volume>:<fpage>912</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.200600259</pub-id><pub-id pub-id-type="pmid">17604389</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newbold</surname><given-names>RR</given-names></name><name><surname>Padilla-Banks</surname><given-names>E</given-names></name><name><surname>Snyder</surname><given-names>RJ</given-names></name><name><surname>Phillips</surname><given-names>TM</given-names></name><name><surname>Jefferson</surname><given-names>WN</given-names></name></person-group>. <article-title>Developmental exposure to endocrine disruptors and the obesity epidemic</article-title>. <source/>Reprod Toxicol. (<year>2007</year>) <volume>23</volume>:<fpage>290</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.reprotox.2006.12.010</pub-id><pub-id pub-id-type="pmid">17321108</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatch</surname><given-names>EE</given-names></name><name><surname>Troisi</surname><given-names>R</given-names></name><name><surname>Palmer</surname><given-names>JR</given-names></name><name><surname>Wise</surname><given-names>LA</given-names></name><name><surname>Titus</surname><given-names>L</given-names></name><name><surname>Strohsnitter</surname><given-names>WC</given-names></name><etal></etal></person-group>. <article-title>Prenatal diethylstilbestrol exposure and risk of obesity in adult women</article-title>. <source/>J Dev Orig Health Dis. (<year>2015</year>) <volume>6</volume>:<fpage>201</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1017/S2040174415000033</pub-id><pub-id pub-id-type="pmid">25697972</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Nagel</surname><given-names>SC</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>
<article-title>Unconventional oil and gas chemicals and wastewater-impacted water samples promote adipogenesis via PPARγ-dependent and independent mechanisms in 3T3-L1 cells</article-title>. <source/>Sci Total Environ. (<year>2018</year>) 640–<volume>1</volume>:<fpage>1601</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2018.05.030</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Bromfield</surname><given-names>JJ</given-names></name><name><surname>Klemp</surname><given-names>KC</given-names></name><name><surname>Meng</surname><given-names>CX</given-names></name><name><surname>Wolfe</surname><given-names>A</given-names></name><name><surname>Zoeller</surname><given-names>RT</given-names></name><etal></etal></person-group>. <article-title>Adverse reproductive and developmental health outcomes following prenatal exposure to a hydraulic fracturing chemical mixture in female C57Bl/6 mice</article-title>. <source/>Endocrinology (<year>2016</year>) <volume>157</volume>:<fpage>3469</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1210/en.2016-1242</pub-id><pub-id pub-id-type="pmid">27560547</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Klemp</surname><given-names>KC</given-names></name><name><surname>Vu</surname><given-names>DC</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Meng</surname><given-names>CX</given-names></name><name><surname>Besch-Williford</surname><given-names>CL</given-names></name><etal></etal></person-group>. <article-title>Endocrine-disrupting activity of hydraulic fracturing chemicals and adverse health outcomes after prenatal exposure in male mice</article-title>. <source/>Endocrinology 156 (<year>2015</year>):4458–73. <pub-id pub-id-type="doi">10.1210/en.2015-1375</pub-id><pub-id pub-id-type="pmid">26465197</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stacy</surname><given-names>SL</given-names></name><name><surname>Brink</surname><given-names>LL</given-names></name><name><surname>Larkin</surname><given-names>JC</given-names></name><name><surname>Sadovsky</surname><given-names>Y</given-names></name><name><surname>Goldstein</surname><given-names>BD</given-names></name><name><surname>Pitt</surname><given-names>BR</given-names></name><etal></etal></person-group>. <article-title>Perinatal outcomes and unconventional natural gas operations in southwest pennsylvania</article-title>. <source/>PLoS ONE (<year>2015</year>) <volume>10</volume>:<fpage>e0126425</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0126425</pub-id><pub-id pub-id-type="pmid">26039051</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenzie</surname><given-names>LM</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Witter</surname><given-names>RZ</given-names></name><name><surname>Savitz</surname><given-names>DA</given-names></name><name><surname>Newman</surname><given-names>LS</given-names></name><name><surname>Adgate</surname><given-names>JL</given-names></name></person-group>. <article-title>Birth outcomes and maternal residential proximity to natural gas development in rural Colorado</article-title>. <source/>Environ Health Perspect. (<year>2014</year>) <volume>122</volume>:<fpage>412</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1306722</pub-id><pub-id pub-id-type="pmid">24474681</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jornayvaz</surname><given-names>FR</given-names></name><name><surname>Vollenweider</surname><given-names>P</given-names></name><name><surname>Bochud</surname><given-names>M</given-names></name><name><surname>Mooser</surname><given-names>V</given-names></name><name><surname>Waeber</surname><given-names>G</given-names></name><name><surname>Marques-Vidal</surname><given-names>P</given-names></name></person-group>. <article-title>Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study</article-title>. <source/>Cardiovasc Diabetol. (<year>2016</year>) <volume>15</volume>:<fpage>73</fpage>. <pub-id pub-id-type="doi">10.1186/s12933-016-0389-2</pub-id><pub-id pub-id-type="pmid">27141948</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curhan</surname><given-names>GC</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><name><surname>Spiegelman</surname><given-names>D</given-names></name><name><surname>Ascherio</surname><given-names>AL</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name></person-group>. <article-title>Birth weight and adult hypertension, diabetes mellitus, and obesity in US men</article-title>. <source/>Circulation (<year>1996</year>) <volume>94</volume>:<fpage>3246</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.94.12.3246</pub-id><pub-id pub-id-type="pmid">8989136</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirschler</surname><given-names>V</given-names></name><name><surname>Bugna</surname><given-names>J</given-names></name><name><surname>Roque</surname><given-names>M</given-names></name><name><surname>Gilligan</surname><given-names>T</given-names></name><name><surname>Gonzalez</surname><given-names>C</given-names></name></person-group>. <article-title>Does low birth weight predict obesity/overweight and metabolic syndrome in elementary school children?</article-title>
<source/>Arch Med Res. (<year>2008</year>) <volume>39</volume>:<fpage>796</fpage>–<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1016/j.arcmed.2008.08.003</pub-id><pub-id pub-id-type="pmid">18996294</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danielzik</surname><given-names>S</given-names></name><name><surname>Czerwinski-Mast</surname><given-names>M</given-names></name><name><surname>Langnase</surname><given-names>K</given-names></name><name><surname>Dilba</surname><given-names>B</given-names></name><name><surname>Muller</surname><given-names>MJ</given-names></name></person-group>. <article-title>Parental overweight, socioeconomic status and high birth weight are the major determinants of overweight and obesity in 5–7 y-old children: baseline data of the Kiel Obesity Prevention Study (KOPS)</article-title>. <source/>Int J Obes Relat Metab Disord. (<year>2004</year>) <volume>28</volume>:<fpage>1494</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ijo.0802756</pub-id><pub-id pub-id-type="pmid">15326465</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolins</surname><given-names>NE</given-names></name><name><surname>Quaynor</surname><given-names>BK</given-names></name><name><surname>Skinner</surname><given-names>JR</given-names></name><name><surname>Tzekov</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>OP9 mouse stromal cells rapidly differentiate into adipocytes: characterization of a useful new model of adipogenesis</article-title>. <source/>J Lipid Res. (<year>2006</year>) <volume>47</volume>:<fpage>450</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.D500037-JLR200</pub-id><pub-id pub-id-type="pmid">16319419</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>JM</given-names></name><name><surname>Doyle</surname><given-names>JR</given-names></name><name><surname>Fortin</surname><given-names>JP</given-names></name><name><surname>Kopin</surname><given-names>AS</given-names></name><name><surname>Ordovas</surname><given-names>JM</given-names></name></person-group>. <article-title>Development of an OP9 derived cell line as a robust model to rapidly study adipocyte differentiation</article-title>. <source/>PLoS ONE (<year>2014</year>) <volume>9</volume>:<fpage>e112123</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0112123</pub-id><pub-id pub-id-type="pmid">25409310</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>HK</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Beglov</surname><given-names>D</given-names></name><name><surname>Kozakov</surname><given-names>D</given-names></name><name><surname>Vajda</surname><given-names>S</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name><etal></etal></person-group>. <article-title>Ligand binding and activation of PPARgamma by Firemaster(R) 550: effects on adipogenesis and osteogenesis in vitro</article-title>. <source/>Environ Health Perspect. (<year>2014</year>) <volume>122</volume>:<fpage>1225</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1408111</pub-id><pub-id pub-id-type="pmid">25062436</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janesick</surname><given-names>AS</given-names></name><name><surname>Dimastrogiovanni</surname><given-names>G</given-names></name><name><surname>Vanek</surname><given-names>L</given-names></name><name><surname>Boulos</surname><given-names>C</given-names></name><name><surname>Chamorro-García</surname><given-names>R</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>On the utility of ToxCast and ToxPi as methods for identifying new obesogens</article-title>. <source/>Environ Health Perspect. (<year>2016</year>) <volume>124</volume>:<fpage>1214</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1510352</pub-id><pub-id pub-id-type="pmid">26757984</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoucri</surname><given-names>BM</given-names></name><name><surname>Martinez</surname><given-names>ES</given-names></name><name><surname>Abreo</surname><given-names>TJ</given-names></name><name><surname>Hung</surname><given-names>VT</given-names></name><name><surname>Moosova</surname><given-names>Z</given-names></name><name><surname>Shioda</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Retinoid X receptor activation alters the chromatin landscape to commit mesenchymal stem cells to the adipose lineage</article-title>. <source/>Endocrinology (<year>2017</year>) <volume>158</volume>:<fpage>3109</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1210/en.2017-00348</pub-id><pub-id pub-id-type="pmid">28977589</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudel</surname><given-names>RA</given-names></name><name><surname>Camann</surname><given-names>DE</given-names></name><name><surname>Spengler</surname><given-names>JD</given-names></name><name><surname>Korn</surname><given-names>LR</given-names></name><name><surname>Brody</surname><given-names>JG</given-names></name></person-group>. <article-title>Phthalates, alkylphenols, pesticides, polybrominated diphenyl ethers, and other endocrine-disrupting compounds in indoor air and dust</article-title>. <source/>Environ Sci Technol. (<year>2003</year>) <volume>37</volume>:<fpage>4543</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1021/es0264596</pub-id><pub-id pub-id-type="pmid">14594359</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapleton</surname><given-names>HM</given-names></name><name><surname>Harner</surname><given-names>T</given-names></name><name><surname>Shoeib</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>JM</given-names></name><name><surname>Schantz</surname><given-names>MM</given-names></name><name><surname>Leigh</surname><given-names>SD</given-names></name><etal></etal></person-group>. <article-title>Determination of polybrominated diphenyl ethers in indoor dust standard reference materials</article-title>. <source/>Anal Bioanal Chem. (<year>2006</year>) <volume>384</volume>:<fpage>791</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1007/s00216-005-0227-y</pub-id><pub-id pub-id-type="pmid">16385413</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapleton</surname><given-names>HM</given-names></name><name><surname>Klosterhaus</surname><given-names>S</given-names></name><name><surname>Eagle</surname><given-names>S</given-names></name><name><surname>Fuh</surname><given-names>J</given-names></name><name><surname>Meeker</surname><given-names>JD</given-names></name><name><surname>Blum</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Detection of organophosphate flame retardants in furniture foam and U</article-title>.S. house dust. <source/>Environ Sci Technol. (<year>2009</year>) <volume>43</volume>:<fpage>7490</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1021/es9014019</pub-id><pub-id pub-id-type="pmid">19848166</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><collab>US Environmental Protection Agency (EPA)</collab></person-group>
<source/>Exposure Factors Handbook Chapter 5 (Update): Soil and Dust Ingestion.
<publisher-loc>Washington, DC</publisher-loc>: <publisher-name>US EPA Office of Research and Development</publisher-name> (<year>2017</year>).</mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>AJ</given-names></name><name><surname>Webster</surname><given-names>TF</given-names></name><name><surname>Watkins</surname><given-names>DJ</given-names></name><name><surname>Nelson</surname><given-names>JW</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name><name><surname>Calafat</surname><given-names>AM</given-names></name><etal></etal></person-group>. <article-title>Polyfluorinated compounds in serum linked to indoor air in office environments</article-title>. <source/>Environ Sci Technol. (<year>2012</year>) <volume>46</volume>:<fpage>1209</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1021/es2038257</pub-id><pub-id pub-id-type="pmid">22148395</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>DJ</given-names></name><name><surname>McClean</surname><given-names>MD</given-names></name><name><surname>Fraser</surname><given-names>AJ</given-names></name><name><surname>Weinberg</surname><given-names>J</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name><name><surname>Webster</surname><given-names>TF</given-names></name></person-group>. <article-title>Associations between PBDEs in office air, dust, and surface wipes</article-title>. <source/>Environ Int. (<year>2013</year>) <volume>59</volume>:<fpage>124</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.envint.2013.06.001</pub-id><pub-id pub-id-type="pmid">23797055</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Garantziotis</surname><given-names>S</given-names></name><name><surname>Birnbaum</surname><given-names>LS</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>. <article-title>Monitoring indoor exposure to organophosphate flame retardants: hand wipes and house dust</article-title>. <source/>Environ Health Perspect. (<year>2015</year>) <volume>123</volume>:<fpage>160</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1408669</pub-id><pub-id pub-id-type="pmid">25343780</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapleton</surname><given-names>HM</given-names></name><name><surname>Misenheimer</surname><given-names>J</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Webster</surname><given-names>TF</given-names></name></person-group>. <article-title>Flame retardant associations between children's handwipes and house dust</article-title>. <source/>Chemosphere (<year>2014</year>) <volume>116</volume>:<fpage>54</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.chemosphere.2013.12.100</pub-id><pub-id pub-id-type="pmid">24485814</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>AL</given-names></name><name><surname>Hammel</surname><given-names>SC</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Lorenzo</surname><given-names>AM</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Webster</surname><given-names>TF</given-names></name><etal></etal></person-group>. <article-title>Children's residential exposure to organophosphate ester flame retardants and plasticizers: Investigating exposure pathways in the TESIE study</article-title>. <source/>Environ Int. (<year>2018</year>) <volume>116</volume>:<fpage>176</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.envint.2018.04.013</pub-id><pub-id pub-id-type="pmid">29689464</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Webster</surname><given-names>TF</given-names></name><name><surname>Sjodin</surname><given-names>A</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>. <article-title>Toddler's behavior and its impacts on exposure to polybrominated diphenyl ethers</article-title>. <source/>J Expo Sci Environ Epidemiol. (<year>2017</year>) <volume>27</volume>:<fpage>193</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/jes.2016.11</pub-id><pub-id pub-id-type="pmid">26956938</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Niemelä</surname><given-names>S</given-names></name><name><surname>Miettinen</surname><given-names>S</given-names></name><name><surname>Sarkanen</surname><given-names>JR</given-names></name><name><surname>Ashammakhi</surname><given-names>N</given-names></name></person-group>
<article-title>Adipose tissue and adipocyte differentiation: molecular and cellular aspects and tissue engineering applications</article-title>. In: <person-group person-group-type="editor"><name><surname>Ashammakhi</surname><given-names>N</given-names></name><name><surname>Reis</surname><given-names>R</given-names></name><name><surname>Chiellini</surname><given-names>F</given-names></name></person-group>, editors. <source/>Topics in Tissue Engineering (<year>2008</year>). p. <fpage>1</fpage>–<lpage>26</lpage>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.oulu.fi/spareparts/ebook_topics_in_t_e_vol4/">https://www.oulu.fi/spareparts/ebook_topics_in_t_e_vol4/</ext-link></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Masse</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Schlezinger</surname><given-names>JJ</given-names></name><name><surname>Webster</surname><given-names>TF</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>. <article-title>Characterization of adipogenic chemicals in three different cell culture systems: implications for reproducibility based on cell source and handling</article-title>. <source/>Sci Rep. (<year>2017</year>) <volume>7</volume>:<fpage>42104</fpage>. <pub-id pub-id-type="doi">10.1038/srep42104</pub-id><pub-id pub-id-type="pmid">28176856</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chappell</surname><given-names>VA</given-names></name><name><surname>Janesick</surname><given-names>A</given-names></name><name><surname>Blumberg</surname><given-names>B</given-names></name><name><surname>Fenton</surname><given-names>SE</given-names></name></person-group>. <article-title>Tetrabromobisphenol-A promotes early adipogenesis and lipogenesis in 3T3-L1 cells</article-title>. <source/>Toxicol Sci. (<year>2018</year>) <volume>166</volume>:<fpage>332</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfy209</pub-id><pub-id pub-id-type="pmid">30496566</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>ED</given-names></name><name><surname>Sarraf</surname><given-names>P</given-names></name><name><surname>Troy</surname><given-names>AE</given-names></name><name><surname>Bradwin</surname><given-names>G</given-names></name><name><surname>Moore</surname><given-names>K</given-names></name><name><surname>Milstone</surname><given-names>DS</given-names></name><etal></etal></person-group>. <article-title>PPAR gamma is required for the differentiation of adipose tissue <italic>in vivo</italic> and <italic>in vitro</italic></article-title>. <source/>Mol Cell (<year>1999</year>) <volume>4</volume>:<fpage>611</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S1097-2765(00)80211-7</pub-id><pub-id pub-id-type="pmid">10549292</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>ED</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group>. <article-title>Molecular regulation of adipogenesis</article-title>. <source/>Annu Rev Cell Dev Biol. (<year>2000</year>) <volume>16</volume>:<fpage>145</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.cellbio.16.1.145</pub-id><pub-id pub-id-type="pmid">11031233</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chawla</surname><given-names>A</given-names></name><name><surname>Schwarz</surname><given-names>EJ</given-names></name><name><surname>Dimaculangan</surname><given-names>DD</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name></person-group>. <article-title>Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation</article-title>. <source/>Endocrinology (<year>1994</year>) <volume>135</volume>:<fpage>798</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1210/endo.135.2.8033830</pub-id><pub-id pub-id-type="pmid">8033830</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>JM</given-names></name><name><surname>Moore</surname><given-names>LB</given-names></name><name><surname>Smith-Oliver</surname><given-names>TA</given-names></name><name><surname>Wilkison</surname><given-names>WO</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name></person-group>
<article-title>An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor y (PPARy)</article-title>. <source/>J Biol Chem. (<year>1995</year>) <volume>270</volume>:<fpage>12953</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.270.22.12953</pub-id><pub-id pub-id-type="pmid">7768881</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group>. <article-title>PPAR-gamma: adipogenic regulator and thiazolidinedione receptor</article-title>. <source/>Diabetes (<year>1998</year>) <volume>47</volume>:<fpage>507</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.47.4.507</pub-id><pub-id pub-id-type="pmid">9568680</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>ED</given-names></name><name><surname>C.-Hsu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sakai</surname><given-names>S</given-names></name><name><surname>Freeman</surname><given-names>MW</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name><etal></etal></person-group>
<article-title>C/EBP-alpha induces adipogenesis through PPAR-gamma: a unified pathway</article-title>. <source/>Genes Dev. (<year>2001</year>) <volume>16</volume>:<fpage>22</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1101/gad.948702</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsusue</surname><given-names>K</given-names></name><name><surname>Peters</surname><given-names>JM</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group>. <article-title>PPARbeta/delta potentiates PPARgamma-stimulated adipocyte differentiation</article-title>. <source/>FASEB J. (<year>2004</year>) <volume>18</volume>:<fpage>1477</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1096/fj.04-1944fje</pub-id><pub-id pub-id-type="pmid">15247146</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmuth</surname><given-names>M</given-names></name><name><surname>Haqq</surname><given-names>CM</given-names></name><name><surname>Cairns</surname><given-names>WJ</given-names></name><name><surname>Holder</surname><given-names>JC</given-names></name><name><surname>Dorsam</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes</article-title>. <source/>J Invest Dermatol. (<year>2004</year>) <volume>122</volume>:<fpage>971</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1111/j.0022-202X.2004.22412.x</pub-id><pub-id pub-id-type="pmid">15102088</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastie</surname><given-names>C</given-names></name><name><surname>Holst</surname><given-names>D</given-names></name><name><surname>Gaillard</surname><given-names>D</given-names></name><name><surname>Jehl-Pietri</surname><given-names>C</given-names></name><name><surname>Grimaldi</surname><given-names>PA</given-names></name></person-group>. <article-title>Expression of peroxisome proliferator-activated receptor PPARdelta promotes induction of PPARgamma and adipocyte differentiation in 3T3C2 fibroblasts</article-title>. <source/>J Biol Chem. (<year>1999</year>) <volume>274</volume>:<fpage>21920</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.31.21920</pub-id><pub-id pub-id-type="pmid">10419513</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastie</surname><given-names>C</given-names></name><name><surname>Luquet</surname><given-names>S</given-names></name><name><surname>Holst</surname><given-names>D</given-names></name><name><surname>Jehl-Pietri</surname><given-names>C</given-names></name><name><surname>Grimaldi</surname><given-names>PA</given-names></name></person-group>. <article-title>Alterations of peroxisome proliferator-activated receptor δ activity affect fatty acid-controlled adipose differentiation</article-title>. <source/>J Biol Chem. (<year>2000</year>) <volume>275</volume>:<fpage>38768</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M006450200</pub-id><pub-id pub-id-type="pmid">10991946</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brun</surname><given-names>RP</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Forman</surname><given-names>BM</given-names></name><name><surname>Ellis</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name><etal></etal></person-group>. <article-title>Differential activation of adipogenesis by multiple PPAR isoforms</article-title>. <source/>Genes Dev. (<year>1996</year>) <volume>10</volume>:<fpage>974</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1101/gad.10.8.974</pub-id><pub-id pub-id-type="pmid">8608944</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YX</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Tiep</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>RT</given-names></name><name><surname>Ham</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity</article-title>. <source/>Cell (<year>2003</year>) <volume>113</volume>:<fpage>159</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(03)00269-1</pub-id><pub-id pub-id-type="pmid">12705865</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Ward</surname><given-names>JM</given-names></name><name><surname>Gavrilova</surname><given-names>O</given-names></name><name><surname>Everett</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)</article-title>. <source/>Mol Cell Biol. (<year>2000</year>) <volume>20</volume>:<fpage>5119</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.20.14.5119-5128.2000</pub-id><pub-id pub-id-type="pmid">10866668</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerre-Millo</surname><given-names>M</given-names></name><name><surname>Gervois</surname><given-names>P</given-names></name><name><surname>Raspe</surname><given-names>E</given-names></name><name><surname>Madsen</surname><given-names>L</given-names></name><name><surname>Poulain</surname><given-names>P</given-names></name><name><surname>Derudas</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity</article-title>. <source/>J Biol Chem. (<year>2000</year>) <volume>275</volume>:<fpage>16638</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.275.22.16638</pub-id><pub-id pub-id-type="pmid">10828060</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>S</given-names></name><name><surname>Yoon</surname><given-names>M</given-names></name></person-group>. <article-title>Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice</article-title>. <source/>Exp Mol Med. (<year>2009</year>) <volume>41</volume>:<fpage>397</fpage>–<lpage>405</lpage>. <pub-id pub-id-type="doi">10.3858/emm.2009.41.6.045</pub-id><pub-id pub-id-type="pmid">19322024</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchida</surname><given-names>A</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Takekawa</surname><given-names>S</given-names></name><name><surname>Hada</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Maki</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination</article-title>. <source/>Diabetes (<year>2005</year>) <volume>54</volume>:<fpage>3358</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.54.12.3358</pub-id><pub-id pub-id-type="pmid">16306350</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>M</given-names></name><name><surname>Irvin</surname><given-names>MR</given-names></name><name><surname>Sha</surname><given-names>J</given-names></name><name><surname>Aslibekyan</surname><given-names>S</given-names></name><name><surname>Hidalgo</surname><given-names>B</given-names></name><name><surname>Perry</surname><given-names>RT</given-names></name><etal></etal></person-group>. <article-title>Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study</article-title>. <source/>Front Genet. (<year>2015</year>) <volume>6</volume>:<fpage>304</fpage>. <pub-id pub-id-type="doi">10.3389/fgene.2015.00304</pub-id><pub-id pub-id-type="pmid">26483836</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forcheron</surname><given-names>F</given-names></name><name><surname>Cachefo</surname><given-names>A</given-names></name><name><surname>Thevenon</surname><given-names>S</given-names></name><name><surname>Pinteur</surname><given-names>C</given-names></name><name><surname>Beylot</surname><given-names>M</given-names></name></person-group>. <article-title>Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients</article-title>. <source/>Diabetes (<year>2002</year>) <volume>51</volume>:<fpage>3486</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.51.12.3486</pub-id><pub-id pub-id-type="pmid">12453904</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliver</surname><given-names>WR</given-names><suffix>Jr</suffix></name><name><surname>Shenk</surname><given-names>JL</given-names></name><name><surname>Snaith</surname><given-names>MR</given-names></name><name><surname>Russell</surname><given-names>CS</given-names></name><name><surname>Plunket</surname><given-names>KD</given-names></name><name><surname>Bodkin</surname><given-names>NL</given-names></name><name><surname>Lewis</surname><given-names>MC</given-names></name><etal></etal></person-group>. <article-title>A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport</article-title>. <source/>Proc Nat Acad Sci USA. (<year>2001</year>) <volume>98</volume>:<fpage>5306</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.091021198</pub-id><pub-id pub-id-type="pmid">11309497</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanayama</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><name><surname>Mamiya</surname><given-names>S</given-names></name><name><surname>Nakanishi</surname><given-names>T</given-names></name><name><surname>Nishikawa</surname><given-names>J</given-names></name></person-group>. <article-title>Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor gamma/retinoid X receptor pathway</article-title>. <source/>Mol Pharmacol. (<year>2005</year>) <volume>67</volume>:<fpage>766</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1124/mol.104.008409</pub-id><pub-id pub-id-type="pmid">15611480</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grun</surname><given-names>F</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Zamanian</surname><given-names>Z</given-names></name><name><surname>Maeda</surname><given-names>L</given-names></name><name><surname>Arima</surname><given-names>K</given-names></name><name><surname>Cubacha</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates</article-title>. <source/>Mol Endocrinol. (<year>2006</year>) <volume>20</volume>:<fpage>2141</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1210/me.2005-0367</pub-id><pub-id pub-id-type="pmid">16613991</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><name><surname>Forman</surname><given-names>BM</given-names></name><name><surname>Sarraf</surname><given-names>P</given-names></name><name><surname>Fletcher</surname><given-names>JA</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name><etal></etal></person-group>. <article-title>Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor</article-title>. <source/>Proc Nat Acad Sci USA. (<year>1997</year>) <volume>94</volume>:<fpage>237</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.94.1.237</pub-id><pub-id pub-id-type="pmid">8990192</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canan Koch</surname><given-names>SS</given-names></name><name><surname>Dardashti</surname><given-names>LJ</given-names></name><name><surname>Cesario</surname><given-names>RM</given-names></name><name><surname>Croston</surname><given-names>GE</given-names></name><name><surname>Boehm</surname><given-names>MF</given-names></name><name><surname>Heyman</surname><given-names>RA</given-names></name><etal></etal></person-group>. <article-title>Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells</article-title>. <source/>J Med Chem. (<year>1999</year>) <volume>42</volume>:<fpage>742</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1021/jm980621r</pub-id><pub-id pub-id-type="pmid">10052980</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>R</given-names></name><name><surname>Pedersen</surname><given-names>TA</given-names></name><name><surname>Hagenbeek</surname><given-names>D</given-names></name><name><surname>Moulos</surname><given-names>P</given-names></name><name><surname>Siersbaek</surname><given-names>R</given-names></name><name><surname>Megens</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis</article-title>. <source/>Genes Dev. (<year>2008</year>) <volume>22</volume>:<fpage>2953</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1101/gad.501108</pub-id><pub-id pub-id-type="pmid">18981474</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Metzger</surname><given-names>D</given-names></name></person-group>. <article-title>Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes</article-title>. <source/>Proc Nat Acad Sci USA. (<year>2001</year>) <volume>98</volume>:<fpage>224</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.011528898</pub-id><pub-id pub-id-type="pmid">11134524</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>R</given-names></name><name><surname>Davies</surname><given-names>PJ</given-names></name><name><surname>Crombie</surname><given-names>DL</given-names></name><name><surname>Bischoff</surname><given-names>ED</given-names></name><name><surname>Cesario</surname><given-names>RM</given-names></name><name><surname>Jow</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists</article-title>. <source/>Nature (<year>1997</year>) <volume>386</volume>:<fpage>407</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1038/386407a0</pub-id><pub-id pub-id-type="pmid">9121558</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadasivuni</surname><given-names>MK</given-names></name><name><surname>Reddy</surname><given-names>BM</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>Anup</surname><given-names>MO</given-names></name><name><surname>Sunil</surname><given-names>V</given-names></name><name><surname>Lakshmi</surname><given-names>MN</given-names></name><etal></etal></person-group>. <article-title>CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models</article-title>. <source/>Diabetol Metab Syndr. (<year>2014</year>) <volume>6</volume>:<fpage>83</fpage>. <pub-id pub-id-type="doi">10.1186/1758-5996-6-83</pub-id><pub-id pub-id-type="pmid">25143786</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emilsson</surname><given-names>V</given-names></name><name><surname>O'Dowd</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>YL</given-names></name><name><surname>Sennitt</surname><given-names>M</given-names></name><name><surname>Heyman</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat</article-title>. <source/>Metabolism (<year>2000</year>) <volume>49</volume>:<fpage>1610</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1053/meta.2000.18692</pub-id><pub-id pub-id-type="pmid">11145125</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoucri</surname><given-names>BM</given-names></name><name><surname>Hung</surname><given-names>VT</given-names></name><name><surname>Chamorro-Garcia</surname><given-names>R</given-names></name><name><surname>Shioda</surname><given-names>T</given-names></name><name><surname>Blumberg</surname><given-names>B</given-names></name></person-group>. <article-title>Retinoid X receptor activation during adipogenesis of female mesenchymal stem cells programs a dysfunctional adipocyte</article-title>. <source/>Endocrinology (<year>2018</year>) <volume>159</volume>:<fpage>2863</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1210/en.2018-00056</pub-id><pub-id pub-id-type="pmid">29860300</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farol</surname><given-names>LT</given-names></name><name><surname>Hymes</surname><given-names>KB</given-names></name></person-group>. <article-title>Bexarotene: a clinical review</article-title>. <source/>Expert Rev Anticancer Ther. (<year>2004</year>) <volume>4</volume>:<fpage>180</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1586/14737140.4.2.180</pub-id><pub-id pub-id-type="pmid">15056048</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de</surname><given-names>Vries-van der Weij J</given-names></name><name><surname>de Haan</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Kuif</surname><given-names>M</given-names></name><name><surname>Oei</surname><given-names>HL</given-names></name><name><surname>van der Hoorn</surname><given-names>JW</given-names></name><etal></etal></person-group>
<article-title>Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein</article-title>. <source/>Endocrinology (<year>2009</year>) <volume>150</volume>:<fpage>2368</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1210/en.2008-1540</pub-id><pub-id pub-id-type="pmid">19147676</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinaire</surname><given-names>JA</given-names></name><name><surname>Reifel-Miller</surname><given-names>A</given-names></name></person-group>. <article-title>Therapeutic potential of retinoid x receptor modulators for the treatment of the metabolic syndrome</article-title>. <source/>PPAR Res. (<year>2007</year>) <volume>2007</volume>:<fpage>94156</fpage>. <pub-id pub-id-type="doi">10.1155/2007/94156</pub-id><pub-id pub-id-type="pmid">17497022</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>AI</given-names></name><name><surname>Mangelsdorf</surname><given-names>DJ</given-names></name></person-group>. <article-title>Retinoid x receptor heterodimers in the metabolic syndrome</article-title>. <source/>N Engl J Med. (<year>2005</year>) <volume>353</volume>:<fpage>604</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra043590</pub-id><pub-id pub-id-type="pmid">16093469</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hummasti</surname><given-names>S</given-names></name><name><surname>Laffitte</surname><given-names>BA</given-names></name><name><surname>Watson</surname><given-names>MA</given-names></name><name><surname>Galardi</surname><given-names>C</given-names></name><name><surname>Chao</surname><given-names>LC</given-names></name><name><surname>Ramamurthy</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Liver X receptors are regulators of adipocyte gene expression but not differentiation: identification of apoD as a direct target</article-title>. <source/>J Lipid Res. (<year>2004</year>) <volume>45</volume>:<fpage>616</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M300312-JLR200</pub-id><pub-id pub-id-type="pmid">14703507</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>JB</given-names></name><name><surname>Moon</surname><given-names>HM</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Jeong</surname><given-names>HW</given-names></name><name><surname>Yoo</surname><given-names>EJ</given-names></name><etal></etal></person-group>. <article-title>Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression</article-title>. <source/>Mol Cell Biol. (<year>2004</year>) <volume>24</volume>:<fpage>3430</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.24.8.3430-3444.2004</pub-id><pub-id pub-id-type="pmid">15060163</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juvet</surname><given-names>LK</given-names></name><name><surname>Andresen</surname><given-names>SM</given-names></name><name><surname>Schuster</surname><given-names>GU</given-names></name><name><surname>Dalen</surname><given-names>KT</given-names></name><name><surname>Tobin</surname><given-names>KA</given-names></name><name><surname>Hollung</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>On the role of liver X receptors in lipid accumulation in adipocytes</article-title>. <source/>Mol Endocrinol. (<year>2003</year>) <volume>17</volume>:<fpage>172</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1210/me.2001-0210</pub-id><pub-id pub-id-type="pmid">12554745</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenson</surname><given-names>BM</given-names></name><name><surname>Ryden</surname><given-names>M</given-names></name><name><surname>Venteclef</surname><given-names>N</given-names></name><name><surname>Dahlman</surname><given-names>I</given-names></name><name><surname>Pettersson</surname><given-names>AM</given-names></name><name><surname>Mairal</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Liver X receptor (LXR) regulates human adipocyte lipolysis</article-title>. <source/>J Biol Chem. (<year>2011</year>) <volume>286</volume>:<fpage>370</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.179499</pub-id><pub-id pub-id-type="pmid">21030586</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerin</surname><given-names>I</given-names></name><name><surname>Dolinsky</surname><given-names>VW</given-names></name><name><surname>Shackman</surname><given-names>JG</given-names></name><name><surname>Kennedy</surname><given-names>RT</given-names></name><name><surname>Chiang</surname><given-names>SH</given-names></name><name><surname>Burant</surname><given-names>CF</given-names></name><etal></etal></person-group>. <article-title>LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function</article-title>. <source/>J Biol Chem. (<year>2005</year>) <volume>280</volume>:<fpage>23024</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M412564200</pub-id><pub-id pub-id-type="pmid">15831500</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korach-Andre</surname><given-names>M</given-names></name><name><surname>Archer</surname><given-names>A</given-names></name><name><surname>Barros</surname><given-names>RP</given-names></name><name><surname>Parini</surname><given-names>P</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group>. <article-title>Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity</article-title>. <source/>Proc Nat Acad Sci USA. (<year>2011</year>) <volume>108</volume>:<fpage>403</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1017884108</pub-id><pub-id pub-id-type="pmid">21173252</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlman</surname><given-names>I</given-names></name><name><surname>Nilsson</surname><given-names>M</given-names></name><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Hoffstedt</surname><given-names>J</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Humphreys</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Liver X receptor gene polymorphisms and adipose tissue expression levels in obesity</article-title>. <source/>Pharmacogenet Genomics (<year>2006</year>) <volume>16</volume>:<fpage>881</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/01.fpc.0000236334.49422.48</pub-id><pub-id pub-id-type="pmid">17108812</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchgessner</surname><given-names>TG</given-names></name><name><surname>Sleph</surname><given-names>P</given-names></name><name><surname>Ostrowski</surname><given-names>J</given-names></name><name><surname>Lupisella</surname><given-names>J</given-names></name><name><surname>Ryan</surname><given-names>CS</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neutrophils</article-title>. <source/>Cell Metab. (<year>2016</year>) <volume>24</volume>:<fpage>223</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2016.07.016</pub-id><pub-id pub-id-type="pmid">27508871</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name></person-group>. <article-title>Targeting xenobiotic receptors PXR and CAR for metabolic diseases</article-title>. <source/>Trends Pharmacol Sci. (<year>2012</year>) <volume>33</volume>:<fpage>552</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2012.07.003</pub-id><pub-id pub-id-type="pmid">22889594</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreau</surname><given-names>A</given-names></name><name><surname>Vilarem</surname><given-names>MJ</given-names></name><name><surname>Maurel</surname><given-names>P</given-names></name><name><surname>Pascussi</surname><given-names>JM</given-names></name></person-group>. <article-title>Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response</article-title>. <source/>Mol Pharm. (<year>2008</year>) <volume>5</volume>:<fpage>35</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1021/mp700103m</pub-id><pub-id pub-id-type="pmid">18159929</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Febbraio</surname><given-names>M</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Zhai</surname><given-names>Y</given-names></name><name><surname>Kuruba</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis</article-title>. <source/>Gastroenterology (<year>2008</year>) <volume>134</volume>:<fpage>556</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2007.11.037</pub-id><pub-id pub-id-type="pmid">18242221</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Stefanovic-Racic</surname><given-names>M</given-names></name><name><surname>O'Doherty</surname><given-names>RM</given-names></name><etal></etal></person-group>. <article-title>PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice</article-title>. <source/>Diabetes (<year>2013</year>) <volume>62</volume>:<fpage>1876</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.2337/db12-1039</pub-id><pub-id pub-id-type="pmid">23349477</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name></person-group>. <article-title>PXR and CAR in energy metabolism</article-title>. <source/>Trends Endocrinol Metabol. (<year>2009</year>) <volume>20</volume>:<fpage>273</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.tem.2009.03.003</pub-id><pub-id pub-id-type="pmid">19595610</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahtela</surname><given-names>JT</given-names></name><name><surname>Arranto</surname><given-names>AJ</given-names></name><name><surname>Sotaniemi</surname><given-names>EA</given-names></name></person-group>. <article-title>Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects</article-title>. <source/>Diabetes (<year>1985</year>) <volume>34</volume>:<fpage>911</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.2337/diab.34.9.911</pub-id><pub-id pub-id-type="pmid">3896900</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotaniemi</surname><given-names>EA</given-names></name><name><surname>Karvonen</surname><given-names>I</given-names></name></person-group>
<article-title>Glucose tolerance and insulin response to glucose load before and after enzyme inducing therapy in subjects with glucose intolerance and patients with NIDDM having hyperinsulinemia or relative insulin deficiency</article-title>. <source/>Diabetes Res. (<year>1989</year>) <volume>11</volume>:<fpage>131</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">2697484</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name></person-group>. <article-title>Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis</article-title>. <source/>Acta Pharmacol Sin. (<year>2015</year>) <volume>36</volume>:<fpage>44</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1038/aps.2014.116</pub-id><pub-id pub-id-type="pmid">25500875</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prawitt</surname><given-names>J</given-names></name><name><surname>Caron</surname><given-names>S</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name></person-group>
<article-title>How to modulate FXR activity to treat the metabolic syndrome</article-title>. <source/>Drug Discov Today Dis Mech. (<year>2009</year>) <volume>6</volume>:<fpage>e55</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddmec.2010.05.002</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>G</given-names></name><name><surname>Disante</surname><given-names>M</given-names></name><name><surname>Mencarelli</surname><given-names>A</given-names></name><name><surname>Renga</surname><given-names>B</given-names></name><name><surname>Gioiello</surname><given-names>A</given-names></name><name><surname>Pellicciari</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function <italic>in vivo</italic></article-title>. <source/>Mol Pharmacol. (<year>2006</year>) <volume>70</volume>:<fpage>1164</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1124/mol.106.023820</pub-id><pub-id pub-id-type="pmid">16778009</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cariou</surname><given-names>B</given-names></name><name><surname>van Harmelen</surname><given-names>K</given-names></name><name><surname>Duran-Sandoval</surname><given-names>D</given-names></name><name><surname>van Dijk</surname><given-names>TH</given-names></name><name><surname>Grefhorst</surname><given-names>A</given-names></name><name><surname>Abdelkarim</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice</article-title>. <source/>J Biol Chem. (<year>2006</year>) <volume>281</volume>:<fpage>11039</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M510258200</pub-id><pub-id pub-id-type="pmid">16446356</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Della-Fera</surname><given-names>MA</given-names></name><name><surname>Baile</surname><given-names>CA</given-names></name></person-group>. <article-title>Guggulsterone inhibits adipocyte differentiation and induces apoptosis in 3T3-L1 cells</article-title>. <source/>Obesity (<year>2008</year>) <volume>16</volume>:<fpage>16</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/oby.2007.24</pub-id><pub-id pub-id-type="pmid">18223606</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Horai</surname><given-names>Y</given-names></name><name><surname>Houten</surname><given-names>SM</given-names></name><name><surname>Morimoto</surname><given-names>K</given-names></name><name><surname>Sugizaki</surname><given-names>T</given-names></name><name><surname>Arita</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure</article-title>. <source/>J Biol Chem. (<year>2011</year>) <volume>286</volume>:<fpage>26913</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.248203</pub-id><pub-id pub-id-type="pmid">21632533</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Liver</surname><given-names>X</given-names></name></person-group>. <article-title>Receptor and farnesoid X receptor as therapeutic targets</article-title>. <source/>Am J Cardiol. (<year>2007</year>) <volume>100</volume>:<fpage>15N</fpage>−<lpage>9N</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2007.08.008</pub-id><pub-id pub-id-type="pmid">18047847</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelkarim</surname><given-names>M</given-names></name><name><surname>Caron</surname><given-names>S</given-names></name><name><surname>Duhem</surname><given-names>C</given-names></name><name><surname>Prawitt</surname><given-names>J</given-names></name><name><surname>Dumont</surname><given-names>J</given-names></name><name><surname>Lucas</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways</article-title>. <source/>J Biol Chem. (<year>2010</year>) <volume>285</volume>:<fpage>36759</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.166231</pub-id><pub-id pub-id-type="pmid">20851881</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prawitt</surname><given-names>J</given-names></name><name><surname>Abdelkarim</surname><given-names>M</given-names></name><name><surname>Stroeve</surname><given-names>JH</given-names></name><name><surname>Popescu</surname><given-names>I</given-names></name><name><surname>Duez</surname><given-names>H</given-names></name><name><surname>Velagapudi</surname><given-names>VR</given-names></name><etal></etal></person-group>. <article-title>Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity</article-title>. <source/>Diabetes (<year>2011</year>) <volume>60</volume>:<fpage>1861</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.2337/db11-0030</pub-id><pub-id pub-id-type="pmid">21593203</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maneschi</surname><given-names>E</given-names></name><name><surname>Vignozzi</surname><given-names>L</given-names></name><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Mello</surname><given-names>T</given-names></name><name><surname>Filippi</surname><given-names>S</given-names></name><name><surname>Cellai</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS</article-title>. <source/>J Endocr. (<year>2013</year>) <volume>218</volume>:<fpage>215</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1530/JOE-13-0109</pub-id><pub-id pub-id-type="pmid">23750014</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice</article-title>. <source/>Gut (<year>2014</year>) <volume>63</volume>:<fpage>170</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2012-303150</pub-id><pub-id pub-id-type="pmid">23348961</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obregon</surname><given-names>MJ</given-names></name></person-group>. <article-title>Thyroid hormone and adipocyte differentiation</article-title>. <source/>Thyroid (<year>2008</year>) <volume>18</volume>:<fpage>185</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1089/thy.2007.0254</pub-id><pub-id pub-id-type="pmid">18279019</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolyvanos Naumann</surname><given-names>U</given-names></name><name><surname>Furer</surname><given-names>J</given-names></name><name><surname>Kaser</surname><given-names>L</given-names></name><name><surname>Vetter</surname><given-names>W</given-names></name></person-group>. <article-title>Hypothyroidism. main symptoms: fatigue, weight gain, depression, myalgia, edema</article-title>. <source/>Praxis (<year>2007</year>) <volume>96</volume>:<fpage>1411</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1024/1661-8157.96.38.1411</pub-id><pub-id pub-id-type="pmid">17933284</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bratusch-Marrain</surname><given-names>P</given-names></name><name><surname>Schmid</surname><given-names>P</given-names></name><name><surname>Waldhausl</surname><given-names>W</given-names></name><name><surname>Schlick</surname><given-names>W</given-names></name></person-group>. <article-title>Specific weight loss in hyperthyroidism</article-title>. <source/>Horm Metab Res. (<year>1978</year>) <volume>10</volume>:<fpage>412</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1055/s-0028-1093403</pub-id><pub-id pub-id-type="pmid">711136</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryzgalova</surname><given-names>G</given-names></name><name><surname>Effendic</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Rehnmark</surname><given-names>S</given-names></name><name><surname>Barbounis</surname><given-names>P</given-names></name><name><surname>Boulet</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141</article-title>. <source/>J Steroid Biochem Mole Biol. (<year>2008</year>) <volume>111</volume>:<fpage>262</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2008.06.010</pub-id><pub-id pub-id-type="pmid">18621127</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname><given-names>J</given-names></name><name><surname>Daykin</surname><given-names>J</given-names></name><name><surname>Holder</surname><given-names>R</given-names></name><name><surname>Sheppard</surname><given-names>MC</given-names></name><name><surname>Franklyn</surname><given-names>JA</given-names></name></person-group>. <article-title>Weight gain following treatment of hyperthyroidism</article-title>. <source/>Clin Endocrinol. (<year>2001</year>) <volume>55</volume>:<fpage>233</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2265.2001.01329.x</pub-id><pub-id pub-id-type="pmid">11531931</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonn</surname><given-names>L</given-names></name><name><surname>Stenlof</surname><given-names>K</given-names></name><name><surname>Ottosson</surname><given-names>M</given-names></name><name><surname>Lindroos</surname><given-names>AK</given-names></name><name><surname>Nystrom</surname><given-names>E</given-names></name><name><surname>Sjostrom</surname><given-names>L</given-names></name></person-group>. <article-title>Body weight and body composition changes after treatment of hyperthyroidism</article-title>. <source/>J Clin Endocr Metabol. (<year>1998</year>) <volume>83</volume>:<fpage>4269</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1210/jc.83.12.4269</pub-id><pub-id pub-id-type="pmid">9851762</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindblom</surname><given-names>JM</given-names></name><name><surname>Gevers</surname><given-names>EF</given-names></name><name><surname>Skrtic</surname><given-names>SM</given-names></name><name><surname>Lindberg</surname><given-names>MK</given-names></name><name><surname>Gothe</surname><given-names>S</given-names></name><name><surname>Tornell</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Increased adipogenesis in bone marrow but decreased bone mineral density in mice devoid of thyroid hormone receptors</article-title>. <source/>Bone (<year>2005</year>) <volume>36</volume>:<fpage>607</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.bone.2005.01.017</pub-id><pub-id pub-id-type="pmid">15780976</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darimont</surname><given-names>C</given-names></name><name><surname>Gaillard</surname><given-names>D</given-names></name><name><surname>Ailhaud</surname><given-names>G</given-names></name><name><surname>Negrel</surname><given-names>R</given-names></name></person-group>. <article-title>Terminal differentiation of mouse preadipocyte cells: adipogenic and antimitogenic role of triiodothyronine</article-title>. <source/>Mol Cell Endocr. (<year>1993</year>) <volume>98</volume>:<fpage>67</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/0303-7207(93)90238-F</pub-id><pub-id pub-id-type="pmid">7511547</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Miyamoto</surname><given-names>T</given-names></name><name><surname>Kakizawa</surname><given-names>T</given-names></name><name><surname>Sakuma</surname><given-names>T</given-names></name><name><surname>Nishio</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Expression of thyroid hormone receptor alpha in 3T3-L1 adipocytes; triiodothyronine increases the expression of lipogenic enzyme and triglyceride accumulation</article-title>. <source/>J Endocr. (<year>2004</year>) <volume>182</volume>:<fpage>295</fpage>–<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1677/joe.0.1820295</pub-id><pub-id pub-id-type="pmid">15283690</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-Delgado</surname><given-names>G</given-names></name><name><surname>Marsch-Moreno</surname><given-names>M</given-names></name><name><surname>Kuri-Harcuch</surname><given-names>W</given-names></name></person-group>. <article-title>Thyroid hormone stimulates adipocyte differentiation of 3T3 cells</article-title>. <source/>Mol Cell Biochem. (<year>1987</year>) <volume>76</volume>:<fpage>35</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1007/BF00219396</pub-id><pub-id pub-id-type="pmid">3627113</pub-id></mixed-citation>
</ref>
<ref id="B131">
<label>131.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>K</given-names></name><name><surname>Marino</surname><given-names>JS</given-names></name><name><surname>Sanchez</surname><given-names>ER</given-names></name><name><surname>Hinds</surname><given-names>TD</given-names><suffix>Jr</suffix></name></person-group>
<article-title>The glucocorticoid receptor: cause of or cure for obesity?</article-title>
<source/>Am J Physiol. Endocr Metabol. (<year>2016</year>) <volume>310</volume>:<fpage>E249</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1152/ajpendo.00478.2015</pub-id></mixed-citation>
</ref>
<ref id="B132">
<label>132.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contador</surname><given-names>D</given-names></name><name><surname>Ezquer</surname><given-names>F</given-names></name><name><surname>Espinosa</surname><given-names>M</given-names></name><name><surname>Arango-Rodriguez</surname><given-names>M</given-names></name><name><surname>Puebla</surname><given-names>C</given-names></name><name><surname>Sobrevia</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Dexamethasone and rosiglitazone are sufficient and necessary for producing functional adipocytes from mesenchymal stem cells</article-title>. <source/>Exp Biol Med. (<year>2015</year>) <volume>240</volume>:<fpage>1235</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1177/1535370214566565</pub-id><pub-id pub-id-type="pmid">25595190</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidal-Puig</surname><given-names>AJ</given-names></name><name><surname>Considine</surname><given-names>RV</given-names></name><name><surname>Jimenez-Linan</surname><given-names>M</given-names></name><name><surname>Werman</surname><given-names>A</given-names></name><name><surname>Pories</surname><given-names>WJ</given-names></name><name><surname>Caro</surname><given-names>JF</given-names></name><etal></etal></person-group>. <article-title>Peroxisome proliferator-activated receptor gene expression in human tissues. effects of obesity, weight loss, and regulation by insulin and glucocorticoids</article-title>. <source/>J Clin Invest (<year>1997</year>) <volume>99</volume>:<fpage>2416</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1172/JCI119424</pub-id><pub-id pub-id-type="pmid">9153284</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sargis</surname><given-names>RM</given-names></name><name><surname>Johnson</surname><given-names>DN</given-names></name><name><surname>Choudhury</surname><given-names>RA</given-names></name><name><surname>Brady</surname><given-names>MJ</given-names></name></person-group>. <article-title>Environmental endocrine disruptors promote adipogenesis in the 3T3-L1 cell line through glucocorticoid receptor activation</article-title>. <source/>Obesity (<year>2010</year>) <volume>18</volume>:<fpage>1283</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/oby.2009.419</pub-id><pub-id pub-id-type="pmid">19927138</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asada</surname><given-names>M</given-names></name><name><surname>Rauch</surname><given-names>A</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Maruyama</surname><given-names>H</given-names></name><name><surname>Miyaki</surname><given-names>S</given-names></name><name><surname>Shibamori</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>DNA binding-dependent glucocorticoid receptor activity promotes adipogenesis via Kruppel-like factor 15 gene expression</article-title>. <source/>Lab Invest. (<year>2011</year>) <volume>91</volume>:<fpage>203</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1038/labinvest.2010.170</pub-id><pub-id pub-id-type="pmid">20956975</pub-id></mixed-citation>
</ref>
<ref id="B136">
<label>136.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberger</surname><given-names>JS</given-names></name></person-group>. <article-title>Corticosteroid-dependent differentiation of human marrow preadipocytes <italic>in vitro</italic></article-title>. <source/>in vitro (<year>1979</year>) <volume>15</volume>:<fpage>823</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/BF02618309</pub-id><pub-id pub-id-type="pmid">521037</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauner</surname><given-names>H</given-names></name><name><surname>Schmid</surname><given-names>P</given-names></name><name><surname>Pfeiffer</surname><given-names>EF</given-names></name></person-group>. <article-title>Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells</article-title>. <source/>J Clin Endocrinol Metabol. (<year>1987</year>) <volume>64</volume>:<fpage>832</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1210/jcem-64-4-832</pub-id><pub-id pub-id-type="pmid">3546356</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pantoja</surname><given-names>C</given-names></name><name><surname>Huff</surname><given-names>JT</given-names></name><name><surname>Yamamoto</surname><given-names>KR</given-names></name></person-group>. <article-title>Glucocorticoid signaling defines a novel commitment state during adipogenesis <italic>in vitro</italic></article-title>. <source/>Mol Biol Cell. (<year>2008</year>) <volume>19</volume>:<fpage>4032</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.e08-04-0420</pub-id><pub-id pub-id-type="pmid">18653467</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caprio</surname><given-names>M</given-names></name><name><surname>Feve</surname><given-names>B</given-names></name><name><surname>Claes</surname><given-names>A</given-names></name><name><surname>Viengchareun</surname><given-names>S</given-names></name><name><surname>Lombes</surname><given-names>M</given-names></name><name><surname>Zennaro</surname><given-names>MC</given-names></name></person-group>. <article-title>Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis</article-title>. <source/>FASEB J. (<year>2007</year>) <volume>21</volume>:<fpage>2185</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1096/fj.06-7970com</pub-id><pub-id pub-id-type="pmid">17384139</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Fried</surname><given-names>SK</given-names></name></person-group>
<article-title>The glucocorticoid receptor, not the mineralocorticoid receptor, plays the dominant role in adipogenesis and adipokine production in human adipocytes</article-title>. <source/>Int J Obes. (<year>2014</year>) <volume>38</volume>:<fpage>1228</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1038/ijo.2014.6</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kershaw</surname><given-names>EE</given-names></name><name><surname>Morton</surname><given-names>NM</given-names></name><name><surname>Dhillon</surname><given-names>H</given-names></name><name><surname>Ramage</surname><given-names>L</given-names></name><name><surname>Seckl</surname><given-names>JR</given-names></name><name><surname>Flier</surname><given-names>JS</given-names></name></person-group>. <article-title>Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity</article-title>. <source/>Diabetes (<year>2005</year>) <volume>54</volume>:<fpage>1023</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.54.4.1023</pub-id><pub-id pub-id-type="pmid">15793240</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Busse</surname><given-names>C</given-names></name><name><surname>Pham</surname><given-names>A</given-names></name><name><surname>Nakamura</surname><given-names>MC</given-names></name><name><surname>Lane</surname><given-names>NE</given-names></name></person-group>. <article-title>Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice</article-title>. <source/>Arthritis Rheum. (<year>2008</year>) <volume>58</volume>:<fpage>1674</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1002/art.23454</pub-id><pub-id pub-id-type="pmid">18512788</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieman</surname><given-names>LK</given-names></name><name><surname>Biller</surname><given-names>BM</given-names></name><name><surname>Findling</surname><given-names>JW</given-names></name><name><surname>Newell-Price</surname><given-names>J</given-names></name><name><surname>Savage</surname><given-names>MO</given-names></name><name><surname>Stewart</surname><given-names>PM</given-names></name><etal></etal></person-group>. <article-title>The diagnosis of cushing's syndrome: an endocrine society clinical practice guideline</article-title>. <source/>J Clin Endocr Metabol. (<year>2008</year>) <volume>93</volume>:<fpage>1526</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2008-0125</pub-id><pub-id pub-id-type="pmid">18334580</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krotkiewski</surname><given-names>M</given-names></name><name><surname>Blohme</surname><given-names>B</given-names></name><name><surname>Lindholm</surname><given-names>N</given-names></name><name><surname>Bjorntorp</surname><given-names>P</given-names></name></person-group>. <article-title>The effects of adrenal corticosteroids on regional adipocyte size in man</article-title>. <source/>J Clin Endocr Metabol. (<year>1976</year>) <volume>42</volume>:<fpage>91</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1210/jcem-42-1-91</pub-id><pub-id pub-id-type="pmid">1249197</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloom</surname><given-names>SL</given-names></name><name><surname>Sheffield</surname><given-names>JS</given-names></name><name><surname>McIntire</surname><given-names>DD</given-names></name><name><surname>Leveno</surname><given-names>KJ</given-names></name></person-group>. <article-title>Antenatal dexamethasone and decreased birth weight</article-title>. <source/>Obstetr Gynecol. (<year>2001</year>) <volume>97</volume>:<fpage>485</fpage>–<lpage>90</lpage>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://journals.lww.com/greenjournal/Fulltext/2001/04000/Antenatal_Dexamethasone_and_Decreased_Birth_Weight.1.aspx">https://journals.lww.com/greenjournal/Fulltext/2001/04000/Antenatal_Dexamethasone_and_Decreased_Birth_Weight.1.aspx</ext-link><pub-id pub-id-type="pmid">11275014</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname><given-names>H</given-names></name></person-group>. <article-title>Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants</article-title>. <source/>J Pediatr. (<year>2001</year>) <volume>139</volume>:<fpage>163</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM200101113440203</pub-id><pub-id pub-id-type="pmid">11463049</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>PS</given-names></name><name><surname>Naaz</surname><given-names>A</given-names></name></person-group>. <article-title>Role of estrogens in adipocyte development and function</article-title>. <source/>Exp Biol Med. (<year>2004</year>) <volume>229</volume>:<fpage>1127</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1177/153537020422901107</pub-id><pub-id pub-id-type="pmid">15564439</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dieudonne</surname><given-names>MN</given-names></name><name><surname>Pecquery</surname><given-names>R</given-names></name><name><surname>Leneveu</surname><given-names>MC</given-names></name><name><surname>Giudicelli</surname><given-names>Y</given-names></name></person-group>. <article-title>Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2</article-title>. <source/>Endocrinology (<year>2000</year>) <volume>141</volume>:<fpage>649</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1210/endo.141.2.7293</pub-id><pub-id pub-id-type="pmid">10650946</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roncari</surname><given-names>DA</given-names></name><name><surname>Van</surname><given-names>RL</given-names></name></person-group>. <article-title>Promotion of human adipocyte precursor replication by 17beta-estradiol in culture</article-title>. <source/>J Clin Invest. (<year>1978</year>) <volume>62</volume>:<fpage>503</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1172/JCI109153</pub-id><pub-id pub-id-type="pmid">690182</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>L</given-names></name><name><surname>Colpan</surname><given-names>A</given-names></name><name><surname>Peptan</surname><given-names>IA</given-names></name></person-group>. <article-title>Modulations of 17-beta estradiol on osteogenic and adipogenic differentiations of human mesenchymal stem cells</article-title>. <source/>Tissue Eng. (<year>2006</year>) <volume>12</volume>:<fpage>2747</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1089/ten.2006.12.2747</pub-id><pub-id pub-id-type="pmid">17518644</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Yuen</surname><given-names>JM</given-names></name><name><surname>Sham</surname><given-names>KW</given-names></name><name><surname>Cheng</surname><given-names>CH</given-names></name></person-group>. <article-title>GPER mediates the inhibitory actions of estrogen on adipogenesis in 3T3-L1 cells through perturbation of mitotic clonal expansion</article-title>. <source/>General Comp Endocrinol. (<year>2013</year>) <volume>193</volume>:<fpage>19</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygcen.2013.07.004</pub-id><pub-id pub-id-type="pmid">23871778</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>R</given-names></name><name><surname>Inoue</surname><given-names>D</given-names></name><name><surname>Shibata</surname><given-names>M</given-names></name><name><surname>Saika</surname><given-names>M</given-names></name><name><surname>Kido</surname><given-names>S</given-names></name><name><surname>Ooka</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta</article-title>. <source/>Endocrinology (<year>2002</year>) <volume>143</volume>:<fpage>2349</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1210/endo.143.6.8854</pub-id><pub-id pub-id-type="pmid">12021200</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heine</surname><given-names>PA</given-names></name><name><surname>Taylor</surname><given-names>JA</given-names></name><name><surname>Iwamoto</surname><given-names>GA</given-names></name><name><surname>Lubahn</surname><given-names>DB</given-names></name><name><surname>Cooke</surname><given-names>PS</given-names></name></person-group>. <article-title>Increased adipose tissue in male and female estrogen receptor-alpha knockout mice</article-title>. <source/>Proc Nat Acad Sci USA. (<year>2000</year>) <volume>97</volume>:<fpage>12729</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.97.23.12729</pub-id><pub-id pub-id-type="pmid">11070086</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>SR</given-names></name><name><surname>Castelo-Branco</surname><given-names>C</given-names></name><name><surname>Chedraui</surname><given-names>P</given-names></name><name><surname>Lumsden</surname><given-names>MA</given-names></name><name><surname>Nappi</surname><given-names>RE</given-names></name><name><surname>Shah</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Understanding weight gain at menopause</article-title>. <source/>Climacteric (<year>2012</year>) <volume>15</volume>:<fpage>419</fpage>–<lpage>429</lpage>. <pub-id pub-id-type="doi">10.3109/13697137.2012.707385</pub-id><pub-id pub-id-type="pmid">22978257</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>155.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stubbins</surname><given-names>RE</given-names></name><name><surname>Holcomb</surname><given-names>VB</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Nunez</surname><given-names>NP</given-names></name></person-group>. <article-title>Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance</article-title>. <source/>Eur J Nutr. (<year>2012</year>) <volume>51</volume>:<fpage>861</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1007/s00394-011-0266-4</pub-id><pub-id pub-id-type="pmid">22042005</pub-id></mixed-citation>
</ref>
<ref id="B156">
<label>156.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blouin</surname><given-names>K</given-names></name><name><surname>Boivin</surname><given-names>A</given-names></name><name><surname>Tchernof</surname><given-names>A</given-names></name></person-group>. <article-title>Androgens and body fat distribution</article-title>. <source/>J Steroid Biochem Mol Biol. (<year>2008</year>) <volume>108</volume>:<fpage>272</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2007.09.001</pub-id><pub-id pub-id-type="pmid">17945484</pub-id></mixed-citation>
</ref>
<ref id="B157">
<label>157.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Reilly</surname><given-names>MW</given-names></name><name><surname>House</surname><given-names>PJ</given-names></name><name><surname>Tomlinson</surname><given-names>JW</given-names></name></person-group>. <article-title>Understanding androgen action in adipose tissue</article-title>. <source/>J Steroid Biochem Mol Biol. (<year>2014</year>) <volume>143</volume>:<fpage>277</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2014.04.008</pub-id><pub-id pub-id-type="pmid">24787657</pub-id></mixed-citation>
</ref>
<ref id="B158">
<label>158.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blouin</surname><given-names>K</given-names></name><name><surname>Nadeau</surname><given-names>M</given-names></name><name><surname>Perreault</surname><given-names>M</given-names></name><name><surname>Veilleux</surname><given-names>A</given-names></name><name><surname>Drolet</surname><given-names>R</given-names></name><name><surname>Marceau</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women</article-title>. <source/>Clin Endocrinol. (<year>2010</year>) <volume>72</volume>:<fpage>176</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2265.2009.03645.x</pub-id><pub-id pub-id-type="pmid">19500113</pub-id></mixed-citation>
</ref>
<ref id="B159">
<label>159.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mammi</surname><given-names>C</given-names></name><name><surname>Calanchini</surname><given-names>M</given-names></name><name><surname>Antelmi</surname><given-names>A</given-names></name><name><surname>Cinti</surname><given-names>F</given-names></name><name><surname>Rosano</surname><given-names>GM</given-names></name><name><surname>Lenzi</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Androgens and adipose tissue in males: a complex and reciprocal interplay</article-title>. <source/>Int J Endocrinol. (<year>2012</year>) <volume>2012</volume>:<fpage>789653</fpage>. <pub-id pub-id-type="doi">10.1155/2012/789653</pub-id><pub-id pub-id-type="pmid">22235202</pub-id></mixed-citation>
</ref>
<ref id="B160">
<label>160.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Bhasin</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Miki</surname><given-names>R</given-names></name><name><surname>Chauhan</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes</article-title>. <source/>Mol Cel Endocrinol. (<year>2008</year>) <volume>296</volume>:<fpage>32</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2008.08.019</pub-id><pub-id pub-id-type="pmid">18801408</pub-id></mixed-citation>
</ref>
<ref id="B161">
<label>161.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chazenbalk</surname><given-names>G</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Irge</surname><given-names>D</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Abbott</surname><given-names>DH</given-names></name><name><surname>Dumesic</surname><given-names>DA</given-names></name></person-group>. <article-title>Androgens inhibit adipogenesis during human adipose stem cell commitment to preadipocyte formation</article-title>. <source/>Steroids (<year>2013</year>) <volume>78</volume>:<fpage>920</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.steroids.2013.05.001</pub-id><pub-id pub-id-type="pmid">23707571</pub-id></mixed-citation>
</ref>
<ref id="B162">
<label>162.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Artaza</surname><given-names>JN</given-names></name><name><surname>Taylor</surname><given-names>WE</given-names></name><name><surname>Gonzalez-Cadavid</surname><given-names>NF</given-names></name><name><surname>Bhasin</surname><given-names>S</given-names></name></person-group>. <article-title>Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway</article-title>. <source/>Endocrinology (<year>2003</year>) <volume>144</volume>:<fpage>5081</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1210/en.2003-0741</pub-id><pub-id pub-id-type="pmid">12960001</pub-id></mixed-citation>
</ref>
<ref id="B163">
<label>163.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Kawano</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name></person-group>. <article-title>Late onset of obesity in male androgen receptor-deficient (AR KO) mice</article-title>. <source/>Biochem Biophys Res Commun. (<year>2003</year>) <volume>300</volume>:<fpage>167</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-291X(02)02774-2</pub-id><pub-id pub-id-type="pmid">12480537</pub-id></mixed-citation>
</ref>
<ref id="B164">
<label>164.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamanti-Kandarakis</surname><given-names>E</given-names></name><name><surname>Mitrakou</surname><given-names>A</given-names></name><name><surname>Raptis</surname><given-names>S</given-names></name><name><surname>Tolis</surname><given-names>G</given-names></name><name><surname>Duleba</surname><given-names>AJ</given-names></name></person-group>. <article-title>The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome</article-title>. <source/>J Clin Endocrinol Metabol. (<year>1998</year>) <volume>83</volume>:<fpage>2699</fpage>–<lpage>705</lpage>. <pub-id pub-id-type="doi">10.1210/jcem.83.8.5041</pub-id><pub-id pub-id-type="pmid">9709934</pub-id></mixed-citation>
</ref>
<ref id="B165">
<label>165.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusin</surname><given-names>I</given-names></name><name><surname>Sainsbury</surname><given-names>A</given-names></name><name><surname>Doyle</surname><given-names>P</given-names></name><name><surname>Rohner-Jeanrenaud</surname><given-names>F</given-names></name><name><surname>Jeanrenaud</surname><given-names>B</given-names></name></person-group>. <article-title>The ob gene and insulin. a relationship leading to clues to the understanding of obesity</article-title>. <source/>Diabetes (<year>1995</year>) <volume>44</volume>:<fpage>1467</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.2337/diab.44.12.1467</pub-id><pub-id pub-id-type="pmid">7589856</pub-id></mixed-citation>
</ref>
<ref id="B166">
<label>166.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusin</surname><given-names>I</given-names></name><name><surname>Rohner-Jeanrenaud</surname><given-names>F</given-names></name><name><surname>Terrettaz</surname><given-names>J</given-names></name><name><surname>Jeanrenaud</surname><given-names>B</given-names></name></person-group>. <article-title>Hyperinsulinemia and its impact on obesity and insulin resistance</article-title>. <source/>Int J Obes Relat Metab Disord. (<year>1992</year>) <volume>16</volume> (<issue>Suppl. 4</issue>):<fpage>S1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="pmid">1338381</pub-id></mixed-citation>
</ref>
<ref id="B167">
<label>167.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeanrenaud</surname><given-names>B</given-names></name></person-group>. <article-title>Insulin and obesity</article-title>. <source/>Diabetologia (<year>1979</year>) <volume>17</volume>:<fpage>133</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/BF01219738</pub-id><pub-id pub-id-type="pmid">389721</pub-id></mixed-citation>
</ref>
<ref id="B168">
<label>168.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garten</surname><given-names>A</given-names></name><name><surname>Schuster</surname><given-names>S</given-names></name><name><surname>Kiess</surname><given-names>W</given-names></name></person-group>. <article-title>The insulin-like growth factors in adipogenesis and obesity</article-title>. <source/>Endocrinol Metab Clin North Am. (<year>2012</year>) <volume>41</volume>:<fpage>283</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.ecl.2012.04.011</pub-id><pub-id pub-id-type="pmid">22682631</pub-id></mixed-citation>
</ref>
<ref id="B169">
<label>169.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bournat</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>CW</given-names></name></person-group>. <article-title>Mitochondrial dysfunction in obesity</article-title>. <source/>Curr Opin Endocrinol Diabet Obes. (<year>2010</year>) <volume>17</volume>:<fpage>446</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1097/MED.0b013e32833c3026</pub-id><pub-id pub-id-type="pmid">20585248</pub-id></mixed-citation>
</ref>
<ref id="B170">
<label>170.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vankoningsloo</surname><given-names>S</given-names></name><name><surname>Piens</surname><given-names>M</given-names></name><name><surname>Lecocq</surname><given-names>C</given-names></name><name><surname>Gilson</surname><given-names>A</given-names></name><name><surname>De Pauw</surname><given-names>A</given-names></name><name><surname>Renard</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Mitochondrial dysfunction induces triglyceride accumulation in 3T3-L1 cells: role of fatty acid beta-oxidation and glucose</article-title>. <source/>J Lipid Res. (<year>2005</year>) <volume>46</volume>:<fpage>1133</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.M400464-JLR200</pub-id><pub-id pub-id-type="pmid">15741651</pub-id></mixed-citation>
</ref>
<ref id="B171">
<label>171.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name></person-group>. <article-title>Role of mitochondrial dysfunction in insulin resistance</article-title>. <source/>Circul Res. (<year>2008</year>) <volume>102</volume>:<fpage>401</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.107.165472</pub-id><pub-id pub-id-type="pmid">18309108</pub-id></mixed-citation>
</ref>
<ref id="B172">
<label>172.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>YM</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name></person-group>. <article-title>Persistent organic pollutants, mitochondrial dysfunction, and metabolic syndrome</article-title>. <source/>Ann NY Acad Sci. (<year>2010</year>) <volume>1201</volume>:<fpage>166</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05622.x</pub-id><pub-id pub-id-type="pmid">20649553</pub-id></mixed-citation>
</ref>
<ref id="B173">
<label>173.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Pulakat</surname><given-names>L</given-names></name><name><surname>Whaley-Connell</surname><given-names>A</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name></person-group>. <article-title>Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease</article-title>. <source/>J Mol Med. (<year>2010</year>) <volume>88</volume>:<fpage>993</fpage>–<lpage>1001</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-010-0663-9</pub-id><pub-id pub-id-type="pmid">20725711</pub-id></mixed-citation>
</ref>
<ref id="B174">
<label>174.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saben</surname><given-names>JL</given-names></name><name><surname>Boudoures</surname><given-names>AL</given-names></name><name><surname>Asghar</surname><given-names>Z</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Drury</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>Maternal metabolic syndrome programs mitochondrial dysfunction via germline changes across three generations</article-title>. <source/>Cell Rep. (<year>2016</year>) <volume>16</volume>:<fpage>1</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.065</pub-id><pub-id pub-id-type="pmid">27320925</pub-id></mixed-citation>
</ref>
<ref id="B175">
<label>175.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Pauw</surname><given-names>A</given-names></name><name><surname>Tejerina</surname><given-names>S</given-names></name><name><surname>Raes</surname><given-names>M</given-names></name><name><surname>Keijer</surname><given-names>J</given-names></name><name><surname>Arnould</surname><given-names>T</given-names></name></person-group>. <article-title>Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations</article-title>. <source/>Am J Pathol. (<year>2009</year>) <volume>175</volume>:<fpage>927</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2009.081155</pub-id><pub-id pub-id-type="pmid">19700756</pub-id></mixed-citation>
</ref>
<ref id="B176">
<label>176.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugger</surname><given-names>H</given-names></name><name><surname>Abel</surname><given-names>ED</given-names></name></person-group>. <article-title>Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome</article-title>. <source/>Clin Sci. (<year>2008</year>) <volume>114</volume>:<fpage>195</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1042/CS20070166</pub-id><pub-id pub-id-type="pmid">18184113</pub-id></mixed-citation>
</ref>
<ref id="B177">
<label>177.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luz</surname><given-names>AL</given-names></name><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name><name><surname>Meyer</surname><given-names>JN</given-names></name></person-group>. <article-title>The high-production volume fungicide pyraclostrobin induces triglyceride accumulation associated with mitochondrial dysfunction, and promotes adipocyte differentiation independent of PPARgamma activation, in 3T3-L1 cells</article-title>. <source/>Toxicol. (<year>2018</year>) <volume>393</volume>:<fpage>150</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2017.11.010</pub-id><pub-id pub-id-type="pmid">29127035</pub-id></mixed-citation>
</ref>
<ref id="B178">
<label>178.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>RH</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>ZG</given-names></name><name><surname>Su</surname><given-names>SS</given-names></name><name><surname>Yang</surname><given-names>GS</given-names></name></person-group>. <article-title>Mitochondrial development and the influence of its dysfunction during rat adipocyte differentiation</article-title>. <source/>Mol Biol Rep. (<year>2010</year>) <volume>37</volume>:<fpage>2173</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1007/s11033-009-9695-z</pub-id><pub-id pub-id-type="pmid">19693701</pub-id></mixed-citation>
</ref>
<ref id="B179">
<label>179.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusminski</surname><given-names>CM</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name></person-group>. <article-title>Mitochondrial dysfunction in white adipose tissue</article-title>. <source/>Trends Endocrinol Metabol. (<year>2012</year>) <volume>23</volume>:<fpage>435</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.tem.2012.06.004</pub-id><pub-id pub-id-type="pmid">22784416</pub-id></mixed-citation>
</ref>
<ref id="B180">
<label>180.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medina-Gomez</surname><given-names>G</given-names></name></person-group>. <article-title>Mitochondria and endocrine function of adipose tissue</article-title>. <source/>Best Prac Res. Clin. Endocrinol Metabol. (<year>2012</year>) <volume>26</volume>:<fpage>791</fpage>–<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1016/j.beem.2012.06.002</pub-id><pub-id pub-id-type="pmid">23168280</pub-id></mixed-citation>
</ref>
<ref id="B181">
<label>181.</label>
<mixed-citation publication-type="webpage"><person-group person-group-type="editor"><collab>U. Survey SG</collab></person-group>
<article-title>Estimated annual agricultural pesticide use - pyraclostrobin</article-title>. In: <person-group person-group-type="editor"><collab>U.S.D.o. Interior</collab></person-group>, editor. <source/>Pesticide National Synthesis Project (<year>2016</year>). Available online at: <ext-link ext-link-type="uri" xlink:href="https://water.usgs.gov/nawqa/pnsp/usage/maps/show_map.php?year=2016&amp;map=PYRACLOSTROBIN&amp;hilo=L">https://water.usgs.gov/nawqa/pnsp/usage/maps/show_map.php?year=2016&amp;map=PYRACLOSTROBIN&amp;hilo=L</ext-link></mixed-citation>
</ref>
<ref id="B182">
<label>182.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>BL</given-names></name><name><surname>Simon</surname><given-names>JM</given-names></name><name><surname>McCoy</surname><given-names>ES</given-names></name><name><surname>Salazar</surname><given-names>G</given-names></name><name><surname>Fragola</surname><given-names>G</given-names></name><name><surname>Zylka</surname><given-names>MJ</given-names></name></person-group>. <article-title>Identification of chemicals that mimic transcriptional changes associated with autism, brain aging and neurodegeneration</article-title>. <source/>Nature Commun. (<year>2016</year>) <volume>7</volume>:<fpage>11173</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms11173</pub-id><pub-id pub-id-type="pmid">27029645</pub-id></mixed-citation>
</ref>
<ref id="B183">
<label>183.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>DW</given-names></name><name><surname>Clough</surname><given-names>JM</given-names></name><name><surname>Godwin</surname><given-names>JR</given-names></name><name><surname>Hall</surname><given-names>AA</given-names></name><name><surname>Hamer</surname><given-names>M</given-names></name><name><surname>Parr-Dobrzanski</surname><given-names>B</given-names></name></person-group>. <article-title>The strobilurin fungicides</article-title>. <source/>Pest Manag Sci. (<year>2002</year>) <volume>58</volume>:<fpage>649</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1002/ps.520</pub-id><pub-id pub-id-type="pmid">12146165</pub-id></mixed-citation>
</ref>
<ref id="B184">
<label>184.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>. <article-title>Characterization of adipogenic activity of semi-volatile indoor contaminants and house dust</article-title>. <source/>Environ Sci Technol In (<year>2017</year>) <volume>51</volume>:<fpage>8735</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.7b01788</pub-id><pub-id pub-id-type="pmid">28699343</pub-id></mixed-citation>
</ref>
<ref id="B185">
<label>185.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>B</given-names></name><name><surname>Doheny</surname><given-names>DL</given-names></name><name><surname>Black</surname><given-names>MB</given-names></name><name><surname>Pendse</surname><given-names>SN</given-names></name><name><surname>Wetmore</surname><given-names>BA</given-names></name><name><surname>Clewell</surname><given-names>RA</given-names></name><etal></etal></person-group>. <article-title>Screening toxcast prioritized chemicals for PPARG function in a human adipose-derived stem cell model of adipogenesis</article-title>. <source/>Toxicol Sci. (<year>2017</year>) <volume>155</volume>:<fpage>85</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfw186</pub-id><pub-id pub-id-type="pmid">27664422</pub-id></mixed-citation>
</ref>
<ref id="B186">
<label>186.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Alharbi</surname><given-names>HA</given-names></name><name><surname>Jones</surname><given-names>PD</given-names></name><name><surname>Giesy</surname><given-names>JP</given-names></name><name><surname>Wiseman</surname><given-names>S</given-names></name></person-group>. <article-title>Peroxisome proliferator-activated receptor γ is a sensitive target for oil sands process-affected water: effects on adipogenesis and identification of ligands</article-title>. <source/>Environ Sci Technol. (<year>2016</year>) <volume>50</volume>:<fpage>7816</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.6b01890</pub-id><pub-id pub-id-type="pmid">27340905</pub-id></mixed-citation>
</ref>
<ref id="B187">
<label>187.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rundle</surname><given-names>K</given-names></name><name><surname>Sharaf</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>D</given-names></name><name><surname>Kamunde</surname><given-names>C</given-names></name><name><surname>Van Den Heuvel</surname><given-names>MR</given-names></name></person-group>. <article-title>Oil sands-derived naphthenic acids are oxidative uncouplers and impair electron transport in isolated mitochondria</article-title>. <source/>Environ Sci Technol. (<year>2018</year>) <volume>52</volume>:<fpage>10803</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.8b02638</pub-id><pub-id pub-id-type="pmid">30102860</pub-id></mixed-citation>
</ref>
<ref id="B188">
<label>188.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tormos</surname><given-names>KV</given-names></name><name><surname>Anso</surname><given-names>E</given-names></name><name><surname>Hamanaka</surname><given-names>RB</given-names></name><name><surname>Eisenbart</surname><given-names>J</given-names></name><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Kalyanaraman</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Mitochondrial complex III ROS regulate adipocyte differentiation</article-title>. <source/>Cell Metab. (<year>2011</year>) <volume>14</volume>:<fpage>537</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2011.08.007</pub-id><pub-id pub-id-type="pmid">21982713</pub-id></mixed-citation>
</ref>
<ref id="B189">
<label>189.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hai</surname><given-names>C</given-names></name></person-group>. <article-title>Redox modulation of adipocyte differentiation: hypothesis of “Redox Chain” and novel insights into intervention of adipogenesis and obesity</article-title>. <source/>Free Radic Biol Med. (<year>2015</year>) <volume>89</volume>:<fpage>99</fpage>–<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.07.012</pub-id><pub-id pub-id-type="pmid">26187871</pub-id></mixed-citation>
</ref>
<ref id="B190">
<label>190.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Ko</surname><given-names>EH</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name></person-group>. <article-title>Reactive oxygen species facilitate adipocyte differentiation by accelerating mitotic clonal expansion</article-title>. <source/>J Biol Chem. (<year>2009</year>) <volume>284</volume>:<fpage>10601</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M808742200</pub-id><pub-id pub-id-type="pmid">19237544</pub-id></mixed-citation>
</ref>
<ref id="B191">
<label>191.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carriere</surname><given-names>A</given-names></name><name><surname>Carmona</surname><given-names>MC</given-names></name><name><surname>Fernandez</surname><given-names>Y</given-names></name><name><surname>Rigoulet</surname><given-names>M</given-names></name><name><surname>Wenger</surname><given-names>RH</given-names></name><name><surname>Penicaud</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Mitochondrial reactive oxygen species control the transcription factor CHOP-10/GADD153 and adipocyte differentiation: a mechanism for hypoxia-dependent effect</article-title>. <source/>J Biol Chem. (<year>2004</year>) <volume>279</volume>:<fpage>40462</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M407258200</pub-id><pub-id pub-id-type="pmid">15265861</pub-id></mixed-citation>
</ref>
<ref id="B192">
<label>192.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carriere</surname><given-names>A</given-names></name><name><surname>Fernandez</surname><given-names>Y</given-names></name><name><surname>Rigoulet</surname><given-names>M</given-names></name><name><surname>Penicaud</surname><given-names>L</given-names></name><name><surname>Casteilla</surname><given-names>L</given-names></name></person-group>. <article-title>Inhibition of preadipocyte proliferation by mitochondrial reactive oxygen species</article-title>. <source/>FEBS Lett. (<year>2003</year>) <volume>550</volume>:<fpage>163</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-5793(03)00862-7</pub-id><pub-id pub-id-type="pmid">12935904</pub-id></mixed-citation>
</ref>
<ref id="B193">
<label>193.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanda</surname><given-names>Y</given-names></name><name><surname>Hinata</surname><given-names>T</given-names></name><name><surname>Kang</surname><given-names>SW</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name></person-group>. <article-title>Reactive oxygen species mediate adipocyte differentiation in mesenchymal stem cells</article-title>. <source/>Life Sci. (<year>2011</year>) <volume>89</volume>:<fpage>250</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2011.06.007</pub-id><pub-id pub-id-type="pmid">21722651</pub-id></mixed-citation>
</ref>
<ref id="B194">
<label>194.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Cho</surname><given-names>YM</given-names></name><name><surname>Kwak</surname><given-names>SH</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Shim</surname><given-names>EB</given-names></name></person-group>. <article-title>Mitochondrial dysfunction and metabolic syndrome-looking for environmental factors</article-title>. <source/>Biochim Biophys Acta (<year>2010</year>) <volume>1800</volume>:<fpage>282</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2009.11.010</pub-id><pub-id pub-id-type="pmid">19914351</pub-id></mixed-citation>
</ref>
<ref id="B195">
<label>195.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>SY</given-names></name><name><surname>Song</surname><given-names>IC</given-names></name><name><surname>Chung</surname><given-names>MH</given-names></name><name><surname>Jang</surname><given-names>HC</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><etal></etal></person-group>. <article-title>Chronic exposure to the herbicide, atrazine, causes mitochondrial dysfunction and insulin resistance</article-title>. <source/>PLoS ONE (<year>2009</year>) <volume>4</volume>:<fpage>e5186</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0005186</pub-id><pub-id pub-id-type="pmid">19365547</pub-id></mixed-citation>
</ref>
<ref id="B196">
<label>196.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>K</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>PCB congeners induced mitochondrial dysfunction in Vero cells</article-title>. <source/>J Hazard Mater. (<year>2011</year>) <volume>185</volume>:<fpage>24</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhazmat.2010.08.061</pub-id><pub-id pub-id-type="pmid">20940083</pub-id></mixed-citation>
</ref>
<ref id="B197">
<label>197.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aly</surname><given-names>HA</given-names></name><name><surname>Domenech</surname><given-names>O</given-names></name></person-group>. <article-title>Aroclor 1254 induced cytotoxicity and mitochondrial dysfunction in isolated rat hepatocytes</article-title>. <source/>Toxicology (<year>2009</year>) <volume>262</volume>:<fpage>175</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2009.05.018</pub-id><pub-id pub-id-type="pmid">19486918</pub-id></mixed-citation>
</ref>
<ref id="B198">
<label>198.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>SL</given-names></name><name><surname>Shaw</surname><given-names>AC</given-names></name><name><surname>Gagne</surname><given-names>AX</given-names></name><name><surname>Chan</surname><given-names>HM</given-names></name></person-group>. <article-title>Chronic exposure to PCBs (Aroclor 1254) exacerbates obesity-induced insulin resistance and hyperinsulinemia in mice</article-title>. <source/>J Toxicol Environ Health. Part A (<year>2013</year>) <volume>76</volume>:<fpage>701</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1080/15287394.2013.796503</pub-id><pub-id pub-id-type="pmid">23980837</pub-id></mixed-citation>
</ref>
<ref id="B199">
<label>199.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donat-Vargas</surname><given-names>C</given-names></name><name><surname>Gea</surname><given-names>A</given-names></name><name><surname>Sayon-Orea</surname><given-names>C</given-names></name><name><surname>Carlos</surname><given-names>S</given-names></name><name><surname>Martinez-Gonzalez</surname><given-names>MA</given-names></name><name><surname>Bes-Rastrollo</surname><given-names>M</given-names></name></person-group>. <article-title>Association between dietary intakes of PCBs and the risk of obesity: the SUN project</article-title>. <source/>J Epidemiol Commun Health (<year>2014</year>) <volume>68</volume>:<fpage>834</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1136/jech-2013-203752</pub-id><pub-id pub-id-type="pmid">24759782</pub-id></mixed-citation>
</ref>
<ref id="B200">
<label>200.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Steffes</surname><given-names>MW</given-names></name><name><surname>Sjodin</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>RS</given-names></name><name><surname>Needham</surname><given-names>LL</given-names></name><name><surname>Jacobs</surname><given-names>DR</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Low dose organochlorine pesticides and polychlorinated biphenyls predict obesity, dyslipidemia, and insulin resistance among people free of diabetes</article-title>. <source/>PLoS ONE (<year>2011</year>) <volume>6</volume>:<fpage>e15977</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0015977</pub-id><pub-id pub-id-type="pmid">21298090</pub-id></mixed-citation>
</ref>
<ref id="B201">
<label>201.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Hirai</surname><given-names>T</given-names></name><name><surname>Mizoue</surname><given-names>T</given-names></name><name><surname>Terauchi</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Congener-specific polychlorinated biphenyls and the prevalence of diabetes in the Saku Control Obesity Program (SCOP)</article-title>. <source/>Endocr J. (<year>2011</year>) <volume>58</volume>:<fpage>589</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1507/endocrj.K10E-361</pub-id><pub-id pub-id-type="pmid">21551956</pub-id></mixed-citation>
</ref>
<ref id="B202">
<label>202.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirinck</surname><given-names>E</given-names></name><name><surname>Jorens</surname><given-names>PG</given-names></name><name><surname>Covaci</surname><given-names>A</given-names></name><name><surname>Geens</surname><given-names>T</given-names></name><name><surname>Roosens</surname><given-names>L</given-names></name><name><surname>Neels</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Obesity and persistent organic pollutants: possible obesogenic effect of organochlorine pesticides and polychlorinated biphenyls</article-title>. <source/>Obesity (<year>2011</year>) <volume>19</volume>:<fpage>709</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1038/oby.2010.133</pub-id><pub-id pub-id-type="pmid">20559302</pub-id></mixed-citation>
</ref>
<ref id="B203">
<label>203.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulos</surname><given-names>SP</given-names></name><name><surname>Dodson</surname><given-names>MV</given-names></name><name><surname>Hausman</surname><given-names>GJ</given-names></name></person-group>. <article-title>Cell line models for differentiation: preadipocytes and adipocytes</article-title>. <source/>Exp Biol Med. (<year>2010</year>) <volume>235</volume>:<fpage>1185</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1258/ebm.2010.010063</pub-id><pub-id pub-id-type="pmid">20864461</pub-id></mixed-citation>
</ref>
<ref id="B204">
<label>204.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Ojeda</surname><given-names>FJ</given-names></name><name><surname>Ruperez</surname><given-names>AI</given-names></name><name><surname>Gomez-Llorente</surname><given-names>C</given-names></name><name><surname>Gil</surname><given-names>A</given-names></name><name><surname>Aguilera</surname><given-names>CM</given-names></name></person-group>. <article-title>Cell models and their application for studying adipogenic differentiation in relation to obesity: a review</article-title>. <source/>Int J Mol Sci. (<year>2016</year>) <volume>17</volume>:<fpage>E1040</fpage>. <pub-id pub-id-type="doi">10.3390/ijms17071040</pub-id><pub-id pub-id-type="pmid">27376273</pub-id></mixed-citation>
</ref>
<ref id="B205">
<label>205.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>H</given-names></name><name><surname>Kehinde</surname><given-names>O</given-names></name></person-group>. <article-title>An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion</article-title>. <source/>Cell (<year>1975</year>) <volume>5</volume>:<fpage>19</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(75)90087-2</pub-id><pub-id pub-id-type="pmid">165899</pub-id></mixed-citation>
</ref>
<ref id="B206">
<label>206.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>H</given-names></name><name><surname>Meuth</surname><given-names>M</given-names></name></person-group>. <article-title>An established pre-adipose cell line and its differentiation in culture</article-title>. <source/>Cell (<year>1974</year>) <volume>3</volume>:<fpage>127</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(74)90116-0</pub-id><pub-id pub-id-type="pmid">4426090</pub-id></mixed-citation>
</ref>
<ref id="B207">
<label>207.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Liao</surname><given-names>K</given-names></name></person-group>. <article-title>Analysis of gene expression profile during 3T3-L1 preadipocyte differentiation</article-title>. <source/>Gene (<year>2000</year>) <volume>251</volume>:<fpage>45</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-1119(00)00192-X</pub-id><pub-id pub-id-type="pmid">10863095</pub-id></mixed-citation>
</ref>
<ref id="B208">
<label>208.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleensang</surname><given-names>A</given-names></name><name><surname>Vantangoli</surname><given-names>MM</given-names></name><name><surname>Odwin-DaCosta</surname><given-names>S</given-names></name><name><surname>Andersen</surname><given-names>ME</given-names></name><name><surname>Boekelheide</surname><given-names>K</given-names></name><name><surname>Bouhifd</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function</article-title>. <source/>Sci Rep. (<year>2016</year>) <volume>6</volume>:<fpage>28994</fpage>
<pub-id pub-id-type="doi">10.1038/srep28994</pub-id><pub-id pub-id-type="pmid">27456714</pub-id></mixed-citation>
</ref>
<ref id="B209">
<label>209.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janderova</surname><given-names>L</given-names></name><name><surname>McNeil</surname><given-names>M</given-names></name><name><surname>Murrell</surname><given-names>AN</given-names></name><name><surname>Mynatt</surname><given-names>RL</given-names></name><name><surname>Smith</surname><given-names>SR</given-names></name></person-group>. <article-title>Human mesenchymal stem cells as an in vitro model for human adipogenesis</article-title>. <source/>Obes Res. (<year>2003</year>) <volume>11</volume>:<fpage>65</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1038/oby.2003.11</pub-id><pub-id pub-id-type="pmid">12529487</pub-id></mixed-citation>
</ref>
<ref id="B210">
<label>210.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muruganandan</surname><given-names>S</given-names></name><name><surname>Roman</surname><given-names>AA</given-names></name><name><surname>Sinal</surname><given-names>CJ</given-names></name></person-group>. <article-title>Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program</article-title>. <source/>Cel Mol Life Sci. (<year>2009</year>) <volume>66</volume>:<fpage>236</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-008-8429-z</pub-id><pub-id pub-id-type="pmid">18854943</pub-id></mixed-citation>
</ref>
<ref id="B211">
<label>211.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>BO</given-names></name><name><surname>Shimada</surname><given-names>IS</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name></person-group>. <article-title>Leptin receptor promotes adipogenesis and reduces osteogenesis by regulating mesenchymal stromal cells in adult bone marrow</article-title>. <source/>Cell Stem Cell (<year>2016</year>) <volume>18</volume>:<fpage>782</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.stem.2016.02.015</pub-id><pub-id pub-id-type="pmid">27053299</pub-id></mixed-citation>
</ref>
<ref id="B212">
<label>212.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csaki</surname><given-names>C</given-names></name><name><surname>Matis</surname><given-names>U</given-names></name><name><surname>Mobasheri</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Shakibaei</surname><given-names>M</given-names></name></person-group>. <article-title>Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study</article-title>. <source/>Histochem Cell Biol. (<year>2007</year>) <volume>128</volume>:<fpage>507</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1007/s00418-007-0337-z</pub-id><pub-id pub-id-type="pmid">17922135</pub-id></mixed-citation>
</ref>
<ref id="B213">
<label>213.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Monti</surname><given-names>S</given-names></name><name><surname>Schlezinger</surname><given-names>JJ</given-names></name></person-group>. <article-title>Tributyltin induces a transcriptional response without a brite adipocyte signature in adipocyte models</article-title>. <source/>Arch Toxicol. (<year>2018</year>) <volume>92</volume>:<fpage>2859</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-018-2268-y</pub-id><pub-id pub-id-type="pmid">30027469</pub-id></mixed-citation>
</ref>
<ref id="B214">
<label>214.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>QQ</given-names></name><name><surname>Otto</surname><given-names>TC</given-names></name><name><surname>Lane</surname><given-names>MD</given-names></name></person-group>. <article-title>Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage</article-title>. <source/>Proc Nat Acad Sci USA. (<year>2004</year>) <volume>101</volume>:<fpage>9607</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0403100101</pub-id><pub-id pub-id-type="pmid">15210946</pub-id></mixed-citation>
</ref>
<ref id="B215">
<label>215.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katagiri</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>A</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Yoshiki</surname><given-names>S</given-names></name><name><surname>Wozney</surname><given-names>JM</given-names></name><name><surname>Rosen</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2</article-title>. <source/>Biochem Biophys Res Commun. (<year>1990</year>) <volume>172</volume>:<fpage>295</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-291X(05)80208-6</pub-id><pub-id pub-id-type="pmid">1699539</pub-id></mixed-citation>
</ref>
<ref id="B216">
<label>216.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Itaka</surname><given-names>K</given-names></name><name><surname>Ohba</surname><given-names>S</given-names></name><name><surname>Nishiyama</surname><given-names>N</given-names></name><name><surname>Chung</surname><given-names>UI</given-names></name><name><surname>Yamasaki</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>3D spheroid culture system on micropatterned substrates for improved differentiation efficiency of multipotent mesenchymal stem cells</article-title>. <source/>Biomaterials (<year>2009</year>) <volume>30</volume>:<fpage>2705</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.01.030</pub-id><pub-id pub-id-type="pmid">19215979</pub-id></mixed-citation>
</ref>
<ref id="B217">
<label>217.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baraniak</surname><given-names>PR</given-names></name><name><surname>McDevitt</surname><given-names>TC</given-names></name></person-group>. <article-title>Scaffold-free culture of mesenchymal stem cell spheroids in suspension preserves multilineage potential</article-title>. <source/>Cell Tissue Res. (<year>2012</year>) <volume>347</volume>:<fpage>701</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1007/s00441-011-1215-5</pub-id><pub-id pub-id-type="pmid">21833761</pub-id></mixed-citation>
</ref>
<ref id="B218">
<label>218.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>NC</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>TH</given-names></name></person-group>. <article-title>The influence of spheroid formation of human adipose-derived stem cells on chitosan films on stemness and differentiation capabilities</article-title>. <source/>Biomaterials (<year>2012</year>) <volume>33</volume>:<fpage>1748</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.11.049</pub-id><pub-id pub-id-type="pmid">22153870</pub-id></mixed-citation>
</ref>
<ref id="B219">
<label>219.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>PA</given-names></name><name><surname>Gurumurthy</surname><given-names>B</given-names></name><name><surname>Bailey</surname><given-names>JL</given-names></name><name><surname>Elks</surname><given-names>CM</given-names></name><name><surname>Janorkar</surname><given-names>AV</given-names></name></person-group>. <article-title>Adipogenic differentiation of human adipose-derived stem cells grown as spheroids</article-title>. <source/>Process Biochem. (<year>2017</year>) <volume>59</volume>:<fpage>312</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.procbio.2017.02.003</pub-id><pub-id pub-id-type="pmid">28966553</pub-id></mixed-citation>
</ref>
<ref id="B220">
<label>220.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>PA</given-names></name><name><surname>Harris</surname><given-names>LM</given-names></name><name><surname>Purser</surname><given-names>CA</given-names></name><name><surname>Baker</surname><given-names>RC</given-names></name><name><surname>Janorkar</surname><given-names>AV</given-names></name></person-group>. <article-title>A surface-tethered spheroid model for functional evaluation of 3T3-L1 adipocytes</article-title>. <source/>Biotechnol Bioeng. (<year>2014</year>) <volume>111</volume>:<fpage>174</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1002/bit.25099</pub-id><pub-id pub-id-type="pmid">24038000</pub-id></mixed-citation>
</ref>
<ref id="B221">
<label>221.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyagawa</surname><given-names>Y</given-names></name><name><surname>Okita</surname><given-names>H</given-names></name><name><surname>Hiroyama</surname><given-names>M</given-names></name><name><surname>Sakamoto</surname><given-names>R</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>A microfabricated scaffold induces the spheroid formation of human bone marrow-derived mesenchymal progenitor cells and promotes efficient adipogenic differentiation</article-title>. <source/>Tissue Eng Part A. (<year>2011</year>) <volume>17</volume>:<fpage>513</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1089/ten.tea.2009.0810</pub-id><pub-id pub-id-type="pmid">20818998</pub-id></mixed-citation>
</ref>
<ref id="B222">
<label>222.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapur</surname><given-names>SK</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shang</surname><given-names>H</given-names></name><name><surname>Yun</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Human adipose stem cells maintain proliferative, synthetic and multipotential properties when suspension cultured as self-assembling spheroids</article-title>. <source/>Biofabrication (<year>2012</year>) <volume>4</volume>:<fpage>025004</fpage>. <pub-id pub-id-type="doi">10.1088/1758-5082/4/2/025004</pub-id><pub-id pub-id-type="pmid">22522924</pub-id></mixed-citation>
</ref>
<ref id="B223">
<label>223.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxton</surname><given-names>D</given-names></name></person-group>
<source/>Toxic Substances Control Act Inventory. US Environmental Protection Agency (<year>2014</year>).</mixed-citation>
</ref>
<ref id="B224">
<label>224.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markell</surname><given-names>D</given-names></name></person-group>
<article-title>An overview of TSCA, its history and key underlying assumptions, and its place in environmental regulation</article-title>. <source/>Washington Univ J Law Pol. (<year>2010</year>) <volume>32</volume>:<fpage>42</fpage> Available online at: <ext-link ext-link-type="uri" xlink:href="https://openscholarship.wustl.edu/law_journal_law_policy/vol32/iss1/11/">https://openscholarship.wustl.edu/law_journal_law_policy/vol32/iss1/11/</ext-link></mixed-citation>
</ref>
<ref id="B225">
<label>225.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>D.o.H.a.Services H</collab></person-group>
<source/>National Report on Human Exposure to Environmental Chemicals. Centers for Disease Control and Prevention (<year>2015</year>).</mixed-citation>
</ref>
<ref id="B226">
<label>226.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houlihan</surname><given-names>J</given-names></name><name><surname>Kropp</surname><given-names>T</given-names></name><name><surname>Wiles</surname><given-names>R</given-names></name><name><surname>Gray</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name></person-group>
<source/>BodyBurden: The Pollution in Newborns. Environmental Working Group (<year>2005</year>).</mixed-citation>
</ref>
<ref id="B227">
<label>227.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>E</given-names></name><name><surname>Rajapakse</surname><given-names>N</given-names></name><name><surname>Kortenkamp</surname><given-names>A</given-names></name></person-group>. <article-title>Something from “nothing”–eight weak estrogenic chemicals combined at concentrations below NOECs produce significant mixture effects</article-title>. <source/>Environ Sci Technol. (<year>2002</year>) <volume>36</volume>:<fpage>1751</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1021/es0101227</pub-id><pub-id pub-id-type="pmid">11993873</pub-id></mixed-citation>
</ref>
<ref id="B228">
<label>228.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajapakse</surname><given-names>N</given-names></name><name><surname>Silva</surname><given-names>E</given-names></name><name><surname>Kortenkamp</surname><given-names>A</given-names></name></person-group>. <article-title>Combining xenoestrogens at levels below individual no-observed-effect concentrations dramatically enhances steroid hormone action</article-title>. <source/>Environ Health Perspect. (<year>2002</year>) <volume>110</volume>:<fpage>917</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.02110917</pub-id><pub-id pub-id-type="pmid">12204827</pub-id></mixed-citation>
</ref>
<ref id="B229">
<label>229.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christiansen</surname><given-names>S</given-names></name><name><surname>Scholze</surname><given-names>M</given-names></name><name><surname>Axelstad</surname><given-names>M</given-names></name><name><surname>Boberg</surname><given-names>J</given-names></name><name><surname>Kortenkamp</surname><given-names>A</given-names></name><name><surname>Hass</surname><given-names>U</given-names></name></person-group>. <article-title>Combined exposure to anti-androgens causes markedly increased frequencies of hypospadias in the rat</article-title>. <source/>Int J Androl. (<year>2008</year>) <volume>31</volume>:<fpage>241</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2605.2008.00866.x</pub-id><pub-id pub-id-type="pmid">18315719</pub-id></mixed-citation>
</ref>
<ref id="B230">
<label>230.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orton</surname><given-names>F</given-names></name><name><surname>Rosivatz</surname><given-names>E</given-names></name><name><surname>Scholze</surname><given-names>M</given-names></name><name><surname>Kortenkamp</surname><given-names>A</given-names></name></person-group>. <article-title>Competitive androgen receptor antagonism as a factor determining the predictability of cumulative antiandrogenic effects of widely used pesticides</article-title>. <source/>Environ Health Perspect. (<year>2012</year>) <volume>120</volume>:<fpage>1578</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1205391</pub-id><pub-id pub-id-type="pmid">23008280</pub-id></mixed-citation>
</ref>
<ref id="B231">
<label>231.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrupp</surname><given-names>TJ</given-names></name><name><surname>Runnalls</surname><given-names>TJ</given-names></name><name><surname>Scholze</surname><given-names>M</given-names></name><name><surname>Kugathas</surname><given-names>S</given-names></name><name><surname>Kortenkamp</surname><given-names>A</given-names></name><name><surname>Sumpter</surname><given-names>JP</given-names></name></person-group>
<article-title>The consequences of exposure to mixtures of chemicals: Something from ‘nothing' and ‘a lot from a little' when fish are exposed to steroid hormones</article-title>. <source/>Sci Total Environ. (<year>2018</year>) 619–<volume>20</volume>:<fpage>1482</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2017.11.081</pub-id></mixed-citation>
</ref>
<ref id="B232">
<label>232.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>LJ</given-names></name><name><surname>Ying</surname><given-names>GG</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>SL</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>FZ</given-names></name><etal></etal></person-group>. <article-title>Screening of multiple hormonal activities in surface water and sediment from the Pearl River system, South China, using effect-directed in vitro bioassays</article-title>. <source/>Environ Toxicol Chem. (<year>2011</year>) <volume>30</volume>:<fpage>2208</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1002/etc.625</pub-id><pub-id pub-id-type="pmid">21766324</pub-id></mixed-citation>
</ref>
<ref id="B233">
<label>233.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>AM</given-names></name><name><surname>Calabro</surname><given-names>JM</given-names></name><name><surname>Prechtl</surname><given-names>NV</given-names></name><name><surname>Yau</surname><given-names>AY</given-names></name><name><surname>Orlando</surname><given-names>EF</given-names></name><name><surname>Daxenberger</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Androgenic and estrogenic activity in water bodies receiving cattle feedlot effluent in Eastern Nebraska, USA. Environ Health Perspect</article-title>. (<year>2003</year>) <volume>112</volume>:<fpage>346</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.6590</pub-id></mixed-citation>
</ref>
<ref id="B234">
<label>234.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlowski</surname><given-names>S</given-names></name><name><surname>Ternes</surname><given-names>TA</given-names></name><name><surname>Bonerz</surname><given-names>M</given-names></name><name><surname>Rastall</surname><given-names>AC</given-names></name><name><surname>Erdinger</surname><given-names>L</given-names></name><name><surname>Braunbeck</surname><given-names>T</given-names></name></person-group>. <article-title>Estrogenicity of solid phase-extracted water samples from two municipal sewage treatment plant effluents and river Rhine water using the yeast estrogen screen</article-title>. <source/>Toxicol in vitro (<year>2004</year>) <volume>18</volume>:<fpage>129</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2003.08.006</pub-id><pub-id pub-id-type="pmid">14630071</pub-id></mixed-citation>
</ref>
<ref id="B235">
<label>235.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Occurrence of thyroid hormone activities in drinking water from eastern China: contributions of phthalate esters</article-title>. <source/>Environ Sci Technol. (<year>2012</year>) <volume>46</volume>:<fpage>1811</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1021/es202625r</pub-id><pub-id pub-id-type="pmid">22191625</pub-id></mixed-citation>
</ref>
<ref id="B236">
<label>236.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schriks</surname><given-names>M</given-names></name><name><surname>Van Leerdam</surname><given-names>JASC</given-names></name><name><surname>Van Der Linden</surname><given-names>B</given-names></name><name><surname>Van Der</surname><given-names>Burg</given-names></name><name><surname>Van Wezel</surname><given-names>AP</given-names></name><name><surname>De Voogt</surname><given-names>P</given-names></name></person-group>. <article-title>High-resolution mass spectrometric identification and quantification of glucocorticoid compounds in various Wastewaters in The Netherlands</article-title>. <source/>Environ Sci Technol. (<year>2010</year>) <volume>44</volume>:<fpage>4766</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1021/es100013x</pub-id><pub-id pub-id-type="pmid">20507090</pub-id></mixed-citation>
</ref>
<ref id="B237">
<label>237.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Linden</surname><given-names>SC</given-names></name><name><surname>Heringa</surname><given-names>MB</given-names></name><name><surname>Man</surname><given-names>HY</given-names></name><name><surname>Sonneveld</surname><given-names>E</given-names></name><name><surname>Puijker</surname><given-names>LM</given-names></name><name><surname>Brouwer</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Detection of multiple hormonal activities in wastewater effluents and surface water, using a panel of steroid receptor CALUX bioassays</article-title>. <source/>Environ Sci Technol. (<year>2008</year>) <volume>42</volume>:<fpage>5814</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1021/es702897y</pub-id><pub-id pub-id-type="pmid">18754514</pub-id></mixed-citation>
</ref>
<ref id="B238">
<label>238.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stavreva</surname><given-names>DA</given-names></name><name><surname>George</surname><given-names>AA</given-names></name><name><surname>Klausmeyer</surname><given-names>P</given-names></name><name><surname>Varticovski</surname><given-names>L</given-names></name><name><surname>Sack</surname><given-names>D</given-names></name><name><surname>Voss</surname><given-names>TC</given-names></name><etal></etal></person-group>. <article-title>Prevalent glucocorticoid and androgen activity in US water sources</article-title>. <source/>Sci Rep. (<year>2012</year>) <volume>2</volume>:<fpage>937</fpage>. <pub-id pub-id-type="doi">10.1038/srep00937</pub-id><pub-id pub-id-type="pmid">23226835</pub-id></mixed-citation>
</ref>
<ref id="B239">
<label>239.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Ying</surname><given-names>GG</given-names></name><name><surname>Zhou</surname><given-names>LJ</given-names></name><name><surname>Zhang</surname><given-names>RQ</given-names></name><name><surname>Chen</surname><given-names>ZF</given-names></name><name><surname>Lai</surname><given-names>HJ</given-names></name></person-group>. <article-title>Steroids in a typical swine farm and their release into the environment</article-title>. <source/>Water Res. (<year>2012</year>) <volume>46</volume>:<fpage>3754</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.watres.2012.04.006</pub-id><pub-id pub-id-type="pmid">22591816</pub-id></mixed-citation>
</ref>
<ref id="B240">
<label>240.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rostkowski</surname><given-names>P</given-names></name><name><surname>Horwood</surname><given-names>J</given-names></name><name><surname>Shears</surname><given-names>JA</given-names></name><name><surname>Lange</surname><given-names>A</given-names></name><name><surname>Oladapo</surname><given-names>FO</given-names></name><name><surname>Besselink</surname><given-names>HT</given-names></name><etal></etal></person-group>. <article-title>Bioassay-Directed identification of novel antiandrogenic compounds in bile of fish exposed to wastewater effluents</article-title>. <source/>Environ Sci Technol. (<year>2011</year>) <volume>45</volume>:<fpage>10660</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1021/es202966c</pub-id><pub-id pub-id-type="pmid">22047186</pub-id></mixed-citation>
</ref>
<ref id="B241">
<label>241.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortenkamp</surname><given-names>A</given-names></name><name><surname>Scholze</surname><given-names>M</given-names></name><name><surname>Ermler</surname><given-names>S</given-names></name></person-group>. <article-title>Mind the gap: can we explain declining male reproductive health with known antiandrogens?</article-title>
<source/>Reproduction (<year>2014</year>) <volume>147</volume>:<fpage>515</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1530/REP-13-0440</pub-id><pub-id pub-id-type="pmid">24435164</pub-id></mixed-citation>
</ref>
<ref id="B242">
<label>242.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Office of Prevention Toxic Substances</collab></person-group>
<source/>OPPTS 890.1300: Estrogen Receptor Transcriptional Activation (Human Cell Line (HeLa-9903)) (<year>2009</year>). p. <fpage>23</fpage>.</mixed-citation>
</ref>
<ref id="B243">
<label>243.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naylor</surname><given-names>LH</given-names></name></person-group>. <article-title>Reporter gene technology: the future looks bright</article-title>. <source/>Biochem Pharmacol. (<year>1999</year>) <volume>58</volume>:<fpage>749</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-2952(99)00096-9</pub-id><pub-id pub-id-type="pmid">10449183</pub-id></mixed-citation>
</ref>
<ref id="B244">
<label>244.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>AM</given-names></name><name><surname>Maffini</surname><given-names>MV</given-names></name><name><surname>Schaeberle</surname><given-names>CM</given-names></name><name><surname>Sonnenschein</surname><given-names>C</given-names></name></person-group>. <article-title>Strengths and weaknesses of <italic>in vitro</italic> assays for estrogenic and androgenic activity</article-title>. <source/>Best Pract Res Clin Endocrinol Metabol. (<year>2006</year>) <volume>20</volume>:<fpage>15</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.beem.2005.09.001</pub-id><pub-id pub-id-type="pmid">16522517</pub-id></mixed-citation>
</ref>
<ref id="B245">
<label>245.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruger</surname><given-names>T</given-names></name><name><surname>Hjelmborg</surname><given-names>PS</given-names></name><name><surname>Jonsson</surname><given-names>BA</given-names></name><name><surname>Hagmar</surname><given-names>L</given-names></name><name><surname>Giwercman</surname><given-names>A</given-names></name><name><surname>Manicardi</surname><given-names>GC</given-names></name><etal></etal></person-group>. <article-title>Xenoandrogenic activity in serum differs across European and Inuit populations</article-title>. <source/>Environ Health Perspect. (<year>2007</year>) <volume>115</volume> (<issue>Suppl. 1</issue>):<fpage>21</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.9353</pub-id><pub-id pub-id-type="pmid">18174946</pub-id></mixed-citation>
</ref>
<ref id="B246">
<label>246.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Espinosa</surname><given-names>MJ</given-names></name><name><surname>Silva</surname><given-names>E</given-names></name><name><surname>Granada</surname><given-names>A</given-names></name><name><surname>Molina-Molina</surname><given-names>JM</given-names></name><name><surname>Fernandez</surname><given-names>MF</given-names></name><name><surname>Aguilar-Garduno</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Assessment of the total effective xenoestrogen burden in extracts of human placentas</article-title>. <source/>Biomarkers (<year>2009</year>) <volume>14</volume>:<fpage>271</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1080/13547500902893744</pub-id><pub-id pub-id-type="pmid">19476411</pub-id></mixed-citation>
</ref>
<ref id="B247">
<label>247.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>MF</given-names></name><name><surname>Aguilar-Garduno</surname><given-names>C</given-names></name><name><surname>Molina-Molina</surname><given-names>JM</given-names></name><name><surname>Arrebola</surname><given-names>JP</given-names></name><name><surname>Olea</surname><given-names>N</given-names></name></person-group>. <article-title>The total effective xenoestrogen burden, a biomarker of exposure to xenoestrogen mixtures, is predicted by the (anti)estrogenicity of its components</article-title>. <source/>Reprod Toxicol. (<year>2008</year>) <volume>26</volume>:<fpage>8</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.reprotox.2008.06.002</pub-id><pub-id pub-id-type="pmid">18586082</pub-id></mixed-citation>
</ref>
<ref id="B248">
<label>248.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrebola</surname><given-names>JP</given-names></name><name><surname>Fernandez</surname><given-names>MF</given-names></name><name><surname>Molina-Molina</surname><given-names>JM</given-names></name><name><surname>Martin-Olmedo</surname><given-names>P</given-names></name><name><surname>Exposito</surname><given-names>J</given-names></name><name><surname>Olea</surname><given-names>N</given-names></name></person-group>. <article-title>Predictors of the total effective xenoestrogen burden (TEXB) in human adipose tissue. A pilot study</article-title>. <source/>Reprod Toxicol. (<year>2012</year>) <volume>33</volume>:<fpage>45</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.reprotox.2011.10.015</pub-id><pub-id pub-id-type="pmid">22107726</pub-id></mixed-citation>
</ref>
<ref id="B249">
<label>249.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>MF</given-names></name><name><surname>Molina-Molina</surname><given-names>JM</given-names></name><name><surname>Lopez-Espinosa</surname><given-names>MJ</given-names></name><name><surname>Freire</surname><given-names>C</given-names></name><name><surname>Campoy</surname><given-names>C</given-names></name><name><surname>Ibarluzea</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Biomonitoring of environmental estrogens in human tissues</article-title>. <source/>Int J Hyg Environ Health (<year>2007</year>) <volume>210</volume>:<fpage>429</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijheh.2007.01.014</pub-id><pub-id pub-id-type="pmid">17296326</pub-id></mixed-citation>
</ref>
<ref id="B250">
<label>250.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>MF</given-names></name><name><surname>Santa-Marina</surname><given-names>L</given-names></name><name><surname>Ibarluzea</surname><given-names>JM</given-names></name><name><surname>Exposito</surname><given-names>J</given-names></name><name><surname>Aurrekoetxea</surname><given-names>JJ</given-names></name><name><surname>Torne</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Analysis of population characteristics related to the total effective xenoestrogen burden: a biomarker of xenoestrogen exposure in breast cancer</article-title>. <source/>Eur J Cancer (<year>2007</year>) <volume>43</volume>:<fpage>1290</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2007.03.010</pub-id><pub-id pub-id-type="pmid">17466515</pub-id></mixed-citation>
</ref>
<ref id="B251">
<label>251.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yordy</surname><given-names>JE</given-names></name><name><surname>Mollenhauer</surname><given-names>MA</given-names></name><name><surname>Wilson</surname><given-names>RM</given-names></name><name><surname>Wells</surname><given-names>RS</given-names></name><name><surname>Hohn</surname><given-names>A</given-names></name><name><surname>Sweeney</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Complex contaminant exposure in cetaceans: a comparative E-Screen analysis of bottlenose dolphin blubber and mixtures of four persistent organic pollutants</article-title>. <source/>Environ Toxicol Chem. (<year>2010</year>) <volume>29</volume>:<fpage>2143</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1002/etc.279</pub-id><pub-id pub-id-type="pmid">20872675</pub-id></mixed-citation>
</ref>
<ref id="B252">
<label>252.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>MF</given-names></name><name><surname>Olmos</surname><given-names>B</given-names></name><name><surname>Granada</surname><given-names>A</given-names></name><name><surname>Lopez-Espinosa</surname><given-names>MJ</given-names></name><name><surname>Molina-Molina</surname><given-names>JM</given-names></name><name><surname>Fernandez</surname><given-names>JM</given-names></name><etal></etal></person-group>. <article-title>Human exposure to endocrine-disrupting chemicals and prenatal risk factors for cryptorchidism and hypospadias: a nested case-control study</article-title>. <source/>Environ Health Perspect. (<year>2007</year>) <volume>115</volume> (<issue>Suppl. 1</issue>):<fpage>8</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.9351</pub-id><pub-id pub-id-type="pmid">18174944</pub-id></mixed-citation>
</ref>
<ref id="B253">
<label>253.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilahur</surname><given-names>N</given-names></name><name><surname>Fernandez</surname><given-names>MF</given-names></name><name><surname>Bustamante</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>R</given-names></name><name><surname>Forns</surname><given-names>J</given-names></name><name><surname>Ballester</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>In utero exposure to mixtures of xenoestrogens and child neuropsychological development</article-title>. <source/>Environ Res. (<year>2014</year>) 134C:98–104. <pub-id pub-id-type="doi">10.1016/j.envres.2014.07.002</pub-id><pub-id pub-id-type="pmid">25086706</pub-id></mixed-citation>
</ref>
<ref id="B254">
<label>254.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibarluzea Jm</surname><given-names>J</given-names></name><name><surname>Fernandez</surname><given-names>MF</given-names></name><name><surname>Santa-Marina</surname><given-names>L</given-names></name><name><surname>Olea-Serrano</surname><given-names>MF</given-names></name><name><surname>Rivas</surname><given-names>AM</given-names></name><name><surname>Aurrekoetxea</surname><given-names>JJ</given-names></name><etal></etal></person-group>. <article-title>Breast cancer risk and the combined effect of environmental estrogens</article-title>. <source/>Cancer Causes Control (<year>2004</year>) <volume>15</volume>:<fpage>591</fpage>–<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1023/B:CACO.0000036167.51236.86</pub-id><pub-id pub-id-type="pmid">15280638</pub-id></mixed-citation>
</ref>
<ref id="B255">
<label>255.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilahur</surname><given-names>N</given-names></name><name><surname>Molina-Molina</surname><given-names>JM</given-names></name><name><surname>Bustamante</surname><given-names>M</given-names></name><name><surname>Murcia</surname><given-names>M</given-names></name><name><surname>Arrebola</surname><given-names>JP</given-names></name><name><surname>Ballester</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Male specific association between xenoestrogen levels in placenta and birthweight</article-title>. <source/>Environ Int. (<year>2013</year>) <volume>51</volume>:<fpage>174</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.envint.2012.10.004</pub-id><pub-id pub-id-type="pmid">23262415</pub-id></mixed-citation>
</ref>
<ref id="B256">
<label>256.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrebola</surname><given-names>JP</given-names></name><name><surname>Pumarega</surname><given-names>J</given-names></name><name><surname>Gasull</surname><given-names>M</given-names></name><name><surname>Fernandez</surname><given-names>MF</given-names></name><name><surname>Martin-Olmedo</surname><given-names>P</given-names></name><name><surname>Molina-Molina</surname><given-names>JM</given-names></name><etal></etal></person-group>. <article-title>Adipose tissue concentrations of persistent organic pollutants and prevalence of type 2 diabetes in adults from Southern Spain</article-title>. <source/>Environ Res. (<year>2013</year>) <volume>122</volume>:<fpage>31</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.envres.2012.12.001</pub-id><pub-id pub-id-type="pmid">23290489</pub-id></mixed-citation>
</ref>
<ref id="B257">
<label>257.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruzzin</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Carpenter</surname><given-names>DO</given-names></name><name><surname>Jacobs</surname><given-names>DR</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Reconsidering metabolic diseases: the impacts of persistent organic pollutants</article-title>. <source/>Atherosclerosis (<year>2012</year>) <volume>224</volume>:<fpage>1</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2012.02.039</pub-id><pub-id pub-id-type="pmid">22472455</pub-id></mixed-citation>
</ref>
<ref id="B258">
<label>258.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>HP</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Ko</surname><given-names>CF</given-names></name><name><surname>Lin</surname><given-names>JY</given-names></name><name><surname>Kawanishi</surname><given-names>M</given-names></name><name><surname>Yagi</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Detection of hormone-like and genotoxic activities in indoor dust from taiwan using a battery of in vitro bioassays</article-title>. <source/>Aerosol Air Qual Res. (<year>2015</year>) <volume>15</volume>:<fpage>1412</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.4209/aaqr.2015.06.0404</pub-id></mixed-citation>
</ref>
<ref id="B259">
<label>259.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>G</given-names></name><name><surname>Takigami</surname><given-names>H</given-names></name><name><surname>Nose</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Asari</surname><given-names>M</given-names></name><name><surname>Sakai</surname><given-names>S</given-names></name></person-group>. <article-title>Dioxin-like and transthyretin-binding compounds in indoor dusts collected from Japan: average daily dose and possible implications for children</article-title>. <source/>Environ Sci Technol. (<year>2007</year>) <volume>41</volume>:<fpage>1487</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1021/es061907l</pub-id><pub-id pub-id-type="pmid">17593761</pub-id></mixed-citation>
</ref>
<ref id="B260">
<label>260.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>G</given-names></name><name><surname>Tue</surname><given-names>NM</given-names></name><name><surname>Malarvannan</surname><given-names>G</given-names></name><name><surname>Sudaryanto</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Tanabe</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Similarities in the endocrine-disrupting potencies of indoor dust and flame retardants by using human osteosarcoma (U2OS) cell-based reporter gene assays</article-title>. <source/>Environm Sci Technol. (<year>2013</year>) <volume>47</volume>:<fpage>2898</fpage>–<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1021/es304691a</pub-id><pub-id pub-id-type="pmid">23398518</pub-id></mixed-citation>
</ref>
<ref id="B261">
<label>261.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Webster</surname><given-names>TF</given-names></name><name><surname>Ferguson</surname><given-names>PL</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>. <article-title>Characterizing the peroxisome proliferator-activated receptor (PPARgamma) ligand binding potential of several major flame retardants, their metabolites, and chemical mixtures in house dust</article-title>. <source/>Environ Health Perspect. (<year>2015</year>) <volume>123</volume>:<fpage>166</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1408522</pub-id><pub-id pub-id-type="pmid">25314719</pub-id></mixed-citation>
</ref>
<ref id="B262">
<label>262.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Webster</surname><given-names>TF</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>. <article-title>Activation of human peroxisome proliferator-activated nuclear receptors (PPARgamma1) by semi-volatile compounds (SVOCs) and chemical mixtures in indoor dust</article-title>. <source/>Environ Sci Technol. (<year>2015</year>) <volume>49</volume>:<fpage>10057</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.5b01523</pub-id><pub-id pub-id-type="pmid">26172262</pub-id></mixed-citation>
</ref>
<ref id="B263">
<label>263.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Webster</surname><given-names>TF</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>. <article-title>Effect-directed analysis of human peroxisome proliferator-activated nuclear receptors (PPARgamma1) ligands in indoor dust</article-title>. <source/>Environ Sci Technol. (<year>2015</year>) <volume>49</volume>:<fpage>10065</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.5b01524</pub-id><pub-id pub-id-type="pmid">26172369</pub-id></mixed-citation>
</ref>
<ref id="B264">
<label>264.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Kollitz</surname><given-names>EM</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Sosa</surname><given-names>JA</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>
<article-title>Thyroid receptor antagonism as a contributory mechanism for adipogenesis induced by environmental mixtures in 3T3-L1 cells</article-title>. (<year>in press</year>).</mixed-citation>
</ref>
<ref id="B265">
<label>265.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollitz</surname><given-names>EM</given-names></name><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Ferguson</surname><given-names>PL</given-names></name><name><surname>Sosa</surname><given-names>JA</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>
<article-title>Chemical mixtures isolated from house dust disrupt thyroid receptor β (TRβ) signaling</article-title>. <source/>Environ Sci Technol. (<year>2018</year>) <volume>52</volume>:<fpage>11857</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.8b03283</pub-id></mixed-citation>
</ref>
<ref id="B266">
<label>266.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowers</surname><given-names>RR</given-names></name><name><surname>Temkin</surname><given-names>AM</given-names></name><name><surname>Guillette</surname><given-names>LJ</given-names></name><name><surname>Baatz</surname><given-names>JE</given-names></name><name><surname>Spyropoulos</surname><given-names>DD</given-names></name></person-group>. <article-title>The commonly used nonionic surfactant Span 80 has RXRalpha transactivation activity, which likely increases the obesogenic potential of oil dispersants and food emulsifiers</article-title>. <source/>General Comparat Endocrinol. (<year>2016</year>) <volume>238</volume>:<fpage>61</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygcen.2016.04.029</pub-id><pub-id pub-id-type="pmid">27131391</pub-id></mixed-citation>
</ref>
<ref id="B267">
<label>267.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Temkin</surname><given-names>AM</given-names></name><name><surname>Bowers</surname><given-names>RR</given-names></name><name><surname>Magaletta</surname><given-names>ME</given-names></name><name><surname>Holshouser</surname><given-names>S</given-names></name><name><surname>Maggi</surname><given-names>A</given-names></name><name><surname>Ciana</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Effects of crude oil/dispersant mixture and dispersant components on ppargamma activity and : identification of dioctyl sodium sulfosuccinate (DOSS; CAS #577–11–7) as a probable obesogen</article-title>. <source/>Environ Health Perspect. (<year>2015</year>) <volume>124</volume>:<fpage>112</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1409672</pub-id><pub-id pub-id-type="pmid">26135921</pub-id></mixed-citation>
</ref>
<ref id="B268">
<label>268.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Tillitt</surname><given-names>DE</given-names></name><name><surname>Davis</surname><given-names>JW</given-names></name><name><surname>Hormann</surname><given-names>AM</given-names></name><name><surname>Nagel</surname><given-names>SC</given-names></name></person-group>. <article-title>Estrogen and androgen receptor activities of hydraulic fracturing chemicals and surface and ground water in a drilling-dense region</article-title>. <source/>Endocrinology (<year>2014</year>) <volume>155</volume>:<fpage>897</fpage>–<lpage>907</lpage>. <pub-id pub-id-type="doi">10.1210/en.2013-1697</pub-id><pub-id pub-id-type="pmid">24424034</pub-id></mixed-citation>
</ref>
<ref id="B269">
<label>269.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Iwanowicz</surname><given-names>LR</given-names></name><name><surname>Akob</surname><given-names>DM</given-names></name><name><surname>Cozzarelli</surname><given-names>IM</given-names></name><name><surname>Mumford</surname><given-names>AC</given-names></name><name><surname>Orem</surname><given-names>WH</given-names></name><etal></etal></person-group>
<article-title>Endocrine disrupting activities of surface water associated with a West Virginia oil and gas industry wastewater disposal site</article-title>. <source/>Sci Total Environ. (<year>2016</year>) 557–<volume>8</volume>:<fpage>901</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2016.03.113</pub-id></mixed-citation>
</ref>
<ref id="B270">
<label>270.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Vu</surname><given-names>DC</given-names></name><name><surname>Vo</surname><given-names>PH</given-names></name><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Cornelius-Green</surname><given-names>JN</given-names></name><name><surname>Patton</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Endocrine disrupting activities and organic contaminants associated with oil and gas operations in wyoming groundwater</article-title>. <source/>Arch Environ Contamin Toxicol. (<year>2018</year>) <volume>75</volume>:<fpage>247</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1007/s00244-018-0521-2</pub-id><pub-id pub-id-type="pmid">29623359</pub-id></mixed-citation>
</ref>
<ref id="B271">
<label>271.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cozzarelli</surname><given-names>IM</given-names></name><name><surname>Skalak</surname><given-names>KJ</given-names></name><name><surname>Kent</surname><given-names>DB</given-names></name><name><surname>Engle</surname><given-names>MA</given-names></name><name><surname>Benthem</surname><given-names>A</given-names></name><name><surname>Mumford</surname><given-names>AC</given-names></name><etal></etal></person-group>. <article-title>Environmental signatures and effects of an oil and gas wastewater spill in the Williston Basin, North Dakota</article-title>. <source/>Sci Total Environ. (<year>2017</year>) <volume>579</volume>:<fpage>1781</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2016.11.157</pub-id><pub-id pub-id-type="pmid">27939081</pub-id></mixed-citation>
</ref>
<ref id="B272">
<label>272.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Kollitz</surname><given-names>EM</given-names></name><name><surname>Ferguson</surname><given-names>PL</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>. <article-title>Nonionic ethoxylated surfactants induce adipogenesis in 3T3-L1 cells</article-title>. <source/>Toxicol Sci. (<year>2018</year>) <volume>162</volume>:<fpage>124</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfx234</pub-id><pub-id pub-id-type="pmid">29106673</pub-id></mixed-citation>
</ref>
<ref id="B273">
<label>273.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Getzinger</surname><given-names>GJ</given-names></name><name><surname>O'Connor</surname><given-names>MP</given-names></name><name><surname>Hoelzer</surname><given-names>K</given-names></name><name><surname>Drollette</surname><given-names>BD</given-names></name><name><surname>Karatum</surname><given-names>O</given-names></name><name><surname>Deshusses</surname><given-names>MA</given-names></name><etal></etal></person-group>. <article-title>Natural gas residual fluids: sources, endpoints, and organic chemical composition after centralized waste treatment in Pennsylvania</article-title>. <source/>Environ Sci Technol. (<year>2015</year>) <volume>49</volume>:<fpage>8347</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.5b00471</pub-id><pub-id pub-id-type="pmid">26147419</pub-id></mixed-citation>
</ref>
<ref id="B274">
<label>274.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Thurman</surname><given-names>EM</given-names></name></person-group>
<article-title>Chemical constituents and analytical approaches for hydraulic fracturing waters</article-title>. <source/>Trends Environ Anal Chem. (<year>2015</year>) <volume>5</volume>:<fpage>18</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.teac.2015.01.003</pub-id></mixed-citation>
</ref>
<ref id="B275">
<label>275.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thurman</surname><given-names>EM</given-names></name><name><surname>Ferrer</surname><given-names>I</given-names></name><name><surname>Blotevogel</surname><given-names>J</given-names></name><name><surname>Borch</surname><given-names>T</given-names></name></person-group>. <article-title>Analysis of hydraulic fracturing flowback and produced waters using accurate mass: identification of ethoxylated surfactants</article-title>. <source/>Anal Chem. (<year>2014</year>) <volume>86</volume>:<fpage>9653</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1021/ac502163k</pub-id><pub-id pub-id-type="pmid">25164376</pub-id></mixed-citation>
</ref>
<ref id="B276">
<label>276.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>TB</given-names></name><name><surname>Keller</surname><given-names>DA</given-names></name><name><surname>Sander</surname><given-names>M</given-names></name><name><surname>Carney</surname><given-names>EW</given-names></name><name><surname>Doerrer</surname><given-names>NG</given-names></name><name><surname>Eaton</surname><given-names>DL</given-names></name><etal></etal></person-group>. <article-title>FutureTox II: <italic>in vitro</italic> data and in silico models for predictive toxicology</article-title>. <source/>Toxicol Sci. (<year>2015</year>) <volume>143</volume>:<fpage>256</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfu234</pub-id><pub-id pub-id-type="pmid">25628403</pub-id></mixed-citation>
</ref>
<ref id="B277">
<label>277.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarzman</surname><given-names>MR</given-names></name><name><surname>Ackerman</surname><given-names>JM</given-names></name><name><surname>Dairkee</surname><given-names>SH</given-names></name><name><surname>Fenton</surname><given-names>SE</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Navarro</surname><given-names>KM</given-names></name><etal></etal></person-group>. <article-title>Screening for chemical contributions to breast cancer risk: a case study for chemical safety evaluation</article-title>. <source/>Environ Health Perspect. (<year>2015</year>) <volume>123</volume>:<fpage>1255</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1408337</pub-id><pub-id pub-id-type="pmid">26032647</pub-id></mixed-citation>
</ref>
<ref id="B278">
<label>278.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>RS</given-names></name><name><surname>Black</surname><given-names>MB</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Healy</surname><given-names>E</given-names></name><name><surname>Chu</surname><given-names>TM</given-names></name><name><surname>Bao</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening</article-title>. <source/>Toxicol Sci. (<year>2012</year>) <volume>128</volume>:<fpage>398</fpage>–<lpage>417</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfs159</pub-id><pub-id pub-id-type="pmid">22543276</pub-id></mixed-citation>
</ref>
<ref id="B279">
<label>279.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>MT</given-names></name><name><surname>Knudsen</surname><given-names>TB</given-names></name><name><surname>Reif</surname><given-names>DM</given-names></name><name><surname>Houck</surname><given-names>KA</given-names></name><name><surname>Judson</surname><given-names>RS</given-names></name><name><surname>Kavlock</surname><given-names>RJ</given-names></name><etal></etal></person-group>. <article-title>Predictive model of rat reproductive toxicity from ToxCast high throughput screening</article-title>. <source/>Biol Reprod. (<year>2011</year>) <volume>85</volume>:<fpage>327</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1095/biolreprod.111.090977</pub-id><pub-id pub-id-type="pmid">21565999</pub-id></mixed-citation>
</ref>
<ref id="B280">
<label>280.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sipes</surname><given-names>NS</given-names></name><name><surname>Martin</surname><given-names>MT</given-names></name><name><surname>Reif</surname><given-names>DM</given-names></name><name><surname>Kleinstreuer</surname><given-names>NC</given-names></name><name><surname>Judson</surname><given-names>RS</given-names></name><name><surname>Singh</surname><given-names>AV</given-names></name><etal></etal></person-group>. <article-title>Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data</article-title>. <source/>Toxicol Sci. (<year>2011</year>) <volume>124</volume>:<fpage>109</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfr220</pub-id><pub-id pub-id-type="pmid">21873373</pub-id></mixed-citation>
</ref>
<ref id="B281">
<label>281.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Mansouri</surname><given-names>K</given-names></name><name><surname>Judson</surname><given-names>RS</given-names></name><name><surname>Martin</surname><given-names>MT</given-names></name><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Predicting hepatotoxicity using ToxCast in vitro bioactivity and chemical structure</article-title>. <source/>Chem Res Toxicol. (<year>2015</year>) <volume>28</volume>:<fpage>738</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1021/tx500501h</pub-id><pub-id pub-id-type="pmid">25697799</pub-id></mixed-citation>
</ref>
<ref id="B282">
<label>282.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auerbach</surname><given-names>S</given-names></name><name><surname>Filer</surname><given-names>D</given-names></name><name><surname>Reif</surname><given-names>D</given-names></name><name><surname>Walker</surname><given-names>V</given-names></name><name><surname>Holloway</surname><given-names>AC</given-names></name><name><surname>Schlezinger</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Prioritizing environmental chemicals for obesity and diabetes outcomes research: a screening approach using toxcast high-throughput data</article-title>. <source/>Environ Health Perspect. (<year>2016</year>) <volume>124</volume>:<fpage>1141</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1510456</pub-id><pub-id pub-id-type="pmid">26978842</pub-id></mixed-citation>
</ref>
<ref id="B283">
<label>283.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassotis</surname><given-names>CD</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Filer</surname><given-names>D</given-names></name><name><surname>Stapleton</surname><given-names>HM</given-names></name></person-group>
<article-title>Building a Predictive Model with ToxCast Data to Evaluate Potential Metabolic Disruption by Environmental Chemicals</article-title>. (<year>in press</year>).</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>